Compositions and Methods Relating to Alzheimer's Disease

Information

  • Patent Application
  • 20230392133
  • Publication Number
    20230392133
  • Date Filed
    October 12, 2021
    3 years ago
  • Date Published
    December 07, 2023
    a year ago
Abstract
Disclosed herein are methods of administering precision gene therapy, treating and/or preventing Alzheimer' disease progression, and reducing expression of APOE and APOE e4. Disclosed herein are isolated nucleic acid molecules, viral vectors, lentiviral vectors, pharmaceutical formulations, host cells, guide RNAs and plasmids for use in the disclosed methods.
Description
II. REFERENCE TO THE SEQUENCE LISTING

The Sequence Listing submitted 12 Oct. 2021 as a text file named “20_940_WO_Sequence_Listing”, created on 12 Oct. 2021 and having a size of 581 kilobytes is hereby incorporated by reference pursuant to 37 C.F.R. § 1.52(e)(5).


III. BACKGROUND

Alzheimer's disease (AD) is sixth leading cause of death in the US and the most common cause of dementia in aging. With a rapidly growing aging population the number of AD cases is growing fast and projected to rise drastically over the next three decades. Today, more than 5 million people are living with AD in the United States alone, and by 2050, this number is projected to reach 14 million. Therefore, AD poses a huge economic burden on society placing overwhelming strain on the healthcare system. In 2020, the cost of AD to the US was $301 billion, including $206 billion in Medicare and Medicaid payments, while the caregivers provided $244 billions worth of care (Alzheimer's Association, Alzheimer's Impact Movement: Factsheet 2020). These trends will only worsen with time because there are no therapies to halt or prevent AD (i.e., projected to cost more than $1.1 trillion annually by 2050). Despite all the research effort, money and commitment, clinical trials to identify disease modifying therapies (DMT) for AD have repeatedly failed. To date, there is no cure and no DMT for AD and there are no methods to delay the onset and/or progression of the disease. Most available treatments are palliative and aimed at relieving symptom (Sharma K. (2019) Mol Med Rep. 20:1479-1487; Olivares D, et al. (2012) Curr Alzheimer Res. 9:746-758).


Late onset AD (LOAD) is a heterogenous disease with various genetic etiologies (Lo M T, et al. (2019). Neurobiol Aging. 84:243 e1-243.e9; Nacmias B, et al. (2018) J Alzheimers Dis. 62:903-911). A major reason for the failure to identify an effective treatment is likely the inaccurate consideration of LOAD as a homogeneous disease. In this respect, increasing evidence demonstrate the heterogeneity in the underlying pathophysiologic processes of LOAD and show variability in the genetic risk and molecular profiles amongst AD patients (Reitz C. (2016) Ann Transl Med. 4:107; Chiba-Falek O, et al. (2017) Expert Rev Precis Med Drug Dev. 2:47-55). Thus, AD remains an unmet medical need underscoring the urgent need for a paradigm shift in AD clinical research.


Accordingly, any advancement in LOAD therapy will require the development and validation of new therapeutic targets including those tailored to sub-groups of patients with specific risk factors. Thus, to date many investigators and funding bodies recognize the need to shift the focus to new potential culprits including candidate gene-targets such as LOAD risk genes and rare mutations (Guerreiro R, et al. (2013) Neurobiol Aging. 34:2890 e1-5). Consistently, recently, alternative targets such as APOE have emerged as potential promising targets for LOAD treatment (Huynh T V, et al. (2017) Neuron. 96:1013-1023 e4; Brody D L, et al. (2008) Annu Rev Neurosci 31:175-193; Kim J, et al. (2012) J Exp Med. 209:2149-2156).


Accordingly, there is a need for a disease modifying therapy for Alzheimer's disease, particularly LOAD.





IV. BRIEF DESCRIPTION OF THE FIGURES


FIG. 1 shows the effect of APOE genotypes on APOE-mRNA levels. FIG. 1A shows a schematic model describing the mechanisms that lead to increased ApoE activity and by that mediate the pathogenic effect of APOE e4 and APOE e3 (differ in amino acid at position 112 Arg and Cys, respectively) on LOAD. FIG. 1B shows a diagram of the different technologies to target ApoE, including antisense oligonucleotide (ASO), monoclonal antibody (mAbs), and CRISPR/Cas9 gene editing technologies. The fold levels of human APOE mRNA were assayed using qRT-PCR in temporal tissues (FIG. 1C) and in occipital tissues (FIG. 1D). FIG. 1E shows the level of human APOE-mRNA in whole brain tissues from humanized mice assayed by qRT-PCR.



FIG. 2 shows a schematic representation of APOE gene. The APOE gene is located at chromosome 19q13.2. The SNP rs429358 changes amino acid in position 112 and defines APOE e4 allele. The SNP rs7412 changes amino acid in position 158 and defines the APOE e2 allele. The CpG island in exon 4 is highlighted. DMRI and DMR2 regions are defined by two CGIs, which are marked in a yellow box. Exons 1-4 are designated in boxes. The translated exons are highlighted in dark blue. 5′-UTR and 3′-UTR of the gene are highlighted in light blue.



FIG. 3 shows the DNA-methylation profile of the APOE LD region in FANS-sorted neuronal and non-neuronal nuclei. FIG. 3A shows a map of MethylEPIC array probes in the chr19: 45,393,000-45,424,000; hg19. The red circles represent probes with >0.5 methylation levels while the blue circles represent probes with <0.5 methylation levels. The APOE promoter region is hypomethylated and is an excellent target region for enhancement of DNA-methylation. FIG. 3B shows that probes showed significant differences in methylation levels between NeuN+ (n=16), NeuN sorted nuclei (n=16), or LOAD (n=8) vs. Normal (n=8). Solid bars represent neuronal population while the hatched bars represent the non-neuronal population. The accompanying table summarizes the p-values for each of the significant probes.



FIG. 4 show the structure of human APOE gene and the design of spCas9 gRNAs to target the promoter region of the gene. FIG. 4 shows the genomic organization of the gene including the two SNPs in exon 4 and the gRNA targeting of the promoter region of the gene. The 5′-UTR and 3′-UTR of the gene are also shown.



FIG. 5 shows the schematic representation of lentiviral vector system carrying DNMT3A to target the promoter and exon 4 regions of APOE gene. The 5′-LTR and the 3′-LTR represent long terminal repeats. Phi represents the packaging signal of the vector. RRE represents the rev responsive element responsible for binding REV protein of the virus. The Sp1 responsive element inclusion (Ortiniski et al. (2017); Kantor et al. (2018)) demonstrated high production yield. The hU6 promoter drives expression of the gRNA and the EFS-NC promoter drives the expression of dCAS9 (to target promoter of APOE) or dVRER to target SNP (112) at the exon 4 region. The p2A signal separates the effector molecule from GFP/Puro reporters. WPRE is the Woodchuck Hepatitis Virus (WHP) Post-Transcriptional Regulatory Element (WPRE), which is a DNA sequence that when transcribed creates a tertiary structure enhancing expression. The arrow pointing to the promoter region highlights the binding of the dCas9-DNMT3A-gRNA to the promoter region or the SNP region that results in the DNA methylation (red lollipops) and downregulation of gene expression (represented with the red cross sign).



FIG. 6 shows the targeting of the promoter region of APOE with gRNA-dCas9-DNMT3A lentiviral vector system. Human hepatocytes HEPG2 cell (having APOEe3/3 genotype) were stably transduced with lentiviral vector carrying 4 different gRNA paired with dCas9-DNMT3A or dCAS9-DNMT3A null vectors. In FIG. 6, the levels of the mRNA and protein downregulation were compared to untransduced naïve HEPG2 cells. The vectors delivering the active version of DNMT3A represented in white bars while the null mutants are shown in black bars. The experiments were repeated three time and the SD bars are highlighted. FIG. 6A shows the levels of RNA knockdown following the transduction with a lentiviral vector as assessed by real-time PCR. gRNA1 showed the most robust reduction in APOE-mRNA. FIG. 6B shows the levels of protein knockdown following the transduction with a lentiviral vector as assessed by western blot. The effects on the protein levels were comparable with the effects on the mRNA shown in FIG. 6A, demonstrating the most robust decrease in protein levels was driven by gRNA1. In FIG. 6, gRNA1 was gacagggggagccctataat (SEQ ID NO:25), gRNA3 was actgggatgtaagccatagc (SEQ ID NO:27), and gRNA4 was gttggagcttagaatgtgaa (SEQ ID NO:28).



FIG. 7 shows the structure of humanAPOE gene and VRER gRNAs design relative to the spCas9 gRNAs positions targeting the promoter region of the gene. Genomic organization of the gene outlined in the lower panel highlighting the 2 SNPs within exon 4. gRNA targeting promoter region of the gene are outlined. spCas9 gRNAs (in green) and VRER gRNAs (in yellow) positions. The 5′-UTR and the 3′-UTR of the gene are indicated in boxes. Structure of a human APOE gene and VRER vs spCas9 gRNAs locations are shown.



FIG. 8A-FIG. 8B show the validation of VRER system using GFP-reporter cells. A GFP-reporter 293T cell line was created by stable transduction using lentiviral vector. GFP was subjected to site-directed mutagenesis to change the PAM motif for VRER enzyme NGCG to GGG, which is recognized by SpCas9. The cells identified as 1003GFP are generated to include this modification. The target cells were transduced with SpCas9-gRNA-to-GFP vector VRER-gRNA-to-GFP vector to assess the specificity and efficacy of the corresponding enzymes. The gRNA sequence selected for targeting is highlighted. The cells identified as 201A GFP cells (FIG. 8A) contained the “naïve” GFP sequence, while 1003 GFP cells (FIG. 8B) were introduced with point-substitution (as above) without changing amino acid residues. A score of 5+ highlights the high efficiency of the GFP cleavage, while a score of 5− highlights incapacity of the enzyme to digest DNA. The specificity of VRER was found to be comparable to that of Cas9 while the efficacy was demonstrated to be significantly lower.



FIG. 9 shows the effect of targeting the promoter region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. Human hepatocytes HEPG2 cells were stably transduced with lentiviral vector carrying 4 different gRNA paired with dVRER-DNMT3A or dVRER-DNMT3A null vectors. FIG. 9 shows the level of RNA knockdown following the transduction using real-time PCR. The levels of the mRNA downregulation was compared to untransduced, naïve HEPG2 cells. The vectors delivering the active version of DNMT3A are represented in white bars while the null mutants are represented in black bars. The experiments were repeated three times and the SD bars are highlighted.



FIG. 10A-FIG. 10F shows the differentiation and characterization of hiPSC-derived neurons. FIG. 10A shows the timeline for neuronal differentiation. FIG. 10B shows representative immunocytochemistry of hiPSC-derived neurons. FIG. 10C shows the FACS-analysis showing co-expression of TUBB3 and VachT (36.4%) while FIG. 10D shows the absence of GFAP signal. FIG. 10E shows the relative expression levels of the neuronal-specific markers (TUBB3 and CHAT) and the astrocyte specific marker (GFAP). FIG. 10F shows APOE-mRNA expression in isogenic APOE 3/3 and 4/4 hiPSC-derived neurons. APOE-mRNA 3/3>4/4 consistent with the observation in human brain, which demonstrated the suitability of the system for drug discovery.



FIG. 11A-FIG. 11C show expression levels and immunohistochemical staining of isogenic APOE-hiPSC. FIG. 11A shows the fold levels of human APOE mRNA assayed by qRT-PCR using TaqMan assay. FIG. 11B (APOE 3/3) and FIG. 11C (APOE 4/4) show hiPSC shows cells stained with pluripotency markers OCT 4 and NANOG. (FROM GRANT)



FIG. 12A-FIG. 12M show the nuclear envelope markers in isogenic APOE 3/3 and 4/4 hiPSC-derived neurons. FIG. 12A shows the immunocytochemistry for lamin B1 in APOE 3/3 hiPSC-derived neurons while FIG. 12B shows lamin B1 staining in APOE 4/4 hiPSC-derived neurons. As demonstrated in FIG. 12C, the quantification of the nuclear envelope circularity showed loss circularity in the APOE 4/4 hiPSC-derived neurons vs. the APOE 3/3 hiPSC-derived neurons before heat treatment while FIG. 12D shows the same comparison after heat treatment. FIG. 12E shows the immunocytochemistry for lamin AC in APOE 3/3 hiPSC-derived neurons while FIG. 12F shows lamin B1 staining in APOE 4/4 hiPSC-derived neurons. FIG. 12G shows the proportion of cells with abnormal nuclear morphology in the APOE 4/4 hiPSC-derived neurons vs. the APOE 3/3 hiPSC-derived neurons before heat treatment while FIG. 12H shows the same comparison after heat treatment. As shown in FIG. 12I, osmotic stress showed an increased sensitivity of the nuclear envelope in the APOE 4/4 neurons compared to the APOE 3/3. FIG. 13J shows the decrease in global 5-mC % in APOE 4/4 hiPSC-derived neurons as compared to APOE 3/3 hiPSC-derived neurons. FIG. 12K and FIG. 12L shows the nuclear leakage as assessed by a dextran assay using 155 kDa fluorescently-label molecule APOE 3/3 hiPSC-derived neurons and 4/4 hiPSC-derived neurons, respectively. FIG. 12M shows the percentage of leaky nuclei for both APOE 3/3 and APO 4/4 hiPSC-derived neurons.



FIG. 13A-FIG. 13E shows the methylation profile of the APOE LD region in isogenic APOE hiPSC-derived neurons. FIG. 13A shows a map of MethylEPIC array probes in chromosome 19 from 45,393,000-45,424,000 (hg19). Those probes with >0.5 methylation levels are highlighted in red. Those probes with <0.5 methylation levels are highlighted in blue. Significant differences in methylation between the APOE neuronal lines are shown using asterisks as follows: black asterisk (>0.1) and red asterisk (>0.2). Because the APOE promoter region was hypomethylated, it became an excellent target region for enhancement of DNA-methylation. FIG. 13B shows a schematic representation of the 27 CpG islands for pyrosequencing in the APOE region, i.e., chromosome 19 from 45,411,858-45,412,079 (hg19). FIG. 13C shows those probes that had significant differences in DNA-methylation levels between isogenic APOE hiPSC-derived neurons. FIG. 13D shows the methylation level (%) of the CpG 11-38 that was quantitatively determined in the isogenic hiPSC-derived neurons using pyrosequencing. FIG. 13E shows a comparison of the methylation level (%) of CpG 11-38 between hiPSC-derived neurons and NeuN+ FANS-sorted nuclei using pyrosequencing. Here, the DNA-methylation profiles of the hiPSC-derived neurons were comparable to those observed for the human brain sorted neuronal nuclei (indicating that the hiPSC-derived neuronal system was suitable for drug discovery studies aiming at DNA-methylation editing).



FIG. 14A-FIG. 14D show the AD-related phenotypes in isogenic APOE 3/3 and 4/4 hiPSC-derived neurons. FIG. 14A shows the ratio of extracellular A042:AD40 secreted from APO 3/3 and APOE 4/4 neurons measured by ELISA. FIG. 14B shows the total tau levels measured by ELISA. FIG. 14C shows the neurite outgrowth evaluated using TUBB3 immunostaining in APOE 3/3 hiPSC-derived neurons. and FIG. 14D shows the neurite outgrowth evaluated using TUBB3 immunostaining in APOE 4/4 hiPSC-derived neurons.



FIG. 15A-15B shows methylation in the target promoter region of APOE and the design of gRNA for targeting. FIG. 15A shows the genome browser view of a map of the targeted region using UCSC genome browser viewer. The black bars in the upper portion of the panel shows the positions of (i) the target region, (ii) the designed gRNAs, and (iii) MethylEpic probes. The lower panel of FIG. 15A shows the APOE gene structure including the promoter, exon 1, intron 1, and the TSS. FIG. 15B shows the analysis of DNA-methylation within the APOE-promoter target region. Relevant probes were those that overlapped the target region and showed differences in DNA-methylation levels between the isogenic APOE hiPSC-derived neurons.



FIG. 16 shows the targeting of the promoter region of APOE with gRNA-dCas9-DNMT3A lentiviral vector system. hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele (APOE 4/4) were stably transduced with lentiviral vector carrying gRNA3 paired with either a dCas9-DNMT3A vector or a dCAS9-DNMT3A null vector. To assess the level of APOE mRNA knockdown following the transduction, qRT-PCR was used.



FIG. 17 shows the targeting of the promoter region of APOE with gRNA-dCas9-DNMT3A lentiviral vector system. hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele (APOE 4/4) were stably transduced with lentiviral vector carrying gRNAs 1-4 paired with dCas9-DNMT3A or a dCas9-DNMT3A vector with no-gRNA. To assess the level of APOE mRNA knockdown following the transduction, qRT-PCR was used.



FIG. 18 shows the targeting of the promoter region of APOE with gRNA-dCas9-DNMT3A lentiviral vector system. hiPSC-derived cholinergic neurons homozygote to the APOE e3 allele (APOE 3/3) were stably transduced with lentiviral vector carrying gRNAs 1-4 paired with dCas9-DNMT3A compared to dCAS9-DNMT3A vector with no-gRNA. To assess the level of APOE mRNA knockdown following the transduction, qRT-PCR was used.



FIG. 19 shows the targeting exon 4 region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele (APOE 4/4) were stably transduced with lentiviral vector carrying a gRNA 2′-paired with dVRER-DNMT3A compared to a dVRER-DNMT3A vector with no-gRNA. Real-time PCR assessed the level of mRNA knockdown following the transduction. A 15% reduction in the level of APOE-mRNA was observed following transduction with the lentiviral vector carrying the gRNA.



FIG. 20 shows the targeting exon 4 region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. hiPSC-derived cholinergic neurons homozygote to the APOE e3 allele (APOE 3/3) were stably transduced with lentiviral vector carrying a gRNA 2′-paired with dVRER-DNMT3A compared to a dVRER-DNMT3A vector with no-gRNA. Real-time PCR assessed the level of mRNA knockdown following the transduction. No changes in APOE-mRNA were observed.



FIG. 21A-FIG. 21B show the schematic strategy to silence APOEe4 allele using DNMT3A-DNMT3L enzymes and KRAB repressor as the effector molecules. FIG. 21 shows a schematic representation of the APOE gene including promoter region and exons 1-4. As shown on the right, two lentiviral vector systems were established. The first system carried dCAS9-gRNA-to-promoter. This vector also contained a SunTag epitope that was recognized by single-chain scFv protein. The second system carried dVRER and a gRNA for specific targeting of SNP rs429358 in the exon 4 (on the e4) and DNMT3A-DNMT3L effectors. gRNA introduced with MS2 binding sites allowed the recruitment of KRAB repressor via the MS2-protein (fusion). FIG. 21B shows that following lentiviral vector delivery of dCAS9-gRNA-SunTag binds to the promoter region on both alleles. However, it was inactive on the e3-allele as it lacked the effector molecules. The recruitment of dVRER via specific binding mediated throughout the recognition of the PAM (NGCG) brings the effector molecules in the action. Following interaction between SunTag-scFv DNA on the e4 will be looped out and two the effector molecules, KRAB and DNMT3A-L repress and methylate the promoter of the e4. This SunTag-MS2-bridging system allows specific repression of the e4 allele.



FIG. 22 shows the schematic of a lentiviral vector carrying gRNA-dCas9/dVRER-repressor transgene. the targeting exon 4 region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. The vector backbone was optimized by inclosing Sp1 binding sites. dCas9-KRAB/MeCP2/KRAB-MeCP2 fusion was expressed from EFS-NC promoter. Human U6 promoter drove the gRNA expression. The vector carried gRNA to target the regulatory element within exon 4 overlapping the e4-SNP (i.e., specifically target the ApoE4 allele).



FIG. 23A-FIG. 23B show the targeting exon 4 region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. FIG. 23A shows that the construct was identical to that of FIG. 5 but for the addition of the repressor to the fused domains of KRAB-MeCP2. FIG. 23B shows the mRNA level in hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele following stable transduction with lentiviral vector carrying a gRNA 2′-paired with dVRER-CRAB MeCp2 or a lentiviral vector carrying a dVRER-KRAB MeCp2 vector with no gRNA. Real-time PCR assessed the levels of mRNA knockdown following the transduction. The vector harboring gRNA2 caused a >50% reduction in the level of APOE mRNA.





V. BRIEF SUMMARY

Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA. Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is a viral vector comprising a disclosed isolated nucleic acid molecule. Disclosed herein is a viral vector comprising a disclosed isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA. Disclosed herein is a viral vector comprising a disclosed isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA. Disclosed herein is a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is pharmaceutical formulation comprising a disclosed isolated nucleic acid molecule and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising a disclosed vector and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising a disclosed lentiviral vector and a pharmaceutically acceptable carrier.


Disclosed herein is a host cell comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


Disclosed herein is a host cell comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is a host cell comprising a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA. Disclosed herein is a host cell comprising a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is a host cell comprising plasmid comprising the sequence set forth in any one of SEQ ID NO:21-24, SEQ ID NO:29-36, SEQ ID NO:43-50, SEQ ID NO:53-56, SEQ ID NO:59-61. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:25-SEQ ID NO:28. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:39-SEQ ID NO:42. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:51-SEQ ID NO:52. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:21-SEQ ID NO:24.


Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:29-SEQ ID NO:36. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:43-SEQ ID NO:50. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:53-SEQ ID NO:56. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:59-SEQ ID NO:61.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, wherein the fusion protein comprises a Cas endonuclease and a polypeptide having an enzymatic activity, and reducing expression of APOE in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of APOE in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, wherein the fusion protein comprises a Cas endonuclease and a polypeptide having an enzymatic activity, and reducing expression of the APOE e4 allele in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, wherein the fusion protein comprises a Cas endonuclease and a polypeptide having an enzymatic activity, and reducing expression of the APOE e4 allele.


Disclosed herein is a method of administering precision gene therapy, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of APOE, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of APOE.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of APOE, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of APOE.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of the APOE e4 allele, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of the APOE e4 allele.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele.


Disclosed herein is a method of reducing expression of APOE, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, thereby reducing expression of APOE.


Disclosed herein is a method of reducing expression of APOE, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, thereby reducing expression of APOE.


Disclosed herein is a method of reducing expression of APOE e4, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, thereby reducing expression of the APOE e4 allele.


Disclosed herein is a method of reducing expression of APOE e4, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, thereby reducing expression of the APOE e4 allele.


Disclosed herein is a kit comprising one or more disclosed isolated nucleic acid molecules, disclosed vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed guide RNAs, disclosed plasmids, or any combination thereof with or without additional therapeutic agents to treat, prevent, inhibit, and/or ameliorate one or more symptoms or complications associated AD or LOAD.


VI. DETAILED DESCRIPTION

The present disclosure describes formulations, compounded compositions, kits, capsules, containers, and/or methods thereof. It is to be understood that the inventive aspects of which are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.


All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited. The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.


A. Relevant Definitions

Before the present compounds, compositions, articles, systems, devices, and/or methods are disclosed and described, it is to be understood that they are not limited to specific synthetic methods unless otherwise specified, or to particular reagents unless otherwise specified, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular aspects only and is not intended to be limiting. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, example methods and materials are now described.


This disclosure describes inventive concepts with reference to specific examples. However, the intent is to cover all modifications, equivalents, and alternatives of the inventive concepts that are consistent with this disclosure.


As used in the specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise.


The phrase “consisting essentially of” limits the scope of a claim to the recited components in a composition or the recited steps in a method as well as those that do not materially affect the basic and novel characteristic or characteristics of the claimed composition or claimed method. The phrase “consisting of” excludes any component, step, or element that is not recited in the claim. The phrase “comprising” is synonymous with “including”, “containing”, or “characterized by”, and is inclusive or open-ended. “Comprising” does not exclude additional, unrecited components or steps.


As used herein, when referring to any numerical value, the term “about” means a value falling within a range that is +10% of the stated value.


Ranges can be expressed herein as from “about” one particular value, and/or to “about” another particular value. When such a range is expressed, a further aspect includes from the one particular value and/or to the other particular value. Similarly, when values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms a further aspect. It will be further understood that the endpoints of each of the ranges are significant both in relation to the other endpoint and independently of the other endpoint. It is also understood that there are a number of values disclosed herein, and that each value is also herein disclosed as “about” that particular value in addition to the value itself. For example, if the value “10” is disclosed, then “about 10” is also disclosed. It is also understood that each unit between two particular units are also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.


References in the specification and concluding claims to parts by weight of a particular element or component in a composition denotes the weight relationship between the element or component and any other elements or components in the composition or article for which a part by weight is expressed. Thus, in a compound containing 2 parts by weight component X and 5 parts by weight component Y, X and Y are present at a weight ratio of 2:5, and are present in such ratio regardless of whether additional components are contained in the compound.


As used herein, the terms “optional” or “optionally” means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where said event or circumstance occurs and instances where it does not. In an aspect, a disclosed method can optionally comprise one or more additional steps, such as, for example, repeating an administering step or altering an administering step.


As used herein, the term “subject” refers to the target of administration, e.g., a human being. The term “subject” also includes domesticated animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.), and laboratory animals (e.g., mouse, rabbit, rat, guinea pig, fruit fly, etc.). Thus, the subject of the herein disclosed methods can be a vertebrate, such as a mammal, a fish, a bird, a reptile, or an amphibian. Alternatively, the subject of the herein disclosed methods can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig, or rodent. The term does not denote a particular age or sex, and thus, adult and child subjects, as well as fetuses, whether male or female, are intended to be covered. In an aspect, a subject can be a human patient. In an aspect, a subject can have Alzheimer's disease (e.g., LOAD), be suspected of having Alzheimer's disease, or be at risk of developing and/or acquiring Alzheimer's disease.


As used herein, the term “diagnosed” means having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition that can be diagnosed or treated by one or more of the disclosed agents, disclosed therapeutic agents, disclosed pharmaceutical formulations, or a combination thereof, or by one or more of the disclosed methods. For example, “diagnosed with Alzheimer's disease or LOAD” means having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition that can be treated by one or more of the disclosed isolated nucleic acid molecules, disclosed viral vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed gRNAs, disclosed plasmids, or any combination thereof, or by one or more of the disclosed methods. For example, “suspected of having Alzheimer's disease” can mean having been subjected to an examination by a person of skill, for example, a physician, and found to have a condition that can likely be treated by one or more of the disclosed isolated nucleic acid molecules, disclosed viral vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed gRNAs, disclosed plasmids, or any combination thereof, or by one or more of the disclosed methods. In an aspect, an examination can be physical, can involve various tests (e.g., blood tests, genotyping, biopsies, etc.) and assays (e.g., enzymatic assay), or a combination thereof.


A “patient” can refer to a subject that has been diagnosed with or is suspected of having Alzheimer's disease (AD) or late-onset Alzheimer's disease (LOAD). In an aspect, a patient can refer to a subject that has been diagnosed with or is suspected of having AD such as for example, LOAD, and is seeking treatment or receiving treatment for AD or LOAD.


As used herein, the phrase “identified to be in need of treatment for a disorder,” or the like, refers to selection of a subject based upon need for treatment of the disorder. For example, a subject can be identified as having a need for treatment of a disorder (e.g., such as Alzheimer's disease) based upon an earlier diagnosis by a person of skill and thereafter subjected to treatment for the disorder (e.g., AD or LOAD). In an aspect, the identification can be performed by a person different from the person making the diagnosis. In an aspect, the administration can be performed by one who performed the diagnosis.


As used herein, “inhibit,” “inhibiting”, and “inhibition” mean to diminish or decrease an activity, level, response, condition, severity, disease, or other biological parameter. This can include, but is not limited to, the complete ablation of the activity, level, response, condition, severity, disease, or other biological parameter. This can also include, for example, a 10% inhibition or reduction in the activity, level, response, condition, severity, disease, or other biological parameter as compared to the native or control level (e.g., a subject not having Alzheimer's disease). Thus, in an aspect, the inhibition or reduction can be a 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or any amount of reduction in between as compared to native or control levels. In an aspect, the inhibition or reduction can be 10-20%, 20-30%, 30-40%, 40-50%, 50-60%, 60-70%, 70-80%, 80-90%, or 90-100% as compared to native or control levels. In an aspect, the inhibition or reduction can be 0-25%, 25-50%, 50-75%, or 75-100% as compared to native or control levels. In an aspect, a native or control level can be a pre-disease or pre-disorder level.


The words “treat” or “treating” or “treatment” include palliative treatment, that is, treatment designed for the relief of symptoms rather than the curing of the disease, pathological condition, or disorder; preventative treatment, that is, treatment directed to minimizing or partially or completely inhibiting the development of the associated disease, pathological condition, or disorder; and supportive treatment, that is, treatment employed to supplement another specific therapy directed toward the improvement of the associated disease, pathological condition, or disorder (such as Alzheimer's disease). In an aspect, the terms cover any treatment of a subject, including a mammal (e.g., a human), and includes: (i) preventing the undesired physiological change, disease, pathological condition, or disorder from occurring in a subject that can be predisposed to the disease but has not yet been diagnosed as having it; (ii) inhibiting the physiological change, disease, pathological condition, or disorder, i.e., arresting its development; or (iii) relieving the physiological change, disease, pathological condition, or disorder, i.e., causing regression of the disease. For example, in an aspect, treating Alzheimer's disease or LOAD can reduce the severity of an established disease in a subject by 1%-100% as compared to a control (such as, for example, an individual not having AD or LOAD). In an aspect, treating can refer to a 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100% reduction in the severity of AD or LOAD. For example, treating Alzheimer's disease can reduce one or more symptoms of AD or LOAD in a subject by 1%-100% as compared to a control (such as, for example, an individual not having AD or LOAD). In an aspect, treating can refer to 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100% reduction of one or more symptoms of an established AD (such as LOAD). It is understood that treatment does not necessarily refer to a cure or complete ablation or eradication of AD. However, in an aspect, treatment can refer to a cure or complete ablation or eradication of AD or LOAD.


As used herein, “SunTag” refers to a tag that allows numerous copies of GFP to be recruited to a protein of interest for bright signals. The SunTag can be used for amplification of a fluorescence signal (Tanenbaum M E, et al. (2014) Cell. 159(3):635-646).


As used herein, a “biomarker” refers to a defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or response to an exposure of intervention. In an aspect, a biomarker can be diagnostic (i.e., detects or classifies a pathological condition), prognostic (i.e., predicts the probability of disease occurrence or progression), pharmacodynamic/responsive (i.e., identifies a change in response to a therapeutic intervention), predictive (i.e., predicts how an individual or subject might respond to a particular intervention or event). In an aspect, a biomarker can be diagnostic, prognostic, pharmacodynamic/responsive, and/or predictive at the same time. In an aspect, a biomarker can be diagnostic, prognostic, pharmacodynamic/responsive, and/or predictive at different times (e.g., first a biomarker can be diagnostic and then later, the same biomarker can be prognostic, pharmacodynamic/responsive, and/or predictive). A biomarker can be an objective measure that can be linked to a clinical outcome assessment. A biomarker can be used by the skilled person to make a clinical decision based on its context of use.


As used herein, “operably linked” means that expression of a gene is under the control of a promoter with which it is spatially connected. A promoter can be positioned 5′ (upstream) or 3′ (downstream) of a gene under its control. The distance between the promoter and a gene can be approximately the same as the distance between that promoter and the gene it controls in the gene from which the promoter is derived. As is known in the art, variation in this distance can be accommodated without loss of promoter function.


As used herein, the term “prevent” or “preventing” or “prevention” refers to precluding, averting, obviating, forestalling, stopping, or hindering something from happening, especially by advance action. It is understood that where reduce, inhibit, or prevent are used herein, unless specifically indicated otherwise, the use of the other two words is also expressly disclosed. In an aspect, preventing Alzheimer's disease (AD) or LOAD and/or AD or LOAD progression is intended. The words “prevent” and “preventing” and “prevention” also refer to prophylactic or preventative measures for protecting or precluding a subject (e.g., an individual) not having AD or LOAD or an AD or LOAD complication from progressing to that complication. In an aspect, preventing or reducing APOE expression and/or activity is intended.


As used herein, the terms “administering” and “administration” refer to any method of providing one or more of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, the following routes: oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, in utero administration, intrahepatic administration, intravaginal administration, ophthalmic administration, intraaural administration, otic administration, intracerebral administration, rectal administration, sublingual administration, buccal administration, and parenteral administration, including injectable such as intravenous administration, intra-CSF administration, intra-arterial administration, intramuscular administration, and subcutaneous administration. Administration can also include hepatic intra-arterial administration or administration through the hepatic portal vein (HPV). Administration of a disclosed therapeutic agent, a disclosed pharmaceutical composition, or a combination thereof can comprise administration directly into the CNS (e.g., intraparenchymal, intracerebroventriular, inthrathecal cisternal, intrathecal (lumbar), deep gray matter delivery, convection-enhanced delivery to deep gray matter) or the PNS. Administration can be continuous or intermittent.


In an aspect, a “therapeutic agent” can be a “biologically active agent” or “biologic active agent” or “bioactive agent”, which refers to an agent that is capable of providing a local or systemic biological, physiological, or therapeutic effect in the biological system to which it is applied. For example, the bioactive agent can act to control infection or inflammation, enhance cell growth and tissue regeneration, control tumor growth, act as an analgesic, promote anti-cell attachment, and enhance bone growth, among other functions. Other suitable bioactive agents can include anti-viral agents, vaccines, hormones, antibodies (including active antibody fragments sFv, Fv, and Fab fragments), aptamers, peptide mimetics, functional nucleic acids, therapeutic proteins, peptides, or nucleic acids. Other bioactive agents include prodrugs, which are agents that are not biologically active when administered but, upon administration to a subject are converted to bioactive agents through metabolism or some other mechanism. Additionally, any of the compositions of the invention can contain combinations of two or more bioactive agents. It is understood that a biologically active agent can be used in connection with administration to various subjects, for example, to humans (i.e., medical administration) or to animals (i.e., veterinary administration). As used herein, the recitation of a biologically active agent inherently encompasses the pharmaceutically acceptable salts thereof.


In an aspect, a “therapeutic agent” can be any agent that effects a desired clinical outcome in a subject having AD or LOAD, suspected of having AD or LOAD, and/or likely to develop or acquire AD or LOAD. In an aspect, a disclosed therapeutic agent can be an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable.


In an aspect, a therapeutic agent can be a “drug” or a “vaccine” and means a molecule, group of molecules, complex or substance administered to an organism for diagnostic, therapeutic, preventative medical, or veterinary purposes. This term includes externally and internally administered topical, localized and systemic human and animal pharmaceuticals, treatments, remedies, nutraceuticals, cosmeceuticals, biologicals, devices, diagnostics and contraceptives, including preparations useful in clinical and veterinary screening, prevention, prophylaxis, healing, wellness, detection, imaging, diagnosis, therapy, surgery, monitoring, cosmetics, prosthetics, forensics and the like. This term may also be used in reference to agriceutical, workplace, military, industrial and environmental therapeutics or remedies comprising selected molecules or selected nucleic acid sequences capable of recognizing cellular receptors, membrane receptors, hormone receptors, therapeutic receptors, microbes, viruses or selected targets comprising or capable of contacting plants, animals and/or humans. Examples include but are not limited to a radiosensitizer, the combination of a radiosensitizer and a chemotherapeutic, a steroid, a xanthine, a beta-2-agonist bronchodilator, an anti-inflammatory agent, an analgesic agent, a calcium antagonist, an angiotensin-converting enzyme inhibitors, a beta-blocker, a centrally active alpha-agonist, an alpha-1-antagonist, carbonic anhydrase inhibitors, prostaglandin analogs, a combination of an alpha agonist and a beta blocker, a combination of a carbonic anhydrase inhibitor and a beta blocker, an anticholinergic/antispasmodic agent, a vasopressin analogue, an antiarrhythmic agent, an antiparkinsonian agent, an antiangina/antihypertensive agent, an anticoagulant agent, an antiplatelet agent, a sedative, an ansiolytic agent, a peptidic agent, a biopolymeric agent, an antineoplastic agent, a laxative, an antidiarrheal agent, an antimicrobial agent, an antifungal agent, or a vaccine. In a further aspect, the pharmaceutically active agent can be coumarin, albumin, bromolidine, steroids such as betamethasone, dexamethasone, methylprednisolone, prednisolone, prednisone, triamcinolone, budesonide, hydrocortisone, and pharmaceutically acceptable hydrocortisone derivatives; xanthines such as theophylline and doxophylline; beta-2-agonist bronchodilators such as salbutamol, fenterol, clenbuterol, bambuterol, salmeterol, fenoterol; antiinflammatory agents, including antiasthmatic anti-inflammatory agents, antiarthritis antiinflammatory agents, and non-steroidal antiinflammatory agents, examples of which include but are not limited to sulfides, mesalamine, budesonide, salazopyrin, diclofenac, pharmaceutically acceptable diclofenac salts, nimesulide, naproxene, acetominophen, ibuprofen, ketoprofen and piroxicam; analgesic agents such as salicylates; calcium channel blockers such as nifedipine, amlodipine, and nicardipine; angiotensin-converting enzyme inhibitors such as captopril, benazepril hydrochloride, fosinopril sodium, trandolapril, ramipril, lisinopril, enalapril, quinapril hydrochloride, and moexipril hydrochloride; beta-blockers (i.e., beta adrenergic blocking agents) such as sotalol hydrochloride, timolol maleate, timol hemihydrate, levobunolol hydrochloride, esmolol hydrochloride, carteolol, propanolol hydrochloride, betaxolol hydrochloride, penbutolol sulfate, metoprolol tartrate, metoprolol succinate, acebutolol hydrochloride, atenolol, pindolol, and bisoprolol fumarate; centrally active alpha-2-agonists (i.e., alpha adrenergic receptor agonist) such as clonidine, brimonidine tartrate, and apraclonidine hydrochloride; alpha-1-antagonists such as doxazosin and prazosin; anticholinergic/antispasmodic agents such as dicyclomine hydrochloride, scopolamine hydrobromide, glycopyrrolate, clidinium bromide, flavoxate, and oxybutynin; vasopressin analogues such as vasopressin and desmopressin; prostaglandin analogs such as latanoprost, travoprost, and bimatoprost; cholinergics (i.e., acetylcholine receptor agonists) such as pilocarpine hydrochloride and carbachol; glutamate receptor agonists such as the N-methyl D-aspartate receptor agonist memantine; anti-Vascular endothelial growth factor (VEGF) aptamers such as pegaptanib; anti-VEGF antibodies (including but not limited to anti-VEGF-A antibodies) such as ranibizumab and bevacizumab; carbonic anhydrase inhibitors such as methazolamide, brinzolamide, dorzolamide hydrochloride, and acetazolamide; antiarrhythmic agents such as quinidine, lidocaine, tocainide hydrochloride, mexiletine hydrochloride, digoxin, verapamil hydrochloride, propafenone hydrochloride, flecaimide acetate, procainamide hydrochloride, moricizine hydrochloride, and diisopyramide phosphate; antiparkinsonian agents, such as dopamine, L-Dopa/Carbidopa, selegiline, dihydroergocryptine, pergolide, lisuride, apomorphine, and bromocryptine; antiangina agents and antihypertensive agents such as isosorbide mononitrate, isosorbide dinitrate, propranolol, atenolol and verapamil; anticoagulant and antiplatelet agents such as coumadin, warfarin, acetylsalicylic acid, and ticlopidine; sedatives such as benzodiazapines and barbiturates; ansiolytic agents such as lorazepam, bromazepam, and diazepam; peptidic and biopolymeric agents such as calcitonin, leuprolide and other LHRH agonists, hirudin, cyclosporin, insulin, somatostatin, protirelin, interferon, desmopressin, somatotropin, thymopentin, pidotimod, erythropoietin, interleukins, melatonin, granulocyte/macrophage-CSF, and heparin; antineoplastic agents such as etoposide, etoposide phosphate, cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, doxorubicin, cisplatin, hydroxyurea, leucovorin calcium, tamoxifen, flutamide, asparaginase, altretamine, mitotane, and procarbazine hydrochloride; laxatives such as senna concentrate, casanthranol, bisacodyl, and sodium picosulphate; antidiarrheal agents such as difenoxine hydrochloride, loperamide hydrochloride, furazolidone, diphenoxylate hydrochloride, and microorganisms; vaccines such as bacterial and viral vaccines; antimicrobial agents such as penicillins, cephalosporins, and macrolides, antifungal agents such as imidazolic and triazolic derivatives; and nucleic acids such as DNA sequences encoding for biological proteins, and antisense oligonucleotides. It is understood that a pharmaceutically active agent can be used in connection with administration to various subjects, for example, to humans (i.e., medical administration) or to animals (i.e., veterinary administration). As used herein, the recitation of a pharmaceutically active agent inherently encompasses the pharmaceutically acceptable salts thereof.


“Sequence identity” and “sequence similarity” can be determined by alignment of two peptide or two nucleotide sequences using global or local alignment algorithms. Sequences may then be referred to as “substantially identical” or “essentially similar” when they are optimally aligned. For example, sequence similarity or identity can be determined by searching against databases such as FASTA, BLAST, etc., but hits should be retrieved and aligned pairwise to compare sequence identity. Two proteins or two protein domains, or two nucleic acid sequences can have “substantial sequence identity” if the percentage sequence identity is at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, 99% or more, preferably 90%, 95%, 98%, 99% or more. Such sequences are also referred to as “variants” herein, e.g., other variants of glycogen branching enzymes and amylases. It should be understood that sequence with substantial sequence identity do not necessarily have the same length and may differ in length. For example, sequences that have the same nucleotide sequence but of which one has additional nucleotides on the 3′- and/or 5′-side are 100% identical.


In an aspect, the skilled person can determine an efficacious dose, an efficacious schedule, and an efficacious route of administration for one or more of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof so as to treat or prevent AD or LOAD. In an aspect, the skilled person can also alter, change, or modify an aspect of an administering step to improve efficacy of one or more of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof. In an aspect, the skilled person can determine an efficacious dose, an efficacious schedule, and an efficacious route of administration for any disclosed isolated nucleic acid molecule, disclosed pharmaceutical formulation, disclosed vector, disclosed therapeutic agent, or any combination thereof.


As used herein, “modifying the method” can comprise modifying or changing one or more features or aspects of one or more steps of a disclosed method. For example, in an aspect, a method can be altered by changing the amount of one or more of the disclosed isolated nucleic acid molecules, disclosed viral vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed gRNAs, disclosed plasmids, or any combination thereof, or administered to a subject, or by changing the frequency of administration of one or more of the disclosed isolated nucleic acid molecules, disclosed viral vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed gRNAs, disclosed plasmids, or any combination thereof, or by changing the duration of time that the one or more of the disclosed isolated nucleic acid molecules, disclosed viral vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed gRNAs, disclosed plasmids, or any combination thereof, or are administered to a subject.


As used herein, “concurrently” means (1) simultaneously in time, or (2) at different times during the course of a common treatment schedule.


The term “contacting” as used herein refers to bringing one or more of disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof together with a target area or intended target area in such a manner that the one or more of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof exert an effect on the intended target or targeted area either directly or indirectly. A target area or intended target area can be one or more of a subject's organs (e.g., lungs, heart, liver, kidney, brain, etc.). In an aspect, a target area or intended target area can be any cell or any organ infected by AD or LOAD (such as cholinergic neurons). In an aspect, a target area or intended target area can be the brain or various neuronal populations.


As used herein, “determining” can refer to measuring or ascertaining the presence and severity of AD such as, for example, LOAD. Methods and techniques used to determine the presence and/or severity of AD are typically known to the medical arts. For example, the art is familiar with the ways to identify and/or diagnose the presence, severity, or both of AD (such as, for example, a LOAD. In an aspect, “determining” can also refer to measuring or ascertaining the level of one or more proteins or peptides in a biosample, or measuring or ascertaining the level or one or more RNAs or miRNAs in a biosample. Methods and techniques for determining the level of proteins/peptides and RNAs/miRNAs are known to the art and are disclosed herein.


As used herein, “effective amount” and “amount effective” can refer to an amount that is sufficient to achieve the desired result such as, for example, the treatment and/or prevention of AD or LOAD. As used herein, the terms “effective amount” and “amount effective” can refer to an amount that is sufficient to achieve the desired an effect on an undesired condition (e.g., a AD or LOAD). For example, a “therapeutically effective amount” refers to an amount that is sufficient to achieve the desired therapeutic result or to have an effect on undesired symptoms, but is generally insufficient to cause adverse side effects. In an aspect, “therapeutically effective amount” means an amount of a disclosed isolated nucleic acid molecule, a disclosed pharmaceutical formulation, a disclosed vector, or any combination thereof that (i) treats the particular disease, condition, or disorder (e.g., AD or LOAD), (ii) attenuates, ameliorates, or eliminates one or more symptoms of the particular disease, condition, or disorder (e.g., AD or LOAD), or (iii) delays the onset of one or more symptoms of the particular disease, condition, or disorder described herein (e.g., AD or LOAD). The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof employed; the disclosed methods employed; the age, body weight, general health, sex and diet of the patient; the time of administration; the route of administration; the rate of excretion of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof employed; the duration of the treatment; drugs used in combination or coincidental with the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof employed, and other like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof at levels lower than those required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, then the effective daily dose can be divided into multiple doses for purposes of administration. Consequently, a single dose of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof can contain such amounts or submultiples thereof to make up the daily dose. The dosage can be adjusted by the individual physician in the event of any contraindications. Dosage can vary, and can be administered in one or more dose administrations daily, for one or several days. Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products. In further various aspects, a preparation can be administered in a “prophylactically effective amount”; that is, an amount effective for prevention of a disease or condition, such as, for example, AD or LOAD


As used herein, the term “pharmaceutically acceptable carrier” refers to sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), carboxymethylcellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate. In an aspect, a pharmaceutical carrier employed can be a solid, liquid, or gas. In an aspect, examples of solid carriers can include lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, and stearic acid. In an aspect, examples of liquid carriers can include sugar syrup, peanut oil, olive oil, and water. In an aspect, examples of gaseous carriers can include carbon dioxide and nitrogen. In preparing a disclosed composition for oral dosage form, any convenient pharmaceutical media can be employed. For example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like can be used to form oral liquid preparations such as suspensions, elixirs and solutions; while carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents, and the like can be used to form oral solid preparations such as powders, capsules and tablets. Because of their ease of administration, tablets and capsules are the preferred oral dosage units whereby solid pharmaceutical carriers are employed. Optionally, tablets can be coated by standard aqueous or nonaqueous techniques. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants. These compositions can also contain adjuvants such as preservatives, wetting agents, emulsifying agents and dispersing agents. Prevention of the action of microorganisms can be ensured by the inclusion of various antibacterial and antifungal agents such as paraben, chlorobutanol, phenol, sorbic acid and the like. It can also be desirable to include isotonic agents such as sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the inclusion of agents, such as aluminum monostearate and gelatin, which delay absorption. Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide, poly(orthoesters) and poly(anhydrides). Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable media just prior to use. Suitable inert carriers can include sugars such as lactose. Desirably, at least 95% by weight of the particles of the active ingredient have an effective particle size in the range of 0.01 to 10 micrometers.


As used herein, the term “excipient” refers to an inert substance which is commonly used as a diluent, vehicle, preservative, binder, or stabilizing agent, and includes, but is not limited to, proteins (e.g., serum albumin, etc.), amino acids (e.g., aspartic acid, glutamic acid, lysine, arginine, glycine, histidine, etc.), fatty acids and phospholipids (e.g., alkyl sulfonates, caprylate, etc.), surfactants (e.g., SDS, polysorbate, nonionic surfactant, etc.), saccharides (e.g., sucrose, maltose, trehalose, etc.) and polyols (e.g., mannitol, sorbitol, etc.). See, also, for reference, Remington's Pharmaceutical Sciences, (1990) Mack Publishing Co., Easton, Pa., which is hereby incorporated by reference in its entirety.


As used herein, the term “package insert” is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, contraindications and/or warnings concerning the use of such therapeutic products.


As used herein, the term “in combination” in the context of the administration of one or more of the disclosed agents, disclosed therapeutic agents, disclosed pharmaceutical formulations or a combination thereof includes the use of more than one therapy (e.g., additional therapeutic agents). Administration “in combination with” one or more additional therapeutic agents includes simultaneous (e.g., concurrent) and consecutive administration in any order. The use of the term “in combination” does not restrict the order in which therapies are administered to a subject. By way of non-limiting example, a first therapy (e.g., one or more of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof) may be administered prior to (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks), concurrently, or after (e.g., 1 minute, 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 24 hours, 48 hours, 72 hours, 96 hours, 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks or longer) the administration of a second therapy (e.g., one or more of the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof or one or more additional therapeutic agents) to a subject having or diagnosed with AD or LOAD.


As used herein, “CRISPR or clustered regularly interspaced short palindromic repeat” is an ideal tool for correction of genetic abnormalities associated with diseases such as Alzheimer's disease or LOAD. The system can be designed to target genomic DNA directly. A CRISPR system involves two main components: a Cas9 enzyme and a guide (gRNA). The gRNA contains a targeting sequence for DNA binding (at, for example, the APOE promoter region) and a scaffold sequence for Cas9 binding. Cas9 nuclease is often used to “knockout” target genes such as for example, the APOE e4 allele. Also, multiple gRNAs can be employed to suppress or activate multiple genes simultaneously, hence increasing the treatment efficacy and reducing resistance potentially caused by new mutations in the target genes.


As used herein, “CRISPR-based endonucleases” include RNA-guided endonucleases that comprise at least one nuclease domain and at least one domain that interacts with a guide RNA. As known to the art, a guide RNA directs the CRISPR-based endonucleases to a targeted site in a nucleic acid at which site the CRISPR-based endonucleases cleaves at least one strand of the targeted nucleic acid sequence. As the guide RNA provides the specificity for the targeted cleavage, the CRISPR-based endonuclease is universal and can be used with different guide RNAs to cleave different target nucleic acid sequences. CRISPR-based endonucleases are RNA-guided endonucleases derived from CRISPR/Cas systems.


In an aspect, a disclosed CRISPR-based endonuclease can be derived from a CRISPR/Cas type I, type II, or type III system. Non-limiting examples of suitable CRISPR/Cas proteins include Cas3, Cas4, Cas5, Cas5e (or CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9, Cas10, Cas10d, CasF, CasG, CasH, Csy1, Csy2, Csy3, Cse1 (or CasA), Cse2 (or CasB), Cse3 (or CasE), Cse4 (or CasC), Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csz1, Csx15, Csf1, Csf2, Csf3, Csf4, and Cu1966.


In an aspect, a disclosed CRISPR-based endonuclease can be derived from a type II CRISPR/Cas system. For example, in an aspect, a CRISPR-based endonuclease can be derived from a Cas9 protein. The Cas9 protein can be from Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp, Nocardiopsis dassonvillei, Streptomyces pristinaespiralis, Streptomyces viridochromogenes, Streptomyces viridochromogenes, Streptosporangium roseum, Streptosporangium roseum, Alicyclobacillus acidocaldarius, Bacillus pseudomycoides, Bacillus selenitireducens, Exiguobacterium sibiricum, Lactobacillus delbrueckii, Lactobacillus salivarius, Microscilla marina, Burkholderiales bacterium, Polaromonas naphthalenivorans, Polaromonas sp., Crocosphaera watsonii, Cyanothece sp., Microcystis aeruginosa, Synechococcus sp., Acetohalobium arabaticum, Ammonifex degensii, Caldicelulosiruptor becscii, Candidatus Desulforudis, Clostridium botulinum, Clostridium difficile, Finegoldia magna, Natranaerobius thermophilus, Pelotomaculum thermopropionicum, Acidithiobacillus caldus, Acidithiobacillus ferrooxidans, Allochromatium vinosum, Marinobacter sp., Nitrosococcus halophilus, Nitrosococcus watsoni, Pseudoalteromonas haloplanktis, Ktedonobacter racemifer, Methanohalobium evestigatum, Anabaena variabilis, Nodularia spumigena, Nostoc sp., Arthrospira maxima, Arthrospira platensis, Arthrospira sp., Lyngbya sp., Microcoleus chthonoplastes, Oscillatoria sp., Petrotoga mobilis, Thermosipho africanus, or Acaryochloris marina. In an aspect, the CRISPR-based nuclease can be derived from a Cas9 protein from Streptococcus pyogenes. In an aspect, the CRISPR-based nuclease can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65.


As used herein, “CRISPRa” refers to CRISPR Activation, which is using a dCas9 or dCas9-activator with a gRNA to increase transcription of a target gene.


As used herein, “CRISPRi” refers to CRISPR Interference, which is using a dCas9 or dCas9-repressor with a gRNA to repress/decrease transcription of a target gene.


As used herein, “dCas9” refers to enzymatically inactive form of Cas9, which can bind, but cannot cleave, DNA.


As used herein, “Protospacer Adjacent Motif” or “PAM” refers to a sequence adjacent to the target sequence that is necessary for Cas enzymes to bind target DNA.


Disclosed are the components to be used to prepare the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof as well the disclosed isolated nucleic acid molecules, disclosed pharmaceutical formulations, disclosed vectors, or any combination thereof used within the methods disclosed herein. These and other materials are disclosed herein, and it is understood that when combinations, subsets, interactions, groups, etc. of these materials are disclosed that while specific reference of each various individual and collective combinations and permutation of these compounds cannot be explicitly disclosed, each is specifically contemplated and described herein. For example, if a particular compound is disclosed and discussed and a number of modifications that can be made to a number of molecules including the compounds are discussed, specifically contemplated is each and every combination and permutation of the compound and the modifications that are possible unless specifically indicated to the contrary. Thus, if a class of molecules A, B, and C are disclosed as well as a class of molecules D, E, and F and an example of a combination molecule, A-D is disclosed, then even if each is not individually recited each is individually and collectively contemplated meaning combinations, A-E, A-F, B-D, B-E, B-F, C-D, C-E, and C-F are considered disclosed. Likewise, any subset or combination of these is also disclosed. Thus, for example, the sub-group of A-E, B-F, and C-E would be considered disclosed. This concept applies to all aspects of this application including, but not limited to, steps in methods of making and using the compositions of the invention. Thus, if there are a variety of additional steps that can be performed it is understood that each of these additional steps can be performed with any specific aspects or combination of aspects of the disclosed methods.


B. Compositions
1. Isolated Nucleic Acid Molecules

Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed VRER can have the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:










(SEQ ID NO: 15)



atggataaaaagtattctattggtttagacatcggcactaattccgttggatgggctgtcataaccgatgaatacaaagtaccttcaaagaaatt






taaggtgttggggaacacagaccgtcattcgattaaaaagaatcttatcggtgccctcctattcgatagtggcgaaacggcagaggcgactc





gcctgaaacgaaccgctcggagaaggtatacacgtcgcaagaaccgaatatgttacttacaagaaatttttagcaatgagatggccaaagtt





gacgattctttctttcaccgtttggaagagtccttccttgtcgaagaggacaagaaacatgaacggcaccccatctttggaaacatagtagatg





aggtggcatatcatgaaaagtacccaacgatttatcacctcagaaaaaagctagttgactcaactgataaagcggacctgaggttaatctact





tggctcttgcccatatgataaagttccgtgggcactttctcattgagggtgatctaaatccggacaactcggatgtcgacaaactgttcatcca





gttagtacaaacctataatcagttgtttgaagagaaccctataaatgcaagtggcgtggatgcgaaggctattcttagcgcccgcctctctaaa





tcccgacggctagaaaacctgatcgcacaattacccggagagaagaaaaatgggttgttcggtaaccttatagcgctctcactaggcctga





caccaaattttaagtcgaacttcgacttagctgaagatgccaaattgcagcttagtaaggacacgtacgatgacgatctcgacaatctactgg





cacaaattggagatcagtatgcggacttatttttggctgccaaaaaccttagcgatgcaatcctcctatctgacatactgagagttaatactgag





attaccaaggcgccgttatccgcttcaatgatcaaaaggtacgatgaacatcaccaagacttgacacttctcaaggccctagtccgtcagca





actgcctgagaaatataaggaaatattctttgatcagtcgaaaaacgggtacgcaggttatattgacggcggagcgagtcaagaggaattct





acaagtttatcaaacccatattagagaagatggatgggacggaagagttgcttgtaaaactcaatcgcgaagatctactgcgaaagcagcg





gactttcgacaacggtagcattccacatcaaatccacttaggcgaattgcatgctatacttagaaggcaggaggatttttatccgttcctcaaa





gacaatcgtgaaaagattgagaaaatcctaacctttcgcataccttactatgtgggacccctggcccgagggaactctcggttcgcatggat





gacaagaaagtccgaagaaacgattactccatggaattttgaggaagttgtcgataaaggtgcgtcagctcaatcgttcatcgagaggatga





ccaactttgacaagaatttaccgaacgaaaaagtattgcctaagcacagtttactttacgagtatttcacagtgtacaatgaactcacgaaagtt





aagtatgtcactgagggcatgcgtaaacccgcctttctaagcggagaacagaagaaagcaatagtagatctgttattcaagaccaaccgca





aagtgacagttaagcaattgaaagaggactactttaagaaaattgaatgcttcgattctgtcgagatctccggggtagaagatcgatttaatgc





gtcacttggtacgtatcatgacctcctaaagataattaaagataaggacttcctggataacgaagagaatgaagatatcttagaagatatagtg





ttgactcttaccctctttgaagatcgggaaatgattgaggaaagactaaaaacatacgctcacctgttcgacgataaggttatgaaacagttaa





agaggcgtcgctatacgggctggggacgattgtcgcggaaacttatcaacgggataagagacaagcaaagtggtaaaactattctcgattt





tctaaagagcgacggcttcgccaataggaactttatgcagctgatccatgatgactctttaaccttcaaagaggatatacaaaaggcacaggt





ttccggacaaggggactcattgcacgaacatattgcgaatcttgctggttcgccagccatcaaaaagggcatactccagacagtcaaagta





gtggatgagctagttaaggtcatgggacgtcacaaaccggaaaacattgtaatcgagatggcacgcgaaaatcaaacgactcagaaggg





gcaaaaaaacagtcgagagcggatgaagagaatagaagagggtattaaagaactgggcagccagatcttaaaggagcatcctgtggaa





aatacccaattgcagaacgagaaactttacctctattacctacaaaatggaagggacatgtatgttgatcaggaactggacataaaccgtttat





ctgattacgacgtcgatcacattgtaccccaatcctttttgaaggacgattcaatcgacaataaagtgcttacacgctcggataagaaccgag





ggaaaagtgacaatgttccaagcgaggaagtcgtaaagaaaatgaagaactattggcggcagctcctaaatgcgaaactgataacgcaaa





gaaagttcgataacttaactaaagctgagaggggggcttgtctgaacttgacaaggccggatttattaaacgtcagctcgtggaaacccgc





caaatcacaaagcatgttgcacagatactagattcccgaatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaagtaa





tcactttaaagtcaaaattggtgtcggacttcagaaaggattttcaattctataaagttagggagataaataactaccaccatgcgcacgacgc





ttatcttaatgccgtcgtagggaccgcactcattaagaaatacccgaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtcc





gtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagccaaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaatggggagacaggtgaaatcgtatgggataagggccgggactt





cgcgacggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaactgaggtgcagaccggagggttttcaaaggaatcgatt





cttccaaaaaggaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaagtacggtggcttcgtgagccctacagttgcct





attctgtcctagtagtggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaattattggggataacgattatggagcgc





tcgtcttttgaaaagaaccccatcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctcataattaaactaccaaagtatagt





ctgtttgagttagaaaatggccgaaaacggatgttggctagcgccagagagcttcaaaaggggaacgaactcgcactaccgtctaaatacg





tgaatttcctgtatttagcgtcccattacgagaagttgaaaggttcacctgaagataacgaacagaagcaactttttgttgagcagcacaaaca





ttatctcgacgaaatcatagagcaaatttcggaattcagtaagagagtcatcctagctgatgccaatctggacaaagtattaagcgcatacaa





caagcacagggataaacccatacgtgagcaggcggaaaatattatccatttgtttactcttaccaacctcggcgctccagccgcattcaagta





ttttgacacaacgatagatcgcaaagagtacagatctaccaaggaggtgctagacgcgacactgattcaccaatccatcacgggattatatg





aaactcggatagatttgtcacagcttgggggtgactga.






In an aspect, dCas9 can have the following sequence:









(SEQ ID NO: 16)


MDKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGA





LLFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHR





LEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKAD





LRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENP





INASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTP





NFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAI





LLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEI





FFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLR





KQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPY





YVGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDK





NLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVD





LLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI





IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQ





LKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDD





SLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKV





MGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHP





VENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDD





SIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNL





TKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLI





REVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKK





YPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEI





TLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEV





QTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVE





KGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPK





YSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPE





DNEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDK





PIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQ





SITGLYETRIDLSQLGGD.






In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, a disclosed DNMT3A can have the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 17)


PSRLQMFFANNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLV





LKDLGIQVDRYIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQE





WGPFDLVIGGSPCNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKE





GDDRPFFWLFENVVAMGVSDKRDISRFLESNPVMIDAKEVSAAHRARY





FWGNLPGMNRPLASTVNDKLELQECLEHGRIAKFSKVRTITTRSNSIK





QGKDQHFPVFMNEKEDILWCTEMERVFGFPVHYTDVSNMSRLARQRLL





GRSWSVPVIRHLFAPLKEYFACV.






In an aspect, a disclosed DNMT3A can have the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 18)


Ccccccggctccagatgttcttcgctaataaccacgaccaggaatttgac





cctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccg





ggtgctgtctctctttgatggaatcgctacagggctcctggtgctgaagg





acttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggac





tccatcacggtgggcatggtgcggcaccaggggaagatcatgtacgtcgg





ggacgtccgcagcgtcacacagaagcatatccaggagtggggcccattcg





atctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccct





gctcgcaagggcctctacgagggcactggccggctcttctttgagttcta





ccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttct





tctggctctttgagaatgtggtggccatgggcgttagtgacaagagggac





atctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagt





gtcagctgcacacagggcccgctacttctggggtaaccttcccggtatga





acaggccgttggcatccactgtgaatgataagctggagctgcaggagtgt





ctggagcatggcaggatagccaagttcagcaaagtgaggaccattactac





gaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttca





tgaatgagaaagaggacatcttatggtgcactgaaatggaaagggtattt





ggtttcccagtccactatactgacgtgtccaacatgagccgcttggcgag





gcagagactgctgggccggtcatggagcgtgccagtcatccgccacctct





tcgctccgctgaaggagtattttgcgtgtgtg.






In an aspect, at least one encoded polypeptide can comprise Kroppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed MeCP2 TRD can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 57)


atgtcggagggtgtgcaggtgaaaagggtcctggagaaaagtcctgggaa





gctccttgtcaagatgccttttcaaacttcgccagggggcaaggctgagg





ggggtggggccaccacatccacccaggtcatggtgatcaaacgccccggc





aggaagcgaaaagctgaggccgaccctcaggccattcccaagaaacgggg





ccgaaagccggggagtgtggtggcagccgctgccgccgaggccaaaaaga





aagccgtgaaggagtcttctatccgatctgtgcaggagacagtactcccc





atcaagaagcgcaagacccgggagtaa.






In an aspect, a disclosed MeCP2 TRD can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 58)


MSEGVQVKRVLEKSPGKLLVKMPFQTSPGGKAEGGGATTSTQVMVIKRPG





RKRKAEADPQAIPKKRGRKPGSVVAAAAAEAKKKAVKESSIRSVQETVLP





IKKRKTRE*.






In an aspect, a disclosed KRAB-MeCP2 repressor can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 62)


atgcggacactggtgaccttcaaggatgtatttgtggacttcaccaggga





ggagtggaagctgctggacactgctcagcagatcgtgtacagaaatgtga





tgctggagaactataagaacctggtttccttgggttatcagcttactaag





ccagatgtgatcctccggttggagaagggagaagagccctcgggaggtgg





ttcgggaggtggttcggagggtgtgcaggtgaaaagggtcctggagaaaa





gtcctgggaagctccttgtcaagatgccttttcaaacttcgccagggggc





aaggctgaggggggtggggccaccacatccacccaggtcatggtgatcaa





acgccccggcaggaagcgaaaagctgaggccgaccctcaggccattccca





agaaacggggccgaaagccggggagtgtggtggcagccgctgccgccgag





gccaaaaagaaagccgtgaaggagtcttctatccgatctgtgcaggagac





Agtactccccatcaagaagcgcaagacccgggagtaa.






In an aspect, a disclosed KRAB-MeCP2 repressor can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 63)


MRTLVTFKDVFVDFTREEWKLLDTAQQIVYRNVMLENYKNLVSLGYQLTK





PDVILRLEKGEEPSGGGSGGGSEGVQVKRVLEKSPGKLLVKMPFQTSPGG





KAEGGGATTSTQVMVIKRPGRKRKAEADPQAIPKKRGRKPGSVVAAAAAE





AKKKAVKESSIRSVQETVLPIKKRKTRE*.






In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed Cas endonuclease can be dCas9 and a disclosed polypeptide can be DNMT3A. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO: 19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed dCas9-DNMT3A fusion protein can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:









(SEQ ID NO: 19)


DKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGAL





LFDSGETAEATRLKRTARRRYTRRKNRICYLQEIFSNEMAKVDDSFFHRL





EESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKADL





RLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPI





NASGVDAKAILSARLSKSRRLENLIAQLPGEKKNGLFGNLIALSLGLTPN





FKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSDAIL





LSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIF





FDQSKNGYAGYIDGGASQEEFYKFIKPILEKMDGTEELLVKLNREDLLRK





QRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYY





VGPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKN





LPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGMRKPAFLSGEQKKAIVDL





LFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKII





KDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQL





KRRRYTGWGRLSRKLINGIRDKQSGKTILDFLKSDGFANRNFMQLIHDDS





LTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVKVM





GRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPV





ENTQLQNEKLYLYYLQNGRDMYVDQELDINRLSDYDVDAIVPQSFLKDDS





IDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLITQRKFDNLT





KAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIR





EVKVITLKSKLVSDFRKDFQFYKVREINNYHHAHDAYLNAVVGTALIKKY





PKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSNIMNFFKTEIT





LANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQ





TGGFSKESILPKRNSDKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEK





GKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKKDLIIKLPKY





SLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPED





NEQKQLFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKP





IREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDATLIHQS





ITGLYETRIDLSQLGGDKRPAATKKAGQAKKKKLEGGGGSGSPSRLQMFF





ANNHDQEFDPPKVYPPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDR





YIASEVCEDSITVGMVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSP





CNDLSIVNPARKGLYEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVV





AMGVSDKRDISRFLESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTV





NDKLELQECLEHGRIAKFSKVRTITTRSNSIKQGKDQHFPVFMNEKEDIL





WCTEMERVFGFPVHYTDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYF





AC.






In an aspect, a disclosed dCas9-DNMT3A fusion protein can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth:










(SEQ ID NO: 20)



gacaagaagtacagcatcggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaaga






aattcaaggtgctgggcaacaccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccga





ggccacccggctgaagagaaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgag





atggccaaggtggacgacagcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttc





ggcaacatcgtggacgaggtggcctaccacgagaagtaccccaccattaccacctgagaaagaaactggtggacagcaccgacaagg





ccgacctgcggctgatctatctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaaca





gcgacgtggacaagctgttcatccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgcc





aaggccatcctgtctgccagactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgtt





cggcaacctgattgccctgagcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagca





aggacacctacgacgacgacctggacaacctgctggcccagateggcgaccagtacgccgacctgtttctggccgccaagaacctgtcc





gacgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacga





gcaccaccaggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaa





cggctacgccggctacattgacggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccg





aggaactgctcgtgaagctgaacagagaggacctgctgcggaagcageggaccttegacaacggcagcatcccccaccagatccacct





gggagagctgcacgccattctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgacctt





ccgcatcccctactacgtgggccctctggccaggggaaacagcagattcgcctggatgaccagaaagagegaggaaaccatcaccccct





ggaacttcgaggaagtggtggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgag





aaggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgaga





aagcccgccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctga





aagaggactacttcaagaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacatacca





cgatctgctgaaaattatcaaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgt





ttgaggacagagagatgatcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggag





atacaccggctggggcaggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagt





ccgacggcttcgccaacagaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccg





gccagggcgatagcctgcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggt





ggacgagctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagg





gacagaagaacagccgcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtg





gaaaacacccagctgcagaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaa





ccggctgtccgactacgatgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcga





caagaaccggggcaagagcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagaga





cagctggtggaaacccggcagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagc





tgatccgggaagtgaaagtgatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaac





aactaccaccacgcccacgacgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgt





gtacggcgactacaaggtgtacgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttct





acagcaacatcatgaactttttcaagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaa





accggggagatcgtgtgggataagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagac





cgaggtgcagacaggcggcttcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggac





cctaagaagtacggcggcttcgacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaact





gaagagtgtgaaagagctgctggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggcta





caaagaagtgaaaaaggacctgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgc





cggcgaactgcagaagggaaacgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagg





gctcccccgaggataatgagcagaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttct





ccaagagagtgatcctggccgacgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggc





cgagaatatcatccacctgtttaccctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtaca





ccagcaccaaagaggtgctggacgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctggg





aggcgacaaaaggccggcggccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatcccc





ctcccggctccagatgttcttcgctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagc





ccatccgggtgctgtctctctttgatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcgg





aggtgtgtgaggactccatcacggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaa





gcatatccaggagtggggcccattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctct





acgagggcactggccggctcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctc





tttgagaatgtggtggccatgggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagt





gtcagctgcacacagggcccgctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctg





caggagtgtctggagcatggcaggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaaga





ccagcattttcctgtgttcatgaatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactg





acgtgtccaacatgagccgcttggcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaag





gagtattttgcgtgtgtg.






In an aspect, a disclosed SpCas9-dVRER-DNMT3A can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:










(SEQ ID NO: 37)



atggactataaggaccacgacggagactacaaggatcatgatattgattacaaagacgatgacgataagatggccccaaagaagaagcg






gaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatcggcctggccatcggcaccaactctgtgggctgggccgtg





atcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacagcatcaagaagaacctgatcggag





ccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagagaaccgccagaagaagatacaccagacggaagaaccgg





atctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgacagcttcttccacagactggaagagtccttcctggtggaag





aggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacctg





agaaagaaactggtggacagcaccgacaaggccgacctgcggctgatctatctggccctggcccacatgatcaagttccggggccactt





cctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcatccagctggtgcagacctacaaccagctgttcgagg





aaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaagagcagacggctggaaaatctgatcgc





ccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctgagcctgggcctgacccccaacttcaagagcaacttcga





cctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacgacctggacaacctgctggcccagateggcgaccagtac





gccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaaggcccc





cctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattgacggcggagccagccaggaagagttctacaagttca





tcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaacagagaggacctgctgcggaagcagcggacctt





cgacaacggcagcatcccccaccagatccacctgggagagctgcacgccattctgcggcggcaggaagatttttacccattcctgaagga





caaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgggccctctggccaggggaaacagcagattcgcctggat





gaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggtggacaagggcgcttccgcccagagcttcatcgagcgg





atgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataacgagctga





ccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaagaaaatcgagtgcttcgactccgtggaaatctccggcgtgg





aagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatcaaggacaaggacttcctggacaatgaggaaaacgagg





acattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatgatcgaggaacggctgaaaacctatgcccacctgttcga





cgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggcaggctgagccggaagctgatcaacggcatccgggaca





agcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatccacgacgacagcctga





cctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcctgcacgagcacattgccaatctggccggcagccccgc





cattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatc





gaaatggccagagagaaccagaccacccagaagggacagaagaacagccgcgagagaatgaagcggatcgaagagggcatcaaag





agctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaagctgtacctgtactacctgcagaatgg





gcgggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacgatgtggacgctatcgtgcctcagagctttctgaaggac





gactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagaggtcgtgaagaag





atgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaagttcgacaatctgaccaaggccgagagaggcggcct





gagcgaactggataaggccggcttcatcaagagacagctggtggaaacccggcagatcacaaagcacgtggcacagatactagattccc





gaatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaagtaatcactttaaagtcaaaattggtgtcggacttcagaaagg





attttcaattctataaagttagggagataaataactaccaccatgcgcacgacgcttatcttaatgccgtcgtagggaccgcactcattaaga





aatacccgaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtccgtaagatgatcgcgaaaagcgaacaggagataggc





aaggctacagccaaatacttcttttattctaacattatgaatttctttaagacggaaatcactctggcaaacggagagatacgcaaacgacct





ttaattgaaaccaatggggagacaggtgaaatcgtatgggataagggccgggacttcgcgacggtgagaaaagttttgtccatgccccaagt





caacatagtaaagaaaactgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaaggaatagtgataagctcatcgctcgta





aaaaggactgggacccgaaaaagtacggtggcttcgtgagccctacagttgcctattctgtcctagtagtggcaaaagttgagaagggaaa





atccaagaaactgaagtcagtcaaagaattattggggataacgattatggagcgctcgtcttttgaaaagaaccccatcgacttccttgaggc





gaaaggttacaaggaagtaaaaaaggatctcataattaaactaccaaagtatagtctgtttgagttagaaaatggccgaaaacggatgttgg





ctagcgccagagagcttcaaaaggggaacgaactcgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccattacgagaagttga





aaggttcacctgaagataacgaacagaagcaactttttgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcggaattca





gtaagagagtcatcctagctgatgccaatctggacaaagtattaagcgcatacaacaagcacagggataaacccatacgtgagcaggcgg





aaaatattatccatttgtttactcttaccaacctcggcgctccagccgcattcaagtattttgacacaacgatagatcgcaaagagtacagat





ctaccaaggaggtgctagacgcgacactgattcaccaatccatcacgggattatatgaaactcggatagatttgtcacagcttgggggtgacg





gatcccccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcgctaataaccac





gaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctctttgatggaatcgc





tacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatcacggtgggcatg





gtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcccattcgatctggt





gattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggctcttctttgagttct





accgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatgggcgttagtga





caagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggcccgctacttctgg





ggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatggcaggatagcc





aagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatgaatgagaaag





aggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttggcgaggcag





agactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtg.






In an aspect, a disclosed VRER-DNMT3A can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:









(SEQ ID NO: 38)


MAPKKKRKVGIHGVPAADKKYSIGLAIGTNSVGWAVITDEYKVPSKKFKV





LGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTRRKNRICYLQE





IFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPT





IYHLRKKLVDSTDKADLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKL





FIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLENLIAQLPGEKK





NGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGD





QYADLFLAAKNLSDAILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTL





LKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYKFIKPILEKMD





GTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLK





DNREKIEKILTFRIPYYVGPLARGNSRFAWMTRKSEETITPWNFEEVVDK





GASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELTKVKYVTEGM





RKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVE





DRFNASLGTYHDLLKIIKDKDFLDNEENEDILEDIVLTLTLFEDREMIEE





RLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQSGKTILDFLK





SDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHANLAGSPAIKK





GILQTVKVVDELVKVMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIE





EGIKELGSQILKEHPVENTQLQNEKLYLYYLONGRDMYVDQELDINRLSD





YDVDAIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQ





LLNAKLITQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQIL





DSRMNTKYDENDKLIREVKVITLKSKLVSDFRKDFQFYKVREINNYHHAH





DAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAK





YFFYSNIMNFFKTEITLAGEIRKRPLIETNGETGEIVWDKGRDFATVRKV





LSMPQVNIVKKTEVQTGGFSKESILPKRNSDKLIARKKDWDPKKYGGFVS





PTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKG





YKEVKKDLIIKLPKYSLFELENGRKRMLASARELQKGNLKGSPEDNEQKQ





LFVEQHKHYLDEIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQA





ENIIHLFTLTNLGAPAAFKYFDTTIDRKEYRSTKEVLDATLIHQSITGLY





ETRIDLSQLGGDGSPKKKVLEGGGGSGSPSRLQMFFANNHDQEFDPPKVY





PPVPAEKRKPIRVLSLFDGIATGLLVLKDLGIQVDRYIASEVCEDSITVG





MVRHQGKIMYVGDVRSVTQKHIQEWGPFDLVIGGSPCNDLSIVNPARKGL





YEGTGRLFFEFYRLLHDARPKEGDDRPFFWLFENVVAMGVSDKRDISRFL





ESNPVMIDAKEVSAAHRARYFWGNLPGMNRPLASTVNDKLELQECLEHRI





AKFSKVRTITTRSNSIKQGKDQHFPVFMNEKEDILWCTEMERVFGFPVHY





TDVSNMSRLARQRLLGRSWSVPVIRHLFAPLKEYFACV.






Disclosed herein is an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


2. Non-Viral Vectors

Disclosed herein is a non-viral vector comprising a disclosed isolated nucleic acid molecule.


Disclosed herein is a non-viral vector comprising a disclosed isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


Disclosed herein is a non-viral vector comprising a disclosed isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


In an aspect, a disclosed non-viral vector can be a polymer based vector, a peptide based vector, a lipid nanoparticle, a solid lipid nanoparticle, or a cationic lipid based vector.


In an aspect, a disclosed non-viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide. In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed non-viral vector can comprise one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed non-viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


3. Viral Vectors

Disclosed herein is a viral vector comprising a disclosed isolated nucleic acid molecule.


Disclosed herein is a viral vector comprising a disclosed isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


In an aspect, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide. In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed viral vector can comprise one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed viral vector can be an adenovirus vector, an AAV vector, a herpes simplex virus vector, a retrovirus vector, a lentivirus vector, and alphavirus vector, a flavivirus vector, a rhabdovirus vector, a measles virus vector, a Newcastle disease viral vector, a poxvirus vector, or a picornavirus vector. In an aspect, a disclosed viral vector can be a lentiviral vector.


Disclosed herein is a viral vector comprising a disclosed isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


In an aspect, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In a aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide. In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed viral vector can comprise one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed viral vector can be a lentiviral vector.


4. Lentiviral Vectors

Disclosed herein is a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


In an aspect, a disclosed lentiviral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO: 17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide. In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Kroppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed lentiviral vector can comprise one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed lentiviral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


Disclosed herein is a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


In an aspect, a disclosed lentiviral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide. In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed lentiviral vector can comprise one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed lentiviral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


5. Pharmaceutical Formulations

Disclosed herein is pharmaceutical formulation comprising a disclosed isolated nucleic acid molecule and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising a disclosed vector and a pharmaceutically acceptable carrier. Disclosed herein is pharmaceutical formulation comprising a disclosed lentiviral vector and a pharmaceutically acceptable carrier.


In an aspect, a disclosed formulation can comprise (i) one or more active agents, (ii) biologically active agents, (iii) one or more pharmaceutically active agents, (iv) one or more immune-based therapeutic agents, (v) one or more clinically approved agents, or (vi) a combination thereof. In an aspect, a disclosed composition can comprise one or more proteasome inhibitors. In an aspect, a disclosed composition can comprise one or more immunosuppressives or immunosuppressive agents. In an aspect, an immunosuppressive agent can be anti-thymocyte globulin (ATG), cyclosporine (CSP), mycophenolate mofetil (MMF), or a combination thereof. In an aspect, a disclosed formulation can comprise a RNA therapeutic. A RNA therapeutic can comprise RNA-mediated interference (RNAi) and/or antisense oligonucleotides (ASO). In an aspect, a disclosed formulation can comprise a disclosed small molecule.


6. Host Cells

Disclosed herein is a host cell comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


Disclosed herein is a host cell comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is a host cell comprising a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA.


Disclosed herein is a host cell comprising a lentiviral vector comprising an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA.


Disclosed herein is a host cell comprising plasmid comprising the sequence set forth in any one of SEQ ID NO:21-24, SEQ ID NO:29-36, SEQ ID NO:43-50, SEQ ID NO:53-56, SEQ ID NO:59-61.


In an aspect, a disclosed viral vector or a disclosed lentiviral vector in a disclosed host cell can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed fusion protein can encode a disclosed Cas endonuclease and a disclosed polypeptide. In an aspect, a disclosed fusion protein can comprise dCas9 and DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed fusion protein can comprise dCas9 and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed fusion protein can comprise dVRER and Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect, a disclosed viral vector or a disclosed lentiviral vector in a disclosed host cell can comprise one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector or a disclosed lentiviral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


7. Guide RNAs (gRNAs)


Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO: 14. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:25-SEQ ID NO:28. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:39-SEQ ID NO:42. Disclosed herein is a guide RNA comprising the sequence set forth in any one of SEQ ID NO:51-SEQ ID NO:52. Disclosed gRNAs are listed below.














SEQ




ID NO.
gRNA Sequence
Description

















5
gacagggggagccctataat
gRNA1 targeting promoter region of ApoE using




SpCas9





6
tcaggagagctactcggggt
gRNA2 targeting promoter region of ApoE using




SpCas9





7
actgggatgtaagccatagc
gRNA3 targeting promoter region of ApoE using




SpCas9





8
gttggagcttagaatgtgaa
gRNA4 targeting promoter region of ApoE using




SpCas9





9
gccctatccctgggggaggg
gRNA1 targeting promoter region of ApoE using VRER




Cas9





10
tcgggcttggggagaggagg
gRNA2 targeting promoter region of ApoE using VRER




Cas9





11
ctctccccaccccaccttct
gRNA3 targeting promoter region of ApoE using VRER




Cas9





12
tgtgaagggagaatgaggaa
gRNA4 targeting promoter region of ApoE using VRER




Cas9





13
ggcgaggagctgttcaccg
gRNA targeting GFP ORF using SpCas9





14
gccacaagttcagcgtgtcc
gRNA targeting GFP ORF using VRER-SpCas9





25
gacagggggagccctataat
gRNA1 cloned into pBK1026 and pBK1030 plasmids





26
tcaggagagctactcggggt
gRNA2 cloned into pBK1027 and pBK1031 plasmids





27
actgggatgtaagccatagc
gRNA3 cloned into pBK1028 and pBK1032 plasmids





28
gttggagcttagaatgtgaa
gRNA4 cloned into pBK1029 and pBK1033 plasmids





39
gccctatccctgggggaggg
gRNA1 cloned into pBK1105 and pBK1109 plasmids





40
tcgggcttggggagaggagg
gRNA2 cloned into pBK1106 and pBK1110 plasmids





41
ctctccccaccccaccttct
gRNA3 cloned into pBK1107 and pBK1111 plasmids





42
tgtgaagggagaatgaggaa
gRNA4 cloned into pBK1108 and pBK1112 plasmids





51
gggcgcggacatggaggacg
gRNA1 cloned into pBK1426 and pBK1428 plasmids





52
gggcgcggacatggaggacg
gRNA2 cloned into pBK1427 and pBK1429 plasmids









As known to the art, a gRNA provides the targeting of a CRISPR/Cas9-based epigenome modifying system. A guide RNA is a specific RNA sequence that recognizes the target DNA region of interest (such as, for example, APOE e4 allele) and directs the Cas endonuclease there for editing. The gRNA is made up of two parts: crispr RNA (crRNA), a 17-20 nucleotide sequence complementary to the target DNA, and a tracer RNA, which serves as a binding scaffold for the Cas nuclease. The CRISPR-associated (Cas) protein is a non-specific endonuclease, which can be directed to the specific DNA locus by a gRNA (where it makes a double-strand break).


In an aspect, a disclosed gRNA can serve to direct a disclosed endonucleases or a disclosed fusion product having an endonuclease to a target area of interest (such as, for example, the promoter of the APOE gene or the APOE e4 allele).


8. Plasmids

Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:21-SEQ ID NO:24. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:29-SEQ ID NO:36. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:43-SEQ ID NO:50. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:53-SEQ ID NO:56. Disclosed herein is a plasmid comprising the sequence set forth in any of SEQ ID NO:59-SEQ ID NO:61. Plasmids disclosed herein include but are not limited to those listed below.













SEQ ID NO
Plasmid Description







21
pBK546 carrying dCas9-DNMT3A fused transgene linked to puromycin



reporter via p2A cleavage signal


22
pBK539 carrying dCas9-DNMT3A fused transgene linked to GFP reporter via



p2A cleavage signal


23
pBK500 carrying all-in-one lentiviral vector containing fusion protein and



gRNA4


24
pBK744 carrying dCas9-DNMT3A fused transgene linked to GFP reporter via



p2A cleavage signal and carrying gRNA3 targeting rat/mouse intron Snca-



intron 1 sequences


29
pBK1026 carrying dCas9-(active) DNMT3A vector targeting promoter region



of ApoE gene and carrying gRNA1 and puromycin reporter separated via p2a



signal from DNMT3A and SpCas9 is present


30
pBK1027 carrying dCas9-(active) DNMT3A vector targeting promoter region



of ApoE gene and carrying gRNA2 and puromycin reporter separated via p2a



signal from DNMT3A and SpCas9 is present


31
pBK1028 carrying dCas9-(active) DNMT3A vector targeting promoter region



of ApoE gene and carrying gRNA3 and puromycin reporter separated via p2a



signal from DNMT3A and SpCas9 is present


32
pBK1029 carrying dCas9-(active) DNMT3A vector targeting promoter region



of ApoE gene and carrying gRNA4 and puromycin reporter separated via p2a



signal from DNMT3A and SpCas9 is present


33
pBK1030 carrying dCas9-(inactive) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA1 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


34
pBK1031 carrying dCas9-(inactive) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA2 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


35
pBK1032 carrying dCas9-(inactive) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA3 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


36
pBK1033 carrying dCas9-(inactive) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA4 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


43
pBK1105 carrying dCas9-VRER (active) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA1 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


44
pBK1106 carrying dCas9-VRER (active) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA2 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


45
pBK1107 carrying dCas9-VRER (active) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA3 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


46
pBK1108 carrying dCas9-VRER (active) DNMT3A vector targeting promoter



region of ApoE gene and carrying gRNA4 and puromycin reporter separated



via p2a signal from DNMT3A and SpCas9 is present


47
pBK1109 carrying dCas9-VRER (inactive) DNMT3A vector targeting



promoter region of ApoE gene and carrying gRNA1 and puromycin reporter



separated via p2a signal from DNMT3A and SpCas9 is present


48
pBK1110 carrying dCas9-VRER (inactive) DNMT3A vector targeting



promoter region of ApoE gene and carrying gRNA2 and puromycin reporter



separated via p2a signal from DNMT3A and SpCas9 is present


49
pBK1111 carrying dCas9-VRER (inactive) DNMT3A vector targeting



promoter region of ApoE gene and carrying gRNA3 and puromycin reporter



separated via p2a signal from DNMT3A and SpCas9 is present


50
pBK1112 carrying dCas9-VRER (inactive) DNMT3A vector targeting



promoter region of ApoE gene and carrying gRNA3 and puromycin reporter



separated via p2a signal from DNMT3A and SpCas9 is present


53
pBK1426 carrying dCas9-VRER (active) DNMT3A vector targeting SNP



region of ApoE4 and carrying gRNA1 and puromycin reporter separated via



p2a signal from DNMT3A and VRER-SpCas9 is present


54
pBK1427 carrying dCas9-VRER (active) DNMT3A vector targeting SNP



region of ApoE4 and carrying gRNA2 and puromycin reporter separated via



p2a signal from DNMT3A and VRER-SpCas9 is present


55
pBK1428 carrying dCas9-VRER (inactive) DNMT3A vector targeting SNP



region of ApoE4 and carrying gRNA1 and puromycin reporter separated via



p2a signal from DNMT3A and VRER-SpCas9 is present


56
pBK1429 carrying dCas9-VRER DNMT3A vector targeting SNP region of



ApoE4 and carrying gRNA2 and puromycin reporter separated via p2a signal



from DNMT3A and VRER-SpCas9 is present


59
pBK1531 carrying a Lentiviral vector with dCas9-VRER-MeCP2



Transcription Repression Domain (TRD) and gRNA1


60
pBK1532 carrying a Lentiviral vector with dCas9-VRER-MeCP2



Transcription Repression Domain (TRD) and gRNA2


61
pBK1536 carrying a Lentiviral vector with dCas9-VRER-MeCP2



Transcription Repression Domain (TRD) without gRNA









In an aspect, a disclosed pBK546 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 21)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataatt





tcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatatct





tgtggaaaggacgaaacaccggagacgtgtacacgtctctgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttg





aaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcaga





gcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaactg





ggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcg





caacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattaca





aagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatcg





gcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaac





accgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagaga





accgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgaca





gcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgagg





tggcctaccacgagaagtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatctat





ctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcc





cacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgegttcgccgactaccccgccacgcgcca





caccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggccc





gcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcgg





ccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgageggcteggcttcaccgtcaccgcc





gacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggatt





acaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgc





ttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgt





gcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgcc





acggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaa





tcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct





ccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattc





actcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaa





cccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagac





ccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttg





cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg





tgtcattctattctggggggtggggggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggt





gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttettcccttcctttctcgccacgttcgccg





gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtga





tggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgg





aacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaat





ttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc





tcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccat





agtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcag





aggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagc





ttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaacta





aaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggctcgggt





tctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtg





ccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtg





cacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttc





cgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaa





ataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtc





tgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtc





gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctc





actgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggata





acgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgc





ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgg





aagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagc





tcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagcc





agttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggt





catgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccag





ccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta





gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggtt





cccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg





ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa





ccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaacttta





aaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgca





cccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg





cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaat





gtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK539 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 22)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataat





ttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatat





cttgtggaaaggacgaaacaccggagacgtgtacacgtctctgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttg





aaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcaga





gcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaactg





ggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttcg





caacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattaca





aagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatcg





gcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaac





accgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagaga





accgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgaca





gcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgagg





tggcctaccacgagaagtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatctat





ctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcategagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggggccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgatggtgag





caagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggc





gagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgt





gaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaagg





ctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtga





accgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgt





ctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgcc





gaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagca





aagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaag





taaagcggccgcgtcgacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtgga





tacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgagga





gttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctc





ctttccgggactttcgctttccccctccctattgccacggeggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttg





ggcactgacaattccgtggtgttgtcggggaagctgacgtcctttccatggctgctcgcctgtgttgccacctggattctgcgcgggacgtc





cttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctettccgcgtcttegccttcgc





cctcagacgagtcggatctccctttgggccgcctccccgcctggaattcgagctcggtacctttaagaccaatgacttacaaggcagctgta





gatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctc





tctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaag





tagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtagtagttcatgtc





atcttattattcagtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttataatggttacaaataaagcaa





tagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggctctagc





tatcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcagag





gccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctagggacgtacccaattcgccctatagtga





gtcgtattacgcgcgctcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatcc





ccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgc





cctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagegcccgctcctttcg





ctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggca





cctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgt





tctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggccta





ttggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtgccggccatgaccgagatcg





gcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtggccgaggagcaggactgacac





gtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatgatcctccagcg





cggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaa





ataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcgacctctagctagagct





tggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctg





gggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatg





aatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctg





cggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaag





gccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga





cgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccga





ccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgta





ggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactategtcttgagtccaacc





cggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttga





agtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagct





cttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagat





cctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcaccta





gatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacct





atctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggcccca





gtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaag





tggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgt





tgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcc





cccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcag





cactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggc





gaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcg





gggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcac





cagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactctt





cctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK500 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 23)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggat





agcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaaga





attattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctccca





accccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttgc





atatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataa





tttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttata





tatcttgtggaaaggacgaaacaccgctgctcagggtagatagctggttttagagctagaaatagcaagttaaaataaggctagtccgttatcaa





cttgaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcag





agcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaact





gggaaagtgatgtcgtgtactggctccgcctttttcccgagggtgggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggttctagagcgctgccaccatggacaagaagtacagcatcggcctggacatcggcac





caactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacagc





atcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagagaaccgccagaagaaga





tacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgacagcttcttccacagactg





gaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgaggtggcctaccacgaga





agtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatctatctggccctggcccac





atgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcatccagctggtgcag





acctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaagagca





gacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggaaacctgattgccctgagcctgggcctgacc





cccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacgacctggacaacctgct





ggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcgacatcctgagagtga





acaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgaccctgctgaaagctctc





gtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattgacggcggagccag





ccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaacagagaggacc





tgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccattctgcggcggcagga





agatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgggccctctggccagg





ggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggtggacaagggcgctt





ccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcacagcctgctgtacgag





tacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagcggcgagcagaaaaa





ggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaagaaaatcgagtgcttcga





ctccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatcaaggacaaggacttc





ctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatgatcgaggaacggctg





aaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggcaggctgagccggaag





ctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaacagaaacttcatgcag





ctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcctgcacgagcacattgc





caatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaagtgatgggccggcac





aagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccgcgagagaatgaagcg





gatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaagctgta





cctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacgatgtggaccatatcgtg





cctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaagagcgacaacgtgccct





ccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaagttcgacaatctgacc





aaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccggcagatcacaaagcac





gtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagtgatcaccctgaagtc





caagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacgacgcctacctgaac





gccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgtacgacgtgcggaa





gatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaactttttcaagaccgagatta





ccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtgggataagggccgggatt





ttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggcttcagcaaagagtct





atcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttcgacagccccaccg





tggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgctggggatcaccatca





tggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacctgatcatcaagctgc





ctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaaacgaactggccctg





ccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagcagaaacagctgtttgt





ggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccgacgctaatctggaca





aagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttaccctgaccaatctgg





gagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctggacgccaccctgatc





caccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaagcgacctgccgccacaaagaaggct





ggacaggctaagaagaagaaagattacaaagacgatgacgataagggatccggcgcaacaaacttctctctgctgaaacaagccggag





atgtcgaagagaatcctggaccgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccct





cgccgccgcgttcgccgactaccccgccacgcgccacacegtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaact





cttcctcacgcgcgtcgggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagag





cgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatgga





aggcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtct





gggcagcgccgtcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacct





ccccttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgcatgaccegcaagcccggt





gcctgaacgcgttaagtcgacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctat





gtggatacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctct





ttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacc





tgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcg





gctgttgggcactgacaattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcggga





cgtccttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttcegcgtcttcgcctt





cgccctcagacgagtcggatctccctttgggccgcctccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactt





tttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagacca





gatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccg





tctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagc





ctcgactgtgccttctagttgccagccatctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcct





aataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggggggggcaggacagcaagggggaggattg





ggaagacaatagcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccc





cacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctc





ctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgct





ttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttg





gagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgcc





gatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtc





cccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggca





gaagtatgcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgcccagttcegcc





cattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggctt





ttttggaggcctaggcttttgcaaaaagctcccgggagcttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcata





gtatatcggcatagtataatacgacaaggtgaggaactaaaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtc





gccggagcggtcgagttctggaccgaccggctcgggttctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgt





gaccctgttcatcagcgcggtccaggaccaggtggtgccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtac





gccgagtggtcggaggtcgtgtccacgaacttccgggacgcctccgggccggccatgaccgagatcggcgagcagccgtgggggcg





ggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattcca





ccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttc





gcccaccccaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattc





tagttgtggtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgt





ttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaa





ctcacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggag





aggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactc





aaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccg





taaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaa





cccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgt





ccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctg





tgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccac





tggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctaca





ctagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccacc





gctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagt





tttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcg





ttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacc





cacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctcca





tccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtg





tcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggtta





gctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatg





ccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtc





aatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttac





cgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaaca





ggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatc





agggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacc





tgac.






In an aspect, a disclosed pBK744 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 24)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttgca





tatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataattt





cttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatatct





tgtggaaaggacgaaacaccgtttttcaagcggaaacgctagttttagagctagaaatagcaagttaaaataaggctagtccgttatcaactt





gaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcag





agcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaact





gggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatc





ggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaa





caccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagag





aaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgac





agcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgag





gtggcctaccacgagaagtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatcta





tctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggggccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgatggtgag





caagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgtaaacggccacaagttcagcgtgtccggc





gagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccaccggcaagctgcccgtgccctggcccaccctcgt





gaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatgaagcagcacgacttcttcaagtccgccatgcccgaagg





ctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaagacccgcgccgaggtgaagttcgagggcgacaccctggtga





accgcatcgagctgaagggcatcgacttcaaggaggacggcaacatcctggggcacaagctggagtacaactacaacagccacaacgt





ctatatcatggccgacaagcagaagaacggcatcaaggtgaacttcaagatccgccacaacatcgaggacggcagcgtgcagctcgcc





gaccactaccagcagaacacccccatcggcgacggccccgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagca





aagaccccaacgagaagcgcgatcacatggtcctgctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaag





taaagcggccgcgtcgacaatcaacctctggattacaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtgga





tacgctgctttaatgcctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgagg





agttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctc





ctttccgggactttcgctttccccctccctattgccacggeggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttg





ggcactgacaattccgtggtgttgtcggggaagctgacgtcctttccatggctgctcgcctgtgttgccacctggattctgcgcgggacgtc





cttctgctacgtcccttcggccctcaatccagcggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgc





cctcagacgagtcggatctccctttgggccgcctccccgcctggaattcgagctcggtacctttaagaccaatgacttacaaggcagctgta





gatcttagccactttttaaaagaaaaggggggactggaagggctaattcactcccaacgaagacaagatctgctttttgcttgtactgggtctc





tctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaag





tagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtagtagttcatgtc





atcttattattcagtatttataacttgcaaagaaatgaatatcagagagtgagaggaacttgtttattgcagcttataatggttacaaataaagcaa





tagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctggctctag





ctatcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcaga





ggccgaggccgcctcggcctctgagctattccagaagtagtgaggaggcttttttggaggcctagggacgtacccaattcgccctatagtga





gtcgtattacgcgcgctcactggccgtcgttttacaacgtcgtgactgggaaaaccctggcgttacccaacttaatcgccttgcagcacatcc





ccctttcgccagctggcgtaatagcgaagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatgggacgcgc





cctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcg





ctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggca





cctcgaccccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgtt





ctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggccta





ttggttaaaaaatgagctgatttaacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttaggtgccggccatgaccgagatcg





gcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtggccgaggagcaggactgacac





gtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggatgatcctccagcg





cggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaat





aaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcgacctctagctagagcttgg





cgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcataaagtgtaaagcctg





gggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatg





aatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgttcggctg





cggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaag





gccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga





cgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctctcctgttccga





ccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagctcacgctgtaggtatctcagttcggtgta





ggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatccggtaactatcgtcttgagtccaacc





cggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttcttga





agtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagccagttaccttcggaaaaagagttggtagct





cttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaaaggatctcaagaagat





cctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcaccta





gatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgcttaatcagtgaggcacct





atctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggagggcttaccatctggcccca





gtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccagccagccggaagggccgagcgcagaag





tggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaacgttgt





tgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagttacatgatcc





cccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggttatggcag





cactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcggc





gaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcg





gggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttttactttcac





cagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaaatgttgaatactcatactctt





cctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggttcc





gcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1026 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 29)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattategtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataat





ttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatat





cttgtggaaaggacgaaacaccggacagggggagccctataatgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaac





ttgaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggca





gagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaac





tgggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatc





ggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaa





caccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagag





aaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgac





agcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgag





gtggcctaccacgagaagtaccccaccattaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatcta





tctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcc





cacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgegttcgccgactaccccgccacgcgcca





caccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggccc





gcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcgg





ccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgageggcteggcttcaccgtcaccgcc





gacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggattaca





aaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgc





ttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtg





gtgtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctcccta





ttgccacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaa





tcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct





ccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattc





actcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaa





cccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagac





ccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttg





cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg





 tgtcattctattctggggggtggggggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggt





gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg





gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtga





tggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgg





aacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaa





atttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc





tcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccat





agtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcag





aggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagc





ttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaacta





aaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggctcgggt





tctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtg





ccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtg





cacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttc





cgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaa





taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtc





tgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtc





gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctc





actgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggata





acgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgc





ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgg





aagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagc





tcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagcc





agttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggt





catgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccag





ccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta





gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggtt





cccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg





ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa





ccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaacttta





aaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgca





cccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg





cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaat





gtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1027 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 30)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataat





ttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatat





cttgtggaaaggacgaaacaccgtcaggagagctactcggggtgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaact





tgaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcag





agcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaact





gggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatc





ggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaa





caccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagag





aaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgac





agcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgag





gtggcctaccacgagaagtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatcta





tctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcc





cacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgegttegccgactaccccgccacgcgcca





caccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggccc





gcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcgg





ccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgageggctcggcttcaccgtcaccgcc





gacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggatt





acaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgc





ttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggt





gtgcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgcc





acggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaa





tcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct





ccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattc





actcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaa





cccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagac





ccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttg





cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg





tgtcattctattctggggggtggggggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggt





gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg





gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtga





tggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgg





aacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaa





atttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc





tcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccat





agtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcag





aggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagc





ttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaacta





aaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggctcgggt





tctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtg





ccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtg





cacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttc





cgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaa





taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtc





tgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtc





gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctc





actgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggata





acgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgc





ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgg





aagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagc





tcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagcc





agttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggt





catgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccag





ccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta





gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggtt





cccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg





ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa





ccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaacttta





aaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgca





cccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg





cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaat





gtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1028 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:










(SEQ ID NO: 31)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataat





ttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatat





cttgtggaaaggacgaaacaccgactgggatgtaagccatagcgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaact





tgaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcag





agcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaact





gggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatc





ggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaa





caccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagag





aaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgac





agcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgag





gtggcctaccacgagaagtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatcta





tctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagateggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcc





cacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgegttcgccgactaccccgccacgcgcca





caccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggccc





gcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcgg





ccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgageggctcggcttcaccgtcaccgcc





gacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggatt





acaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgc





ttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgt





gcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgcc





acggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaa





tcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct





ccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattc





actcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaa





cccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagac





ccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttg





cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg





tgtcattctattctggggggtggggggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggt





gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg





gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtga





tggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgg





aacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaat





ttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc





tcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccat





agtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcag





aggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagc





ttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaacta





aaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggctcgggt





tctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtg





ccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtg





cacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttc





cgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaa





taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtc





tgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtc





gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctc





actgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggata





acgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgc





ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgg





aagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagc





tcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagcc





agttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggt





catgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccag





ccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta





gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggtt





cccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg





ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa





ccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaacttta





aaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgca





cccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg





cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaa





tgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1029 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:










(SEQ ID NO: 32)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatcgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatggggggacgttaacggggggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataat





ttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatat





cttgtggaaaggacgaaacaccggttggagcttagaatgtgaagttttagagctagaaatagcaagttaaaataaggctagtccgttatcaactt





gaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggcag





agcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaact





gggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatc





ggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaa





caccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagag





aaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgac





gtggcctaccacgagaagtaccccaccattaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatcta





tctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagatcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcc





cacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgegttcgccgactaccccgccacgcgcca





caccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggccc





gcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcgg





ccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgageggcteggcttcaccgtcaccgcc





gacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggatt





acaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgc





ttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggt





gcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgetttccccctccctattgcc





gtacggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaa





tcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct





ccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattc





actcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaa





cccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagac





ccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttg





cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg





tgtcattctattctggggggtggggggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggt





gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccg





gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtga





tggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgg





aacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaa





atttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc





tcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccat





agtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcag





aggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagc





ttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaacta





aaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggctcgggt





tctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtg





ccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtg





cacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttc





cgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaa





taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtc





tgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtc





gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctc





actgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggata





acgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgc





ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgg





aagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagc





tcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagcc





agttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggt





catgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccag





ccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta





gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggtt





cccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg





ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa





ccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaacttta





aaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgca





cccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg





cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaa





tgtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1030 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth










(SEQ ID NO: 33)



gtcgacggatcgggagatctcccgatcccctatggtgcactctcagtacaatctgctctgatgccgcatagttaagccagtatctgctccctg






cttgtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatgaagaatctgctt





agggttaggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgacattgattattgactagttattaatagtaatcaattacggg





gtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgacccccgcccatt





gacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacgtcaatgggtggagtatttacggtaaactgcccacttg





gcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgac





cttatgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggata





gcggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt





cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcagcgcgttttgcctgtactgggtct





ctctggttagaccagatctgagcctgggagctctctggctaactagggaacccactgcttaagcctcaataaagcttgccttgagtgcttcaa





gtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagacccttttagtcagtgtggaaaatctctagcagtggcgcccgaa





cagggacttgaaagcgaaagggaaaccagaggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaagaggcgagg





ggcggcgactggtgagtacgccaaaaattttgactagcggaggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaagaaaaaatataaattaaaacatatagtatgggcaagcaggga





gctagaacgattcgcagttaatcctggcctgttagaaacatcagaaggctgtagacaaatactgggacagctacaaccatcccttcagacag





gatcagaagaacttagatcattatataatacagtagcaaccctctattgtgtgcatcaaaggatagagataaaagacaccaaggaagctttag





acaagatagaggaagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatcttcagacctggaggaggagatatgagg





gacaattggagaagtgaattatataaatataaagtagtaaaaattgaaccattaggagtagcacccaccaaggcaaagagaagagtggtgc





agagagaaaaaagagcagtgggaataggagctttgttccttgggttcttgggagcagcaggaagcactatgggcgcagcgtcaatgacg





ctgacggtacaggccagacaattattgtctggtatagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagcatctgttgca





actcacagtctggggcatcaagcagctccaggcaagaatcctggctgtggaaagatacctaaaggatcaacagctcctggggatttgggg





ttgctctggaaaactcatttgcaccactgctgtgccttggaatgctagttggagtaataaatctctggaacagatttggaatcacacgacctgg





atggagtgggacagagaaattaacaattacacaagcttaatacactccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaag





aattattggaattagataaatgggcaagtttgtggaattggtttaacataacaaattggctgtggtatataaaattattcataatgatagtaggag





gcttggtaggtttaagaatagtttttgctgtactttctatagtgaatagagttaggcagggatattcaccattatgtttcagacccacctcccaac





cccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagagagagacagagacagatccattcgattagtgaacggatc





ggcactgcgtgcgccaattctgcagacaaatggcagtattcatccacaattttaaaagaaaaggggggattggggggtacagtgcagggg





aaagaatagtagacataatagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaattcaaaattttcgggtttattacaggg





acagcagagatccagtttggttaattaatgggcgggacgttaacggggcggaacggtaccgagggcctatttcccatgattccttcatatttg





catatacgatacaaggctgttagagagataattagaattaatttgactgtaaacacaaagatattagtacaaaatacgtgacgtagaaagtaataat





ttcttgggtagtttgcagttttaaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaagtatttcgatttcttggctttatatatct





tgtggaaaggacgaaacaccggacagggggagccctataatgttttagagctagaaatagcaagttaaaataaggctagtccgttatcaac





ttgaaaaagtggcaccgagtcggtgcttttttgaattcgctagctaggtcttgaaaggagtgggaattggctccggtgcccgtcagtgggca





gagcgcacatcgcccacagtccccgagaagttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgcggggtaaac





tgggaaagtgatgtcgtgtactggctccgcctttttcccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttctttttc





gcaacgggtttgccgccagaacacaggaccggtgccaccatggactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggtatccacggagtcccagcagccgacaagaagtacagcatc





ggcctggccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaaggtgcccagcaagaaattcaaggtgctgggcaa





caccgaccggcacagcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaacagccgaggccacccggctgaagag





aaccgccagaagaagatacaccagacggaagaaccggatctgctatctgcaagagatcttcagcaacgagatggccaaggtggacgac





agcttcttccacagactggaagagtccttcctggtggaagaggataagaagcacgagcggcaccccatcttcggcaacatcgtggacgag





gtggcctaccacgagaagtaccccaccatctaccacctgagaaagaaactggtggacagcaccgacaaggccgacctgcggctgatcta





tctggccctggcccacatgatcaagttccggggccacttcctgatcgagggcgacctgaaccccgacaacagcgacgtggacaagctgtt





catccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaacgccagcggcgtggacgccaaggccatcctgtctgcca





gactgagcaagagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaagaatggcctgttcggcaacctgattgccctg





agcctgggcctgacccccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagctgagcaaggacacctacgacgacg





acctggacaacctgctggcccagateggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgacgccatcctgctgagcg





acatcctgagagtgaacaccgagatcaccaaggcccccctgagcgcctctatgatcaagagatacgacgagcaccaccaggacctgacc





ctgctgaaagctctcgtgcggcagcagctgcctgagaagtacaaagagattttcttcgaccagagcaagaacggctacgccggctacattg





acggcggagccagccaggaagagttctacaagttcatcaagcccatcctggaaaagatggacggcaccgaggaactgctcgtgaagct





gaacagagaggacctgctgcggaagcagcggaccttcgacaacggcagcatcccccaccagatccacctgggagagctgcacgccatt





ctgcggcggcaggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaagatcctgaccttccgcatcccctactacgtgg





gccctctggccaggggaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcaccccctggaacttcgaggaagtggt





ggacaagggcgcttccgcccagagcttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaaggtgctgcccaagcac





agcctgctgtacgagtacttcaccgtgtataacgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgccttcctgagc





ggcgagcagaaaaaggccatcgtggacctgctgttcaagaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaaga





aaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcggttcaacgcctccctgggcacataccacgatctgctgaaaattatc





aaggacaaggacttcctggacaatgaggaaaacgaggacattctggaagatatcgtgctgaccctgacactgtttgaggacagagagatg





atcgaggaacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcagctgaagcggcggagatacaccggctggggca





ggctgagccggaagctgatcaacggcatccgggacaagcagtccggcaagacaatcctggatttcctgaagtccgacggcttcgccaac





agaaacttcatgcagctgatccacgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtccggccagggcgatagcct





gcacgagcacattgccaatctggccggcagccccgccattaagaagggcatcctgcagacagtgaaggtggtggacgagctcgtgaaa





gtgatgggccggcacaagcccgagaacatcgtgatcgaaatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagccagatcctgaaagaacaccccgtggaaaacacccagctgca





gaacgagaagctgtacctgtactacctgcagaatggggggatatgtacgtggaccaggaactggacatcaaccggctgtccgactacga





tgtggacgctatcgtgcctcagagctttctgaaggacgactccatcgacaacaaggtgctgaccagaagcgacaagaaccggggcaaga





gcgacaacgtgccctccgaagaggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagctgattacccagagaaa





gttcgacaatctgaccaaggccgagagaggcggcctgagcgaactggataaggccggcttcatcaagagacagctggtggaaacccgg





cagatcacaaagcacgtggcacagatcctggactcccggatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaagt





gatcaccctgaagtccaagctggtgtccgatttccggaaggatttccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacg





acgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccctaagctggaaagcgagttcgtgtacggcgactacaaggtgt





acgacgtgcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgccaagtacttcttctacagcaacatcatgaacttttt





caagaccgagattaccctggccaacggcgagatccggaagcggcctctgatcgagacaaacggcgaaaccggggagatcgtgtggga





taagggccgggattttgccaccgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccgaggtgcagacaggcggct





tcagcaaagagtctatcctgcccaagaggaacagcgataagctgatcgccagaaagaaggactgggaccctaagaagtacggcggcttc





gacagccccaccgtggcctattctgtgctggtggtggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagctgct





ggggatcaccatcatggaaagaagcagcttcgagaagaatcccatcgactttctggaagccaagggctacaaagaagtgaaaaaggacc





tgatcatcaagctgcctaagtactccctgttcgagctggaaaacggccggaagagaatgctggcctctgccggcgaactgcagaagggaa





acgaactggccctgccctccaaatatgtgaacttcctgtacctggccagccactatgagaagctgaagggctcccccgaggataatgagca





gaaacagctgtttgtggaacagcacaagcactacctggacgagatcatcgagcagatcagcgagttctccaagagagtgatcctggccga





cgctaatctggacaaagtgctgtccgcctacaacaagcaccgggataagcccatcagagagcaggccgagaatatcatccacctgtttac





cctgaccaatctgggagcccctgccgccttcaagtactttgacaccaccatcgaccggaagaggtacaccagcaccaaagaggtgctgg





acgccaccctgatccaccagagcatcaccggcctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggccggcgg





ccacgaaaaaggccggacaggccaaaaagaaaaagctcgagggcggaggcgggagcggatccccctcccggctccagatgttcttcg





ctaataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcccatccgggtgctgtctctcttt





gatggaatcgctacagggctcctggtgctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtgtgaggactccatca





cggtgggcatggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtggggcc





cattcgatctggtgattgggggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagggagatgatcgccccttcttctggctctttgcgaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcagctgcacacagggccc





gctacttctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaatgataagctggagctgcaggagtgtctggagcatgg





caggatagccaagttcagcaaagtgaggaccattactacgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgttcatg





aatgagaaagaggacatcttatggtgcactgaaatggaaagggtatttggtttcccagtccactatactgacgtgtccaacatgagccgcttg





gcgaggcagagactgctgggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccg





gccggcccggatccggcgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaatcctggaccgaccgagtacaagcc





cacggtgcgcctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgccacgcgcca





caccgtcgatccggaccgccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccgagatcggccc





gcgcatggccgagttgagcggttcccggctggccgcgcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgctccccggagtggaggcgg





ccgagcgcgccggggtgcccgccttcctggagacctccgcgccccgcaacctccccttctacgageggcteggcttcaccgtcaccgcc





gacgtcgaggtgcccgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctctggatt





acaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgcctttgtatcatgctattgc





ttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtggcgtggtgt





gcactgtgtttgctgacgcaacccccactggttggggcattgccaccacctgtcagctcctttccgggactttcgctttccccctccctattgcc





acggcggaactcatcgccgcctgccttgcccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaaa





tcatcgtcctttccttggctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccgcct





ccccgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagccactttttaaaagaaaaggggggactggaagggctaattc





actcccaacgaagacaagatctgctttttgcttgtactgggtctctctggttagaccagatctgagcctgggagctctctggctaactagggaa





cccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagagatccctcagac





ccttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttg





cccctcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtctgagtagg





tgtcattctattctggggggtggggggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggtatccccacgcgccctgtagcggcgcattaagcgcggcgggt





gtggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttctegccacgttcgccg





gctttccccgtcaagctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtga





tggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtggactcttgttccaaactgg





aacaacactcaaccctatctcggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaat





ttaacgcgaattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc





tcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccat





agtcccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaattttttttatttatgcag





aggccgaggccgcctctgcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagc





ttgtatatccattttcggatctgatcagcacgtgttgacaattaatcatcggcatagtatatcggcatagtataatacgacaaggtgaggaacta





aaccatggccaagttgaccagtgccgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctggaccgaccggctcgggt





tctcccgggacttcgtggaggacgacttcgccggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggaccaggtggtg





ccggacaacaccctggcctgggtgtgggtgcgcggcctggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtggggggggagttcgccctgcgcgacccggccggcaactgcgtg





cacttcgtggccgaggagcaggactgacacgtgctacgagatttcgattccaccgccgccttctatgaaaggttgggcttcggaatcgttttc





cgggacgccggctggatgatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttattgcagcttataatggttacaaa





taaagcaatagcatcacaaatttcacaaataaagcatttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatcatgtc





tgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcgctcactgcccgctttccagtc





gggaaacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctc





actgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggttatccacagaatcaggggata





acgcaggaaagaacatgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccataggctccgc





ccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaacccgacaggactataaagataccaggcgtttccccctgg





aagctccctcgtgcgctctcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctcatagc





tcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacggctacactagaagaacagtatttggtatctgcgctctgctgaagcc





agttaccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacgaaaactcacgttaagggattttggt





catgagattatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctccagatttatcagcaataaaccag





ccagccggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagta





gttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttggtatggcttcattcagctccggtt





cccaacgatcaaggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgttgtcagaagtaagttgg





ccgcagtgttatcactcatggttatggcagcactgcataattctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaa





ccaagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgccacatagcagaacttta





aaagtgctcatcattggaaaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgtaacccactcgtgca





cccaactgatcttcagcatcttttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataaggg





cgacacggaaatgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggttattgtctcatgagcggatacatatttgaat





gtatttagaaaaataaacaaataggggttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1031 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 34)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cgtcaggagagctactcggggtgttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatcctggactcccg





gatgaacactaagtacgacgagaatgacaagctgatccgggaagtgaa





agtgatcaccctgaagtccaagctggtgtccgatttccggaaggattt





ccagttttacaaagtgcgcgagatcaacaactaccaccacgcccacga





cgcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccc





taagctggaaagcgagttcgtgtacggcgactacaaggtgtacgacgt





gcggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgc





caagtacttcttctacagcaacatcatgaactttttcaagaccgagat





taccctggccaacggcgagatccggaagcggcctctgatcgagacaaa





cggcgaaaccggggagatcgtgtgggataagggccgggattttgccac





cgtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagac





cgaggtgcagacaggcggcttcagcaaagagtctatcctgcccaagag





gaacagcgataagctgatcgccagaaagaaggactgggaccctaagaa





gtacggcggcttcgacagccccaccgtggcctattctgtgctggtggt





ggccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaaga





gctgctggggatcaccatcatggaaagaagcagcttcgagaagaatcc





catcgactttctggaagccaagggctacaaagaagtgaaaaaggacct





gatcatcaagctgcctaagtactccctgttcgagctggaaaacggccg





gaagagaatgctggcctctgccggcgaactgcagaagggaaacgaact





ggccctgccctccaaatatgtgaacttcctgtacctggccagccacta





tgagaagctgaagggctcccccgaggataatgagcagaaacagctgtt





tgtggaacagcacaagcactacctggacgagatcatcgagcagatcag





cgagttctccaagagagtgatcctggccgacgctaatctggacaaagt





gctgtccgcctacaacaagcaccgggataagcccatcagagagcaggc





cgagaatatcatccacctgtttaccctgaccaatctgggagcccctgc





cgccttcaagtactttgacaccaccatcgaccggaagaggtacaccag





caccaaagaggtgctggacgccaccctgatccaccagagcatcaccgg





cctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaag





gccggcggccacgaaaaaggccggacaggccaaaaagaaaaagctcga





gggcggaggcgggagcggatccccctcccggctccagatgttcttcgc





taataaccacgaccaggaatttgaccctccaaaggtttacccacctgt





cccagctgagaagaggaagcccatccgggtgctgtctctctttgatgg





aatcgctacagggctcctggtgctgaaggacttgggcattcaggtgga





ccgctacattgcctcggaggtgtgtgaggactccatcacggtgggcat





ggtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgt





cacacagaagcatatccaggagtggggcccattcgatctggtgattgg





gggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaaggg





cctctacgagggcactggccggctcttctttgagttctaccgcctcct





gcatgatgcgcggcccaaggagggagatgatcgccccttcttctggct





ctttgcgaatgtggtggccatgggcgttagtgacaagagggacatctc





gcgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtc





agctgcacacagggcccgctacttctggggtaaccttcccggtatgaa





caggccgttggcatccactgtgaatgataagctggagctgcaggagtg





tctggagcatggcaggatagccaagttcagcaaagtgaggaccattac





tacgaggtcaaactccataaagcagggcaaagaccagcattttcctgt





gttcatgaatgagaaagaggacatcttatggtgcactgaaatggaaag





ggtatttggtttcccagtccactatactgacgtgtccaacatgagccg





cttggcgaggcagagactgctgggccggtcatggagcgtgccagtcat





ccgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccgg





ccggcccggatccggcgcaacaaacttctctctgctgaaacaagccgg





agatgtcgaagagaatcctggaccgaccgagtacaagcccacggtgcg





cctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgc





cgcgttcgccgactaccccgccacgcgccacaccgtcgatccggaccg





ccacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgt





cgggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggt





ggcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgc





cgagatcggcccgcgcatggccgagttgagcggttcccggctggccgc





gcagcaacagatggaaggcctcctggcgccgcaccggcccaaggagcc





cgcgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaa





gggtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcg





cgccggggtgcccgccttcctggagacctccgcgccccgcaacctccc





cttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcc





cgaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaac





gcgttaagtcgacaatcaacctctggattacaaaatttgtgaaagatt





gactggtattcttaactatgttgctccttttacgctatgtggatacgc





tgctttaatgcctttgtatcatgctattgcttcccgtatggctttcat





tttctcctccttgtataaatcctggttgctgtctctttatgaggagtt





gtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctga





cgcaacccccactggttggggcattgccaccacctgtcagctcctttc





cgggactttcgctttccccctccctattgccacggcggaactcatcgc





cgcctgccttgcccgctgctggacaggggctcggctgttgggcactga





caattccgtggtgttgtcggggaaatcatcgtcctttccttggctgct





cgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgt





cccttcggccctcaatccagcggaccttccttcccgcggcctgctgcc





ggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcg





gatctccctttgggccgcctccccgcgtcgactttaagaccaatgact





tacaaggcagctgtagatcttagccactttttaaaagaaaagggggga





ctggaagggctaattcactcccaacgaagacaagatctgctttttgct





tgtactgggtctctctggttagaccagatctgagcctgggagctctct





ggctaactagggaacccactgcttaagcctcaataaagcttgccttga





gtgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactag





agatccctcagacccttttagtcagtgtggaaaatctctagcagggcc





cgtttaaacccgctgatcagcctcgactgtgccttctagttgccagcc





atctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgc





cactcccactgtcctttcctaataaaatgaggaaattgcatcgcattg





tctgagtaggtgtcattctattctggggggtggggggggcaggacagc





aagggggaggattgggaagacaatagcaggcatgctggggatgcggtg





ggctctatggcttctgaggcggaaagaaccagctggggctctaggggg





tatccccacgcgccctgtagcggcgcattaagcgcggcgggtgtggtg





gttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgct





cctttcgctttcttcccttcctttctcgccacgttcgccggctttccc





cgtcaagctctaaatcgggggctccctttagggttccgatttagtgct





ttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgt





agtgggccatcgccctgatagacggtttttcgccctttgacgttggag





tccacgttctttaatagtggactcttgttccaaactggaacaacactc





aaccctatctcggtctattcttttgatttataagggattttgccgatt





tcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcg





aattaattctgtggaatgtgtgtcagttagggtgtggaaagtccccag





gctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcag





caaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgc





aaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactc





cgcccatcccgcccctaactccgcccagttccgcccattctccgcccc





atggctgactaattttttttatttatgcagaggccgaggccgcctctg





cctctgagctattccagaagtagtgaggaggcttttttggaggcctag





gcttttgcaaaaagctcccgggagcttgtatatccattttcggatctg





atcagcacgtgttgacaattaatcatcggcatagtatatcggcatagt





ataatacgacaaggtgaggaactaaaccatggccaagttgaccagtgc





cgttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctg





gaccgaccggctcgggttctcccgggacttcgtggaggacgacttcgc





cggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccagga





ccaggtggtgccggacaacaccctggcctgggtgtgggtgcgcggcct





ggacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccg





ggacgcctccgggccggccatgaccgagatcggcgagcagccgtgggg





ggggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtg





gccgaggagcaggactgacacgtgctacgagatttcgattccaccgcc





gccttctatgaaaggttgggcttcggaatcgttttccgggacgccggc





tggatgatcctccagcgcggggatctcatgctggagttcttcgcccac





cccaacttgtttattgcagcttataatggttacaaataaagcaatagc





atcacaaatttcacaaataaagcatttttttcactgcattctagttgt





ggtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcg





acctctagctagagcttggcgtaatcatggtcatagctgtttcctgtg





tgaaattgttatccgctcacaattccacacaacatacgagccggaagc





ataaagtgtaaagcctggggtgcctaatgagtgagctaactcacatta





attgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgc





cagctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgt





attgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtc





gttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacgg





ttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaa





ggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgttt





ttccataggctccgcccccctgacgagcatcacaaaaatcgacgctca





agtcagaggtggcgaaacccgacaggactataaagataccaggcgttt





ccccctggaagctccctcgtgcgctctcctgttccgaccctgccgctt





accggatacctgtccgcctttctcccttcgggaagcgtggcgctttct





catagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctcc





aagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcc





ttatccggtaactatcgtcttgagtccaacccggtaagacacgactta





tcgccactggcagcagccactggtaacaggattagcagagcgaggtat





gtaggcggtgctacagagttcttgaagtggtggcctaactacggctac





actagaagaacagtatttggtatctgcgctctgctgaagccagttacc





ttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgct





ggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaa





aaaggatctcaagaagatcctttgatcttttctacggggtctgacgct





cagtggaacgaaaactcacgttaagggattttggtcatgagattatca





aaaaggatcttcacctagatccttttaaattaaaaatgaagttttaaa





tcaatctaaagtatatatgagtaaacttggtctgacagttaccaatgc





ttaatcagtgaggcacctatctcagcgatctgtctatttcgttcatcc





atagttgcctgactccccgtcgtgtagataactacgatacgggagggc





ttaccatctggccccagtgctgcaatgataccgcgagacccacgctca





ccggctccagatttatcagcaataaaccagccagccggaagggccgag





cgcagaagtggtcctgcaactttatccgcctccatccagtctattaat





tgttgccgggaagctagagtaagtagttcgccagttaatagtttgcgc





aacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgttt





ggtatggcttcattcagctccggttcccaacgatcaaggcgagttaca





tgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccg





atcgttgtcagaagtaagttggccgcagtgttatcactcatggttatg





gcagcactgcataattctcttactgtcatgccatccgtaagatgcttt





tctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatg





cggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcg





ccacatagcagaactttaaaagtgctcatcattggaaaacgttcttcg





gggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatg





taacccactcgtgcacccaactgatcttcagcatcttttactttcacc





agcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaag





ggaataagggcgacacggaaatgttgaatactcatactcttccttttt





caatattattgaagcatttatcagggttattgtctcatgagcggatac





atatttgaatgtatttagaaaaataaacaaataggggttccgcgcaca





tttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1032 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 35)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggggtaggcgtgtacggtgggaggtctatataagcag





cgcgttttgcctgtactgggtctctctggttagaccagatctgagcct





gggagctctctggctaactagggaacccactgcttaagcctcaataaa





gcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact





ctggtaactagagatccctcagacccttttagtcagtgtggaaaatct





ctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccaga





ggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag





aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcgg





aggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaa





gaaaaaatataaattaaaacatatagtatgggcaagcagggagctaga





acgattcgcagttaatcctggcctgttagaaacatcagaaggctgtag





acaaatactgggacagctacaaccatcccttcagacaggatcagaaga





acttagatcattatataatacagtagcaaccctctattgtgtgcatca





aaggatagagataaaagacaccaaggaagctttagacaagatagagga





agagcaaaaaaaagtaagaccaccgcacagcaagcggccgctgatctt





cagacctggaggaggagatatgagggacaattggagaagtgaattata





taaatataaagtagtaaaaattgaaccattaggagtagcacccaccaa





ggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatagg





agctttgttccttgggttcttgggagcagcaggaagcactatgggcgc





agcgtcaatgacgctgacggtacaggccagacaattattgtctggtat





agtgcagcagcagaacaatttgctgagggctattgaggcgcaacagca





tctgttgcaactcacagtctggggcatcaagcagctccaggcaagaat





cctggctgtggaaagatacctaaaggatcaacagctcctggggatttg





gggttgctctggaaaactcatttgcaccactgctgtgccttggaatgc





tagttggagtaataaatctctggaacagatttggaatcacacgacctg





gatggagtgggacagagaaattaacaattacacaagcttaatacactc





cttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaatt





attggaattagataaatgggcaagtttgtggaattggtttaacataac





aaattggctgtggtatataaaattattcataatgatagtaggaggctt





ggtaggtttaagaatagtttttgctgtactttctatagtgaatagagt





taggcagggatattcaccattatcgtttcagacccacctcccaacccc





gaggggacccgacaggcccgaaggaatagaagaagaaggtggagagag





agacagagacagatccattcgattagtgaacggatcggcactgcgtgc





gccaattctgcagacaaatggcagtattcatccacaattttaaaagaa





aaggggggattggggggtacagtgcaggggaaagaatagtagacataa





tagcaacagacatacaaactaaagaattacaaaaacaaattacaaaaa





ttcaaaattttcgggtttattacagggacagcagagatccagtttggt





taattaatggggggacgttaacggggcggaacggtaccgagggcctat





ttcccatgattccttcatatttgcatatacgatacaaggctgttagag





agataattagaattaatttgactgtaaacacaaagatattagtacaaa





atacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaa





aattatgttttaaaatggactatcatatgcttaccgtaacttgaaagt





atttcgatttcttggctttatatatcttgtggaaaggacgaaacaccg





actgggatgtaagccatagcgttttagagctagaaatagcaagttaaa





ataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc





ttttttgaattcgctagctaggtcttgaaaggagtgggaattggctcc





ggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaag





ttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgc





ggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttccc





gaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttc





tttttcgcaacgggtttgccgccagaacacaggaccggtgccaccatg





gactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggt





atccacggagtcccagcagccgacaagaagtacagcatcggcctggcc





atcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaag





gtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacagc





atcaagaagaacctgatcggagccctgctgttcgacagcggcgaaaca





gccgaggccacccggctgaagagaaccgccagaagaagatacaccaga





cggaagaaccggatctgctatctgcaagagatcttcagcaacgagatg





gccaaggtggacgacagcttcttccacagactggaagagtccttcctg





gtggaagaggataagaagcacgagcggcaccccatcttcggcaacatc





gtggacgaggtggcctaccacgagaagtaccccaccatctaccacctg





agaaagaaactggtggacagcaccgacaaggccgacctgcggctgatc





tatctggccctggcccacatgatcaagttccggggccacttcctgatc





gagggcgacctgaaccccgacaacagcgacgtggacaagctgttcatc





cagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaac





gccagcggcgtggacgccaaggccatcctgtctgccagactgagcaag





agcagacggctggaaaatctgatcgcccagctgcccggcgagaagaag





aatggcctgttcggcaacctgattgccctgagcctgggcctgaccccc





aacttcaagagcaacttcgacctggccgaggatgccaaactgcagctg





agcaaggacacctacgacgacgacctggacaacctgctggcccagatc





ggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgac





gccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaag





gcccccctgagcgcctctatgatcaagagatacgacgagcaccaccag





gacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaag





tacaaagagattttcttcgaccagagcaagaacggctacgccggctac





attgacggcggagccagccaggaagagttctacaagttcatcaagccc





atcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaac





agagaggacctgctgcggaagcagcggaccttcgacaacggcagcatc





ccccaccagatccacctgggagagctgcacgccattctgcggcggcag





gaagatttttacccattcctgaaggacaaccgggaaaagatcgagaag





atcctgaccttccgcatcccctactacgtgggccctctggccagggga





aacagcagattcgcctggatgaccagaaagagcgaggaaaccatcacc





ccctggaacttcgaggaagtggtggacaagggcgcttccgcccagagc





ttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaag





gtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataac





gagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgcc





ttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaag





accaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaag





aaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcgg





ttcaacgcctccctgggcacataccacgatctgctgaaaattatcaag





gacaaggacttcctggacaatgaggaaaacgaggacattctggaagat





atcgtgctgaccctgacactgtttgaggacagagagatgatcgaggaa





cggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcag





ctgaagcggcggagatacaccggctggggcaggctgagccggaagctg





atcaacggcatccgggacaagcagtccggcaagacaatcctggatttc





ctgaagtccgacggcttcgccaacagaaacttcatgcagctgatccac





gacgacagcctgacctttaaagaggacatccagaaagcccaggtgtcc





ggccagggcgatagcctgcacgagcacattgccaatctggccggcagc





cccgccattaagaagggcatcctgcagacagtgaaggtggtggacgag





ctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcgaa





atggccagagagaaccagaccacccagaagggacagaagaacagccgc





gagagaatgaagcggatcgaagagggcatcaaagagctgggcagccag





atcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaag





ctgtacctgtactacctgcagaatggggggatatgtacgtggaccagg





aactggacatcaaccggctgtccgactacgatgtggacgctatcgtgc





ctcagagctttctgaaggacgactccatcgacaacaaggtgctgacca





gaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagagg





tcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagc





tgattacccagagaaagttcgacaatctgaccaaggccgagagaggcg





gcctgagcgaactggataaggccggcttcatcaagagacagctggtgg





aaacccggcagatcacaaagcacgtggcacagatcctggactcccgga





tgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaag





tgatcaccctgaagtccaagctggtgtccgatttccggaaggatttcc





agttttacaaagtgcgcgagatcaacaactaccaccacgcccacgacg





cctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtacccta





agctggaaagcgagttcgtgtacggcgactacaaggtgtacgacgtgc





ggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgcca





agtacttcttctacagcaacatcatgaactttttcaagaccgagatta





ccctggccaacggcgagatccggaagcggcctctgatcgagacaaacg





gcgaaaccggggagatcgtgtgggataagggccgggattttgccaccg





tgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagaccg





aggtgcagacaggcggcttcagcaaagagtctatcctgcccaagagga





acagcgataagctgatcgccagaaagaaggactgggaccctaagaagt





acggcggcttcgacagccccaccgtggcctattctgtgctggtggtgg





ccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagagc





tgctggggatcaccatcatggaaagaagcagcttcgagaagaatccca





tcgactttctggaagccaagggctacaaagaagtgaaaaaggacctga





tcatcaagctgcctaagtactccctgttcgagctggaaaacggccgga





agagaatgctggcctctgccggcgaactgcagaagggaaacgaactgg





ccctgccctccaaatatgtgaacttcctgtacctggccagccactatg





agaagctgaagggctcccccgaggataatgagcagaaacagctgtttg





tggaacagcacaagcactacctggacgagatcatcgagcagatcagcg





agttctccaagagagtgatcctggccgacgctaatctggacaaagtgc





tgtccgcctacaacaagcaccgggataagcccatcagagagcaggccg





agaatatcatccacctgtttaccctgaccaatctgggagcccctgccg





ccttcaagtactttgacaccaccatcgaccggaagaggtacaccagca





ccaaagaggtgctggacgccaccctgatccaccagagcatcaccggcc





tgtacgagacacggatcgacctgtctcagctgggaggcgacaaaaggc





cggcggccacgaaaaaggccggacaggccaaaaagaaaaagctcgagg





gcggaggcgggagcggatccccctcccggctccagatgttcttcgcta





ataaccacgaccaggaatttgaccctccaaaggtttacccacctgtcc





cagctgagaagaggaagcccatccgggtgctgtctctctttgatggaa





tcgctacagggctcctggtgctgaaggacttgggcattcaggtggacc





gctacattgcctcggaggtgtgtgaggactccatcacggtgggcatgg





tgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtca





cacagaagcatatccaggagtggggcccattcgatctggtgattgggg





gcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggcc





tctacgagggcactggccggctcttctttgagttctaccgcctcctgc





atgatgcgcggcccaaggagggagatgatcgccccttcttctggctct





ttgcgaatgtggtggccatgggcgttagtgacaagagggacatctcgc





gatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtcag





ctgcacacagggcccgctacttctggggtaaccttcccggtatgaaca





ggccgttggcatccactgtgaatgataagctggagctgcaggagtgtc





tggagcatggcaggatagccaagttcagcaaagtgaggaccattacta





cgaggtcaaactccataaagcagggcaaagaccagcattttcctgtgt





tcatgaatgagaaagaggacatcttatggtgcactgaaatggaaaggg





tatttggtttcccagtccactatactgacgtgtccaacatgagccgct





tggcgaggcagagactgctgggccggtcatggagcgtgccagtcatcc





gccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccggcc





ggcccggatccggcgcaacaaacttctctctgctgaaacaagccggag





atgtcgaagagaatcctggaccgaccgagtacaagcccacggtgcgcc





tcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgccg





cgttcgccgactaccccgccacgcgccacaccgtcgatccggaccgcc





acatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtcg





ggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtgg





cggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgccg





agatcggcccgcgcatggccgagttgagcggttcccggctggccgcgc





agcaacagatggaaggcctcctggcgccgcaccggcccaaggagcccg





cgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaagg





gtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcgcg





ccggggtgcccgccttcctggagacctccgcgccccgcaacctcccct





tctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgcccg





aaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacgc





gttaagtcgacaatcaacctctggattacaaaatttgtgaaagattga





ctggtattcttaactatgttgctccttttacgctatgtggatacgctg





ctttaatgcctttgtatcatgctattgcttcccgtatggctttcattt





tctcctccttgtataaatcctggttgctgtctctttatgaggagttgt





ggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacg





caacccccactggttggggcattgccaccacctgtcagctcctttccg





ggactttcgctttccccctccctattgccacggcggaactcatcgccg





cctgccttgcccgctgctggacaggggctcggctgttgggcactgaca





attccgtggtgttgtcggggaaatcatcgtcctttccttggctgctcg





cctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcc





cttcggccctcaatccagcggaccttccttcccgcggcctgctgccgg





ctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcgga





tctccctttgggccgcctccccgcgtcgactttaagaccaatgactta





caaggcagctgtagatcttagccactttttaaaagaaaaggggggact





ggaagggctaattcactcccaacgaagacaagatctgctttttgcttg





tactgggtctctctggttagaccagatctgagcctgggagctctctgg





ctaactagggaacccactgcttaagcctcaataaagcttgccttgagt





gcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactagag





atccctcagacccttttagtcagtgtggaaaatctctagcagggcccg





tttaaacccgctgatcagcctcgactgtgccttctagttgccagccat





ctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgcca





ctcccactgtcctttcctaataaaatgaggaaattgcatcgcattgtc





tgagtaggtgtcattctattctggggggtggggggggcaggacagcaa





gggggaggattgggaagacaatagcaggcatgctggggatgcggtggg





ctctatggcttctgaggcggaaagaaccagctggggctctagggggta





tccccacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggt





tacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcc





tttcgctttcttcccttcctttctcgccacgttcgccggctttccccg





tcaagctctaaatcgggggctccctttagggttccgatttagtgcttt





acggcacctcgaccccaaaaaacttgattagggtgatggttcacgtag





tgggccatcgccctgatagacggtttttcgccctttgacgttggagtc





cacgttctttaatagtggactcttgttccaaactggaacaacactcaa





ccctatctcggtctattcttttgatttataagggattttgccgatttc





ggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaa





ttaattctgtggaatgtgtgtcagttagggtgtggaaagtccccaggc





tccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagca





accaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaa





agcatgcatctcaattagtcagcaaccatagtcccgcccctaactccg





cccatcccgcccctaactccgcccagttccgcccattctccgccccat





ggctgactaattttttttatttatgcagaggccgaggccgcctctgcc





tctgagctattccagaagtagtgaggaggcttttttggaggcctaggc





ttttgcaaaaagctcccgggagcttgtatatccattttcggatctgat





cagcacgtgttgacaattaatcatcggcatagtatatcggcatagtat





aatacgacaaggtgaggaactaaaccatggccaagttgaccagtgccg





ttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctgga





ccgaccggctcgggttctcccgggacttcgtggaggacgacttcgccg





gtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggacc





aggtggtgccggacaacaccctggcctgggtgtgggtgcgcggcctgg





acgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccggg





acgcctccgggccggccatgaccgagatcggcgagcagccgtgggggg





ggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtggc





cgaggagcaggactgacacgtgctacgagatttcgattccaccgccgc





cttctatgaaaggttgggcttcggaatcgttttccgggacgccggctg





gatgatcctccagcgcggggatctcatgctggagttcttcgcccaccc





caacttgtttattgcagcttataatggttacaaataaagcaatagcat





cacaaatttcacaaataaagcatttttttcactgcattctagttgtgg





tttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcgac





ctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgtg





aaattgttatccgctcacaattccacacaacatacgagccggaagcat





aaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaat





tgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgcca





gctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgtat





tgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcgt





tcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggtt





atccacagaatcaggggataacgcaggaaagaacatgtgagcaaaagg





ccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgttttt





ccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaag





tcagaggtggcgaaacccgacaggactataaagataccaggcgtttcc





ccctggaagctccctcgtgcgctctcctgttccgaccctgccgcttac





cggatacctgtccgcctttctcccttcgggaagcgtggcgctttctca





tagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctccaa





gctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcctt





atccggtaactatcgtcttgagtccaacccggtaagacacgacttatc





gccactggcagcagccactggtaacaggattagcagagcgaggtatgt





aggcggtgctacagagttcttgaagtggtggcctaactacggctacac





tagaagaacagtatttggtatctgcgctctgctgaagccagttacctt





cggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctgg





tagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaa





aggatctcaagaagatcctttgatcttttctacggggtctgacgctca





gtggaacgaaaactcacgttaagggattttggtcatgagattatcaaa





aaggatcttcacctagatccttttaaattaaaaatgaagttttaaatc





aatctaaagtatatatgagtaaacttggtctgacagttaccaatgctt





aatcagtgaggcacctatctcagcgatctgtctatttcgttcatccat





agttgcctgactccccgtcgtgtagataactacgatacgggagggctt





accatctggccccagtgctgcaatgataccgcgagacccacgctcacc





ggctccagatttatcagcaataaaccagccagccggaagggccgagcg





cagaagtggtcctgcaactttatccgcctccatccagtctattaattg





ttgccgggaagctagagtaagtagttcgccagttaatagtttgcgcaa





cgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttgg





tatggcttcattcagctccggttcccaacgatcaaggcgagttacatg





atcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgat





cgttgtcagaagtaagttggccgcagtgttatcactcatggttatggc





agcactgcataattctcttactgtcatgccatccgtaagatgcttttc





tgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgcg





gcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgcc





acatagcagaactttaaaagtgctcatcattggaaaacgttcttcggg





gcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgta





acccactcgtgcacccaactgatcttcagcatcttttactttcaccag





cgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaaggg





aataagggcgacacggaaatgttgaatactcatactcttcctttttca





atattattgaagcatttatcagggttattgtctcatgagcggatacat





atttgaatgtatttagaaaaataaacaaataggggttccgcgcacatt





tccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1033 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 36)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggggagtatttacggtaaactgcccacttggcagtacatcaagt





gtatcatatgccaagtacgccccctattgacgtcaatgacggtaaatg





gcccgcctggcattatgcccagtacatgaccttatgggactttcctac





ttggcagtacatctacgtattagtcatcgctattaccatggtgatgcg





gttttggcagtacatcaatgggcgtggatagcggtttgactcacgggg





atttccaagtctccaccccattgacgtcaatgggagtttgttttggca





ccaaaatcaacgggactttccaaaatgtcgtaacaactccgccccatt





gacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcag





cgcgttttgcctgtactgggtctctctggttagaccagatctgagcct





gggagctctctggctaactagggaacccactgcttaagcctcaataaa





gcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact





ctggtaactagagatccctcagacccttttagtcagtgtggaaaatct





ctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccaga





ggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag





aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcgg





aggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaa





gaaaaaatataaattaaaacatatagtatgggcaagcagggagctaga





acgattcgcagttaatcctggcctgttagaaacatcagaaggctgtag





acaaatactgggacagctacaaccatcccttcagacaggatcagaaga





acttagatcattatataatacagtagcaaccctctattgtgtgcatca





aaggatagagataaaagacaccaaggaagctttagacaagatagagga





agagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggcggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





ggttggagcttagaatgtgaagttttagagctagaaatagcaagttaa





aataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtg





cttttttgaattcgctagctaggtcttgaaaggagtgggaattggctc





cggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaa





gttggggggaggggtcggcaattgatccggtgcctagagaaggtggcg





cggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcc





cgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgtt





ctttttcgcaacgggtttgccgccagaacacaggaccggtgccaccat





ggactataaggaccacgacggagactacaaggatcatgatattgatta





caaagacgatgacgataagatggccccaaagaagaagcggaaggtcgg





tatccacggagtcccagcagccgacaagaagtacagcatcggcctggc





catcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaa





ggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacag





catcaagaagaacctgatcggagccctgctgttcgacagcggcgaaac





agccgaggccacccggctgaagagaaccgccagaagaagatacaccag





acggaagaaccggatctgctatctgcaagagatcttcagcaacgagat





ggccaaggtggacgacagcttcttccacagactggaagagtccttcct





ggtggaagaggataagaagcacgagcggcaccccatcttcggcaacat





cgtggacgaggtggcctaccacgagaagtaccccaccatctaccacct





gagaaagaaactggtggacagcaccgacaaggccgacctgcggctgat





ctatctggccctggcccacatgatcaagttccggggccacttcctgat





cgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcat





ccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaa





cgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaa





gagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaa





gaatggcctgttcggcaacctgattgccctgagcctgggcctgacccc





caacttcaagagcaacttcgacctggccgaggatgccaaactgcagct





gagcaaggacacctacgacgacgacctggacaacctgctggcccagat





cggcgaccagtacgccgacctgtttctggccgccaagaacctgtccga





cgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaa





ggcccccctgagcgcctctatgatcaagagatacgacgagcaccacca





ggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaa





gtacaaagagattttcttcgaccagagcaagaacggctacgccggcta





cattgacggcggagccagccaggaagagttctacaagttcatcaagcc





catcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaa





cagagaggacctgctgcggaagcagcggaccttcgacaacggcagcat





cccccaccagatccacctgggagagctgcacgccattctgcggcggca





ggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaa





gatcctgaccttccgcatcccctactacgtgggccctctggccagggg





aaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcac





cccctggaacttcgaggaagtggtggacaagggcgcttccgcccagag





cttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaa





ggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataa





cgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgc





cttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaa





gaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcg





gttcaacgcctccctgggcacataccacgatctgctgaaaattatcaa





ggacaaggacttcctggacaatgaggaaaacgaggacattctggaaga





tatcgtgctgaccctgacactgtttgaggacagagagatgatcgagga





acggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagca





gctgaagcggcggagatacaccggctggggcaggctgagccggaagct





gatcaacggcatccgggacaagcagtccggcaagacaatcctggattt





cctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcca





cgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtc





cggccagggcgatagcctgcacgagcacattgccaatctggccggcag





ccccgccattaagaagggcatcctgcagacagtgaaggtggtggacga





gctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcga





aatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcca





gatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaa





gctgtacctgtactacctgcagaatggggggatatgtacgtggaccag





gaactggacatcaaccggctgtccgactacgatgtggacgctatcgtg





cctcagagctttctgaaggacgactccatcgacaacaaggtgctgacc





agaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagag





gtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaag





ctgattacccagagaaagttcgacaatctgaccaaggccgagagaggc





ggcctgagcgaactggataaggccggcttcatcaagagacagctggtg





gaaacccggcagatcacaaagcacgtggcacagatcctggactcccgg





atgaacactaagtacgacgagaatgacaagctgatccgggaagtgaaa





gtgatcaccctgaagtccaagctggtgtccgatttccggaaggatttc





cagttttacaaagtgcgcgagatcaacaactaccaccacgcccacgac





gcctacctgaacgccgtcgtgggaaccgccctgatcaaaaagtaccct





aagctggaaagcgagttcgtgtacggcgactacaaggtgtacgacgtg





cggaagatgatcgccaagagcgagcaggaaatcggcaaggctaccgcc





aagtacttcttctacagcaacatcatgaactttttcaagaccgagatt





accctggccaacggcgagatccggaagcggcctctgatcgagacaaac





ggcgaaaccggggagatcgtgtgggataagggccgggattttgccacc





gtgcggaaagtgctgagcatgccccaagtgaatatcgtgaaaaagacc





gaggtgcagacaggcggcttcagcaaagagtctatcctgcccaagagg





aacagcgataagctgatcgccagaaagaaggactgggaccctaagaag





tacggcggcttcgacagccccaccgtggcctattctgtgctggtggtg





gccaaagtggaaaagggcaagtccaagaaactgaagagtgtgaaagag





ctgctggggatcaccatcatggaaagaagcagcttcgagaagaatccc





atcgactttctggaagccaagggctacaaagaagtgaaaaaggacctg





atcatcaagctgcctaagtactccctgttcgagctggaaaacggccgg





aagagaatgctggcctctgccggcgaactgcagaagggaaacgaactg





gccctgccctccaaatatgtgaacttcctgtacctggccagccactat





gagaagctgaagggctcccccgaggataatgagcagaaacagctgttt





gtggaacagcacaagcactacctggacgagatcatcgagcagatcagc





gagttctccaagagagtgatcctggccgacgctaatctggacaaagtg





ctgtccgcctacaacaagcaccgggataagcccatcagagagcaggcc





gagaatatcatccacctgtttaccctgaccaatctgggagcccctgcc





gccttcaagtactttgacaccaccatcgaccggaagaggtacaccagc





accaaagaggtgctggacgccaccctgatccaccagagcatcaccggc





ctgtacgagacacggatcgacctgtctcagctgggaggcgacaaaagg





ccggcggccacgaaaaaggccggacaggccaaaaagaaaaagctcgag





ggcggaggcgggagcggatccccctcccggctccagatgttcttcgct





aataaccacgaccaggaatttgaccctccaaaggtttacccacctgtc





ccagctgagaagaggaagcccatccgggtgctgtctctctttgatgga





atcgctacagggctcctggtgctgaaggacttgggcattcaggtggac





cgctacattgcctcggaggtgtgtgaggactccatcacggtgggcatg





gtgcggcaccaggggaagatcatgtacgtcggggacgtccgcagcgtc





acacagaagcatatccaggagtggggcccattcgatctggtgattggg





ggcagtccctgcaatgacctctccatcgtcaaccctgctcgcaagggc





ctctacgagggcactggccggctcttctttgagttctaccgcctcctg





catgatgcgcggcccaaggagggagatgatcgccccttcttctggctc





tttgcgaatgtggtggccatgggcgttagtgacaagagggacatctcg





cgatttctcgagtccaaccctgtgatgattgatgccaaagaagtgtca





gctgcacacagggcccgctacttctggggtaaccttcccggtatgaac





aggccgttggcatccactgtgaatgataagctggagctgcaggagtgt





ctggagcatggcaggatagccaagttcagcaaagtgaggaccattact





acgaggtcaaactccataaagcagggcaaagaccagcattttcctgtg





ttcatgaatgagaaagaggacatcttatggtgcactgaaatggaaagg





gtatttggtttcccagtccactatactgacgtgtccaacatgagccgc





ttggcgaggcagagactgctgggccggtcatggagcgtgccagtcatc





cgccacctcttcgctccgctgaaggagtattttgcgtgtgtgtccggc





cggcccggatccggcgcaacaaacttctctctgctgaaacaagccgga





gatgtcgaagagaatcctggaccgaccgagtacaagcccacggtgcgc





ctcgccacccgcgacgacgtccccagggccgtacgcaccctcgccgcc





gcgttcgccgactaccccgccacgcgccacaccgtcgatccggaccgc





cacatcgagcgggtcaccgagctgcaagaactcttcctcacgcgcgtc





gggctcgacatcggcaaggtgtgggtcgcggacgacggcgccgcggtg





gcggtctggaccacgccggagagcgtcgaagcgggggcggtgttcgcc





gagatcggcccgcgcatggccgagttgagcggttcccggctggccgcg





cagcaacagatggaaggcctcctggcgccgcaccggcccaaggagccc





gcgtggttcctggccaccgtcggagtctcgcccgaccaccagggcaag





ggtctgggcagcgccgtcgtgctccccggagtggaggcggccgagcgc





gccggggtgcccgccttcctggagacctccgcgccccgcaacctcccc





ttctacgagcggctcggcttcaccgtcaccgccgacgtcgaggtgccc





gaaggaccgcgcacctggtgcatgacccgcaagcccggtgcctgaacg





cgttaagtcgacaatcaacctctggattacaaaatttgtgaaagattg





actggtattcttaactatgttgctccttttacgctatgtggatacgct





gctttaatgcctttgtatcatgctattgcttcccgtatggctttcatt





ttctcctccttgtataaatcctggttgctgtctctttatgaggagttg





tggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgac





gcaacccccactggttggggcattgccaccacctgtcagctcctttcc





gggactttcgctttccccctccctattgccacggcggaactcatcgcc





gcctgccttgcccgctgctggacaggggctcggctgttgggcactgac





aattccgtggtgttgtcggggaaatcatcgtcctttccttggctgctc





gcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtc





ccttcggccctcaatccagcggaccttccttcccgcggcctgctgccg





gctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcgg





atctccctttgggccgcctccccgcgtcgactttaagaccaatgactt





acaaggcagctgtagatcttagccactttttaaaagaaaaggggggac





tggaagggctaattcactcccaacgaagacaagatctgctttttgctt





gtactgggtctctctggttagaccagatctgagcctgggagctctctg





gctaactagggaacccactgcttaagcctcaataaagcttgccttgag





tgcttcaagtagtgtgtgcccgtctgttgtgtgactctggtaactaga





gatccctcagacccttttagtcagtgtggaaaatctctagcagggccc





gtttaaacccgctgatcagcctcgactgtgccttctagttgccagcca





tctgttgtttgcccctcccccgtgccttccttgaccctggaaggtgcc





actcccactgtcctttcctaataaaatgaggaaattgcatcgcattgt





ctgagtaggtgtcattctattctggggggtggggggggcaggacagca





agggggaggattgggaagacaatagcaggcatgctggggatgcggtgg





gctctatggcttctgaggcggaaagaaccagctggggctctagggggt





atccccacgcgccctgtagcggcgcattaagcgcggcgggtgtggtgg





ttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctc





ctttcgctttcttcccttcctttctcgccacgttcgccggctttcccc





gtcaagctctaaatcgggggctccctttagggttccgatttagtgctt





tacggcacctcgaccccaaaaaacttgattagggtgatggttcacgta





gtgggccatcgccctgatagacggtttttcgccctttgacgttggagt





ccacgttctttaatagtggactcttgttccaaactggaacaacactca





accctatctcggtctattcttttgatttataagggattttgccgattt





cggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcga





attaattctgtggaatgtgtgtcagttagggtgtggaaagtccccagg





ctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagc





aaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgca





aagcatgcatctcaattagtcagcaaccatagtcccgcccctaactcc





gcccatcccgcccctaactccgcccagttccgcccattctccgcccca





tggctgactaattttttttatttatgcagaggccgaggccgcctctgc





ctctgagctattccagaagtagtgaggaggcttttttggaggcctagg





cttttgcaaaaagctcccgggagcttgtatatccattttcggatctga





tcagcacgtgttgacaattaatcatcggcatagtatatcggcatagta





taatacgacaaggtgaggaactaaaccatggccaagttgaccagtgcc





gttccggtgctcaccgcgcgcgacgtcgccggagcggtcgagttctgg





accgaccggctcgggttctcccgggacttcgtggaggacgacttcgcc





ggtgtggtccgggacgacgtgaccctgttcatcagcgcggtccaggac





caggtggtgccggacaacaccctggcctgggtgtgggtgcgcggcctg





gacgagctgtacgccgagtggtcggaggtcgtgtccacgaacttccgg





gacgcctccgggccggccatgaccgagatcggcgagcagccgtggggg





gggagttcgccctgcgcgacccggccggcaactgcgtgcacttcgtgg





ccgaggagcaggactgacacgtgctacgagatttcgattccaccgccg





ccttctatgaaaggttgggcttcggaatcgttttccgggacgccggct





ggatgatcctccagcgcggggatctcatgctggagttcttcgcccacc





ccaacttgtttattgcagcttataatggttacaaataaagcaatagca





tcacaaatttcacaaataaagcatttttttcactgcattctagttgtg





gtttgtccaaactcatcaatgtatcttatcatgtctgtataccgtcga





cctctagctagagcttggcgtaatcatggtcatagctgtttcctgtgt





gaaattgttatccgctcacaattccacacaacatacgagccggaagca





taaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaa





ttgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgtgcc





agctgcattaatgaatcggccaacgcgcggggagaggcggtttgcgta





ttgggcgctcttccgcttcctcgctcactgactcgctgcgctcggtcg





ttcggctgcggcgagcggtatcagctcactcaaaggcggtaatacggt





tatccacagaatcaggggataacgcaggaaagaacatgtgagcaaaag





gccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttt





tccataggctccgcccccctgacgagcatcacaaaaatcgacgctcaa





gtcagaggtggcgaaacccgacaggactataaagataccaggcgtttc





cccctggaagctccctcgtgcgctctcctgttccgaccctgccgctta





ccggatacctgtccgcctttctcccttcgggaagcgtggcgctttctc





atagctcacgctgtaggtatctcagttcggtgtaggtcgttcgctcca





agctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgcct





tatccggtaactatcgtcttgagtccaacccggtaagacacgacttat





cgccactggcagcagccactggtaacaggattagcagagcgaggtatg





taggcggtgctacagagttcttgaagtggtggcctaactacggctaca





ctagaagaacagtatttggtatctgcgctctgctgaagccagttacct





tcggaaaaagagttggtagctcttgatccggcaaacaaaccaccgctg





gtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaa





aaggatctcaagaagatcctttgatcttttctacggggtctgacgctc





agtggaacgaaaactcacgttaagggattttggtcatgagattatcaa





aaaggatcttcacctagatccttttaaattaaaaatgaagttttaaat





caatctaaagtatatatgagtaaacttggtctgacagttaccaatgct





taatcagtgaggcacctatctcagcgatctgtctatttcgttcatcca





tagttgcctgactccccgtcgtgtagataactacgatacgggagggct





taccatctggccccagtgctgcaatgataccgcgagacccacgctcac





cggctccagatttatcagcaataaaccagccagccggaagggccgagc





gcagaagtggtcctgcaactttatccgcctccatccagtctattaatt





gttgccgggaagctagagtaagtagttcgccagttaatagtttgcgca





acgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgtttg





gtatggcttcattcagctccggttcccaacgatcaaggcgagttacat





gatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccga





tcgttgtcagaagtaagttggccgcagtgttatcactcatggttatgg





cagcactgcataattctcttactgtcatgccatccgtaagatgctttt





ctgtgactggtgagtactcaaccaagtcattctgagaatagtgtatgc





ggcgaccgagttgctcttgcccggcgtcaatacgggataataccgcgc





cacatagcagaactttaaaagtgctcatcattggaaaacgttcttcgg





ggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgt





aacccactcgtgcacccaactgatcttcagcatcttttactttcacca





gcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaaagg





gaataagggcgacacggaaatgttgaatactcatactcttcctttttc





aatattattgaagcatttatcagggttattgtctcatgagcggataca





tatttgaatgtatttagaaaaataaacaaataggggttccgcgcacat





ttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1105 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 43)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cggccctatccctgggggaggggttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





ccccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatc





cccctcccggctccagatgttcttcgctaataaccacgaccaggaatt





tgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcc





catccgggtgctgtctctctttgatggaatcgctacagggctcctggt





gctgaaggacttgggcattcaggtggaccgctacattgcctcggaggt





gtgtgaggactccatcacggtgggcatggtgcggcaccaggggaagat





catgtacgtcggggacgtccgcagcgtcacacagaagcatatccagga





gtggggcccattcgatctggtgattgggggcagtccctgcaatgacct





ctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccg





gctcttctttgagttctaccgcctcctgcatgatgcgcggcccaagga





gggagatgatcgccccttcttctggctctttgagaatgtggtggccat





gggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccc





tgtgatgattgatgccaaagaagtgtcagctgcacacagggcccgcta





cttctggggtaaccttcccggtatgaacaggccgttggcatccactgt





gaatgataagctggagctgcaggagtgtctggagcatggcaggatagc





caagttcagcaaagtgaggaccattactacgaggtcaaactccataaa





gcagggcaaagaccagcattttcctgtgttcatgaatgagaaagagga





catcttatggtgcactgaaatggaaagggtatttggtttcccagtcca





ctatactgacgtgtccaacatgagccgcttggcgaggcagagactgct





gggccggtcatggagcgtgccagtcatccgccacctcttcgctccgct





gaaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaac





aaacttctctctgctgaaacaagccggagatgtcgaagagaatcctgg





accgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgt





ccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgc





cacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccga





gctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggt





gtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccgga





gagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggc





cgagttgagcggttcccggctggccgcgcagcaacagatggaaggcct





cctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgt





cggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgt





gctccccggagtggaggcggccgagcgcgccggggtgcccgccttcct





ggagacctccgcgccccgcaacctccccttctacgagcggctcggctt





caccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtg





catgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacc





tctggattacaaaatttgtgaaagattgactggtattcttaactatgt





tgctccttttacgctatgtggatacgctgctttaatgcctttgtatca





tgctattgcttcccgtatggctttcattttctcctccttgtataaatc





ctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacg





tggcgtggtgtgcactgtgtttgctgacgcaacccccactggttgggg





cattgccaccacctgtcagctcctttccgggactttcgctttccccct





ccctattgccacggggaactcatcgccgcctgccttgcccgctgctgg





acaggggctcggctgttgggcactgacaattccgtggtgttgtcgggg





aaatcatcgtcctttccttggctgctcgcctgtgttgccacctggatt





ctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg





gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgt





cttcgccttcgccctcagacgagtcggatctccctttgggccgcctcc





ccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctta





gccactttttaaaagaaaaggggggactggaagggctaattcactccc





aacgaagacaagatctgctttttgcttgtactgggtctctctggttag





accagatctgagcctgggagctctctggctaactagggaacccactgc





ttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccc





gtctgttgtgtgactctggtaactagagatccctcagacccttttagt





cagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcc





tcgactgtgccttctagttgccagccatctgttgtttgcccctccccc





gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa





taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt





ctggggggtggggggggcaggacagcaagggggaggattgggaagaca





atagcaggcatgctggggatgcggtgggctctatggcttctgaggcgg





aaagaaccagctggggctctagggggtatccccacgcgccctgtagcg





gcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgcta





cacttgccagcgccctagcgcccgctcctttcgctttcttcccttcct





ttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggc





tccctttagggttccgatttagtgctttacggcacctcgaccccaaaa





aacttgattagggtgatggttcacgtagtgggccatcgccctgataga





cggtttttcgccctttgacgttggagtccacgttctttaatagtggac





tcttgttccaaactggaacaacactcaaccctatctcggtctattctt





ttgatttataagggattttgccgatttcggcctattggttaaaaaatg





agctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtg





tcagttagggtgtggaaagtccccaggctccccagcaggcagaagtat





gcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccc





aggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtc





agcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc





gcccagttccgcccattctccgccccatggctgactaattttttttat





ttatgcagaggccgaggccgcctctgcctctgagctattccagaagta





gtgaggaggcttttttggaggcctaggcttttgcaaaaagctccctac





cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttc





ctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg





gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactca





cattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgt





cgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtt





tgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgct





cggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaa





tacggttatccacagaatcaggggataacgcaggaaagaacatgtgag





caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg





cgtttttccataggctccgcccccctgacgagcatcacaaaaatcgac





gctcaagtcagaggtggcgaaacccgacaggactataaagataccagg





cgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgc





cgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgc





tttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttc





gctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgct





gcgccttatccggtaactatcgtcttgagtccaacccggtaagacacg





acttatcgccactggcagcagccactggtaacaggattagcagagcga





ggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacg





gctacactagaagaacagtatttggtatctgcgctctgctgaagccag





ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacca





ccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgca





gaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagat





tatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtt





ttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacc





aatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgtt





catccatagttgcctgactccccgtcgtgtagataactacgatacggg





agggcttaccatctggccccagtgctgcaatgataccgcgagacccac





gctcaccggctccagatttatcagcaataaaccagccagccggaaggg





ccgagcgcagaagtggtcctgcaactttatccgcctccatccagtcta





ttaattgttgccgggaagctagagtaagtagttcgccagttaatagtt





tgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgt





cgtttggtatggcttcattcagctccggttcccaacgatcaaggcgag





ttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtc





ctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatgg





ttatggcagcactgcataattctcttactgtcatgccatccgtaagat





gcttttctgtgactggtgagtactcaaccaagtcattctgagaatagt





gtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataata





ccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgtt





cttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt





cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactt





tcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa





aaaagggaataagggcgacacggaaatgttgaatactcatactcttcc





tttttcaatattattgaagcatttatcagggttattgtctcatgagcg





gatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1106 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 44)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggggtaggcgtgtacggtgggaggtctatataagcag





cgcgttttgcctgtactgggtctctctggttagaccagatctgagcct





gggagctctctggctaactagggaacccactgcttaagcctcaataaa





gcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact





ctggtaactagagatccctcagacccttttagtcagtgtggaaaatct





ctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccaga





ggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag





aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcgg





aggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaa





gaaaaaatataaattaaaacatatagtatgggcaagcagggagctaga





acgattcgcagttaatcctggcctgttagaaacatcagaaggctgtag





acaaatactgggacagctacaaccatcccttcagacaggatcagaaga





acttagatcattatataatacagtagcaaccctctattgtgtgcatca





aaggatagagataaaagacaccaaggaagctttagacaagatagagga





agagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggggaacggtaccgagggcctat





ttcccatgattccttcatatttgcatatacgatacaaggctgttagag





agataattagaattaatttgactgtaaacacaaagatattagtacaaa





atacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaa





aattatgttttaaaatggactatcatatgcttaccgtaacttgaaagt





atttcgatttcttggctttatatatcttgtggaaaggacgaaacaccg





tcgggcttggggagaggagggttttagagctagaaatagcaagttaaa





ataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc





ttttttgaattcgctagctaggtcttgaaaggagtgggaattggctcc





ggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaag





ttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgc





ggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttccc





gaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttc





tttttcgcaacgggtttgccgccagaacacaggaccggtgccaccatg





gactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggt





atccacggagtcccagcagccgacaagaagtacagcatcggcctggcc





atcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaag





gtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacagc





atcaagaagaacctgatcggagccctgctgttcgacagcggcgaaaca





gccgaggccacccggctgaagagaaccgccagaagaagatacaccaga





cggaagaaccggatctgctatctgcaagagatcttcagcaacgagatg





gccaaggtggacgacagcttcttccacagactggaagagtccttcctg





gtggaagaggataagaagcacgagcggcaccccatcttcggcaacatc





gtggacgaggtggcctaccacgagaagtaccccaccatctaccacctg





agaaagaaactggtggacagcaccgacaaggccgacctgcggctgatc





tatctggccctggcccacatgatcaagttccggggccacttcctgatc





gagggcgacctgaaccccgacaacagcgacgtggacaagctgttcatc





cagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaac





gccagcggcgtggacgccaaggccatcctgtctgccagactgagcaag





agcagacggctggaaaatctgatcgcccagctgcccggcgagaagaag





aatggcctgttcggcaacctgattgccctgagcctgggcctgaccccc





aacttcaagagcaacttcgacctggccgaggatgccaaactgcagctg





agcaaggacacctacgacgacgacctggacaacctgctggcccagatc





ggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgac





gccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaag





gcccccctgagcgcctctatgatcaagagatacgacgagcaccaccag





gacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaag





tacaaagagattttcttcgaccagagcaagaacggctacgccggctac





attgacggcggagccagccaggaagagttctacaagttcatcaagccc





atcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaac





agagaggacctgctgcggaagcagcggaccttcgacaacggcagcatc





ccccaccagatccacctgggagagctgcacgccattctgcggcggcag





gaagatttttacccattcctgaaggacaaccgggaaaagatcgagaag





atcctgaccttccgcatcccctactacgtgggccctctggccagggga





aacagcagattcgcctggatgaccagaaagagcgaggaaaccatcacc





ccctggaacttcgaggaagtggtggacaagggcgcttccgcccagagc





ttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaag





gtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataac





gagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgcc





ttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaag





accaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaag





aaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcgg





ttcaacgcctccctgggcacataccacgatctgctgaaaattatcaag





gacaaggacttcctggacaatgaggaaaacgaggacattctggaagat





atcgtgctgaccctgacactgtttgaggacagagagatgatcgaggaa





cggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcag





ctgaagcggcggagatacaccggctggggcaggctgagccggaagctg





atcaacggcatccgggacaagcagtccggcaagacaatcctggatttc





ctgaagtccgacggcttcgccaacagaaacttcatgcagctgatccac





gacgacagcctgacctttaaagaggacatccagaaagcccaggtgtcc





ggccagggcgatagcctgcacgagcacattgccaatctggccggcagc





cccgccattaagaagggcatcctgcagacagtgaaggtggtggacgag





ctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcgaa





atggccagagagaaccagaccacccagaagggacagaagaacagccgc





gagagaatgaagcggatcgaagagggcatcaaagagctgggcagccag





atcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaag





ctgtacctgtactacctgcagaatggggggatatgtacgtggaccagg





aactggacatcaaccggctgtccgactacgatgtggacgctatcgtgc





ctcagagctttctgaaggacgactccatcgacaacaaggtgctgacca





gaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagagg





tcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagc





tgattacccagagaaagttcgacaatctgaccaaggccgagagaggcg





gcctgagcgaactggataaggccggcttcatcaagagacagctggtgg





aaacccggcagatcacaaagcacgtggcacagatactagattcccgaa





tgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaag





taatcactttaaagtcaaaattggtgtcggacttcagaaaggattttc





aattctataaagttagggagataaataactaccaccatgcgcacgacg





cttatcttaatgccgtcgtagggaccgcactcattaagaaatacccga





agctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtcc





gtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcca





aatacttcttttattctaacattatgaatttctttaagacggaaatca





ctctggcaaacggagagatacgcaaacgacctttaattgaaaccaatg





gggagacaggtgaaatcgtatgggataagggccgggacttcgcgacgg





tgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaactg





aggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagga





atagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaagt





acggtggcttcgtgagccctacagttgcctattctgtcctagtagtgg





caaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaat





tattggggataacgattatggagcgctcgtcttttgaaaagaacccca





tcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctca





taattaaactaccaaagtatagtctgtttgagttagaaaatggccgaa





aacggatgttggctagcgccagagagcttcaaaaggggaacgaactcg





cactaccgtctaaatacgtgaatttcctgtatttagcgtcccattacg





agaagttgaaaggttcacctgaagataacgaacagaagcaactttttg





ttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcgg





aattcagtaagagagtcatcctagctgatgccaatctggacaaagtat





taagcgcatacaacaagcacagggataaacccatacgtgagcaggcgg





aaaatattatccatttgtttactcttaccaacctcggcgctccagccg





cattcaagtattttgacacaacgatagatcgcaaagagtacagatcta





ccaaggaggtgctagacgcgacactgattcaccaatccatcacgggat





tatatgaaactcggatagatttgtcacagcttgggggtgacggatccc





ccaagaagaagaggaaagtcctcgagggcggagggggagcggatcccc





ctcccggctccagatgttcttcgctaataaccacgaccaggaatttga





ccctccaaaggtttacccacctgtcccagctgagaagaggaagcccat





ccgggtgctgtctctctttgatggaatcgctacagggctcctggtgct





gaaggacttgggcattcaggtggaccgctacattgcctcggaggtgtg





tgaggactccatcacggtgggcatggtgcggcaccaggggaagatcat





gtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagtg





gggcccattcgatctggtgattgggggcagtccctgcaatgacctctc





catcgtcaaccctgctcgcaagggcctctacgagggcactggccggct





cttctttgagttctaccgcctcctgcatgatgcgcggcccaaggaggg





agatgatcgccccttcttctggctctttgagaatgtggtggccatggg





cgttagtgacaagagggacatctcgcgatttctcgagtccaaccctgt





gatgattgatgccaaagaagtgtcagctgcacacagggcccgctactt





ctggggtaaccttcccggtatgaacaggccgttggcatccactgtgaa





tgataagctggagctgcaggagtgtctggagcatggcaggatagccaa





gttcagcaaagtgaggaccattactacgaggtcaaactccataaagca





gggcaaagaccagcattttcctgtgttcatgaatgagaaagaggacat





cttatggtgcactgaaatggaaagggtatttggtttcccagtccacta





tactgacgtgtccaacatgagccgcttggcgaggcagagactgctggg





ccggtcatggagcgtgccagtcatccgccacctcttcgctccgctgaa





ggagtattttgcgtgtgtgtccggccggcccggatccggcgcaacaaa





cttctctctgctgaaacaagccggagatgtcgaagagaatcctggacc





gaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtccc





cagggccgtacgcaccctcgccgccgcgttcgccgactaccccgccac





gcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgagct





gcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgtg





ggtcgcggacgacggcgccgcggtggcggtctggaccacgccggagag





cgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggccga





gttgagcggttcccggctggccgcgcagcaacagatggaaggcctcct





ggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcgg





agtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgct





ccccggagtggaggcggccgagcgcgccggggtgcccgccttcctgga





gacctccgcgccccgcaacctccccttctacgagcggctcggcttcac





cgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgcat





gacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctct





ggattacaaaatttgtgaaagattgactggtattcttaactatgttgc





tccttttacgctatgtggatacgctgctttaatgcctttgtatcatgc





tattgcttcccgtatggctttcattttctcctccttgtataaatcctg





gttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtgg





cgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcat





tgccaccacctgtcagctcctttccgggactttcgctttccccctccc





tattgccacggcggaactcatcgccgcctgccttgcccgctgctggac





aggggctcggctgttgggcactgacaattccgtggtgttgtcggggaa





atcatcgtcctttccttggctgctcgcctgtgttgccacctggattct





gcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgga





ccttccttcccgcggcctgctgccggctctgcggcctcttccgcgtct





tcgccttcgccctcagacgagtcggatctccctttgggccgcctcccc





gcgtcgactttaagaccaatgacttacaaggcagctgtagatcttagc





cactttttaaaagaaaagggggactggaagggctaattcactcccaac





gaagacaagatctgctttttgcttgtactgggtctctctggttagacc





agatctgagcctgggagctctctggctaactagggaacccactgctta





agcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccgtc





tgttgtgtgactctggtaactagagatccctcagacccttttagtcag





tgtggaaaatctctagcagggcccgtttaaacccgctgatcagcctcg





actgtgccttctagttgccagccatctgttgtttgcccctcccccgtg





ccttccttgaccctggaaggtgccactcccactgtcctttcctaataa





aatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctg





gggggtggggggggcaggacagcaagggggaggattgggaagacaata





gcaggcatgctggggatgcggtgggctctatggcttctgaggcggaaa





gaaccagctggggctctagggggtatccccacgcgccctgtagcggcg





cattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacac





ttgccagcgccctagcgcccgctcctttcgctttcttcccttcctttc





tcgccacgttcgccggctttccccgtcaagctctaaatcgggggctcc





ctttagggttccgatttagtgctttacggcacctcgaccccaaaaaac





ttgattagggtgatggttcacgtagtgggccatcgccctgatagacgg





tttttcgccctttgacgttggagtccacgttctttaatagtggactct





tgttccaaactggaacaacactcaaccctatctcggtctattcttttg





atttataagggattttgccgatttcggcctattggttaaaaaatgagc





tgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtgtca





gttagggtgtggaaagtccccaggctccccagcaggcagaagtatgca





aagcatgcatctcaattagtcagcaaccaggtgtggaaagtccccagg





ctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagc





aaccatagtcccgcccctaactccgcccatcccgcccctaactccgcc





cagttccgcccattctccgccccatggctgactaattttttttattta





tgcagaggccgaggccgcctctgcctctgagctattccagaagtagtg





aggaggcttttttggaggcctaggcttttgcaaaaagctccctaccgt





cgacctctagctagagcttggcgtaatcatggtcatagctgtttcctg





tgtgaaattgttatccgctcacaattccacacaacatacgagccggaa





gcataaagtgtaaagcctggggtgcctaatgagtgagctaactcacat





taattgcgttgcgctcactgcccgctttccagtcgggaaacctgtcgt





gccagctgcattaatgaatcggccaacgcgcggggagaggcggtttgc





gtattgggcgctcttccgcttcctcgctcactgactcgctgcgctcgg





tcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaatac





ggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaa





aaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgt





ttttccataggctccgcccccctgacgagcatcacaaaaatcgacgct





caagtcagaggtggcgaaacccgacaggactataaagataccaggcgt





ttccccctggaagctccctcgtgcgctctcctgttccgaccctgccgc





ttaccggatacctgtccgcctttctcccttcgggaagcgtggcgcttt





ctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcgct





ccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcg





ccttatccggtaactatcgtcttgagtccaacccggtaagacacgact





tatcgccactggcagcagccactggtaacaggattagcagagcgaggt





atgtaggcggtgctacagagttcttgaagtggtggcctaactacggct





acactagaagaacagtatttggtatctgcgctctgctgaagccagtta





ccttcggaaaaagagttggtagctcttgatccggcaaacaaaccaccg





ctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaa





aaaaaggatctcaagaagatcctttgatcttttctacggggtctgacg





ctcagtggaacgaaaactcacgttaagggattttggtcatgagattat





caaaaaggatcttcacctagatccttttaaattaaaaatgaagtttta





aatcaatctaaagtatatatgagtaaacttggtctgacagttaccaat





gcttaatcagtgaggcacctatctcagcgatctgtctatttcgttcat





ccatagttgcctgactccccgtcgtgtagataactacgatacgggagg





gcttaccatctggccccagtgctgcaatgataccgcgagacccacgct





caccggctccagatttatcagcaataaaccagccagccggaagggccg





agcgcagaagtggtcctgcaactttatccgcctccatccagtctatta





attgttgccgggaagctagagtaagtagttcgccagttaatagtttgc





gcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtcgt





ttggtatggcttcattcagctccggttcccaacgatcaaggcgagtta





catgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctc





cgatcgttgtcagaagtaagttggccgcagtgttatcactcatggtta





tggcagcactgcataattctcttactgtcatgccatccgtaagatgct





tttctgtgactggtgagtactcaaccaagtcattctgagaatagtgta





tgcggcgaccgagttgctcttgcccggcgtcaatacgggataataccg





cgccacatagcagaactttaaaagtgctcatcattggaaaacgttctt





cggggcgaaaactctcaaggatcttaccgctgttgagatccagttcga





tgtaacccactcgtgcacccaactgatcttcagcatcttttactttca





ccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaaaa





agggaataagggcgacacggaaatgttgaatactcatactcttccttt





ttcaatattattgaagcatttatcagggttattgtctcatgagcggat





acatatttgaatgtatttagaaaaataaacaaataggggttccgcgca





catttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1107 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 45)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggggtaggcgtgtacggtgggaggtctatataagcag





cgcgttttgcctgtactgggtctctctggttagaccagatctgagcct





gggagctctctggctaactagggaacccactgcttaagcctcaataaa





gcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact





ctggtaactagagatccctcagacccttttagtcagtgtggaaaatct





ctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccaga





ggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag





aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcgg





aggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaa





gaaaaaatataaattaaaacatatagtatgggcaagcagggagctaga





acgattcgcagttaatcctggcctgttagaaacatcagaaggctgtag





acaaatactgggacagctacaaccatcccttcagacaggatcagaaga





acttagatcattatataatacagtagcaaccctctattgtgtgcatca





aaggatagagataaaagacaccaaggaagctttagacaagatagagga





agagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggcggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





gctctccccaccccaccttctgttttagagctagaaatagcaagttaa





aataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtg





cttttttgaattcgctagctaggtcttgaaaggagtgggaattggctc





cggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaa





gttggggggaggggtcggcaattgatccggtgcctagagaaggtggcg





cggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcc





cgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgtt





ctttttcgcaacgggtttgccgccagaacacaggaccggtgccaccat





ggactataaggaccacgacggagactacaaggatcatgatattgatta





caaagacgatgacgataagatggccccaaagaagaagcggaaggtcgg





tatccacggagtcccagcagccgacaagaagtacagcatcggcctggc





catcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaa





ggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacag





catcaagaagaacctgatcggagccctgctgttcgacagcggcgaaac





agccgaggccacccggctgaagagaaccgccagaagaagatacaccag





acggaagaaccggatctgctatctgcaagagatcttcagcaacgagat





ggccaaggtggacgacagcttcttccacagactggaagagtccttcct





ggtggaagaggataagaagcacgagcggcaccccatcttcggcaacat





cgtggacgaggtggcctaccacgagaagtaccccaccatctaccacct





gagaaagaaactggtggacagcaccgacaaggccgacctgcggctgat





ctatctggccctggcccacatgatcaagttccggggccacttcctgat





cgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcat





ccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaa





cgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaa





gagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaa





gaatggcctgttcggcaacctgattgccctgagcctgggcctgacccc





caacttcaagagcaacttcgacctggccgaggatgccaaactgcagct





gagcaaggacacctacgacgacgacctggacaacctgctggcccagat





cggcgaccagtacgccgacctgtttctggccgccaagaacctgtccga





cgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaa





ggcccccctgagcgcctctatgatcaagagatacgacgagcaccacca





ggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaa





gtacaaagagattttcttcgaccagagcaagaacggctacgccggcta





cattgacggcggagccagccaggaagagttctacaagttcatcaagcc





catcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaa





cagagaggacctgctgcggaagcagcggaccttcgacaacggcagcat





cccccaccagatccacctgggagagctgcacgccattctgcggcggca





ggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaa





gatcctgaccttccgcatcccctactacgtgggccctctggccagggg





aaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcac





cccctggaacttcgaggaagtggtggacaagggcgcttccgcccagag





cttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaa





ggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataa





cgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgc





cttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaa





gaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcg





gttcaacgcctccctgggcacataccacgatctgctgaaaattatcaa





ggacaaggacttcctggacaatgaggaaaacgaggacattctggaaga





tatcgtgctgaccctgacactgtttgaggacagagagatgatcgagga





acggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagca





gctgaagcggcggagatacaccggctggggcaggctgagccggaagct





gatcaacggcatccgggacaagcagtccggcaagacaatcctggattt





cctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcca





cgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtc





cggccagggcgatagcctgcacgagcacattgccaatctggccggcag





ccccgccattaagaagggcatcctgcagacagtgaaggtggtggacga





gctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcga





aatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcca





gatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaa





gctgtacctgtactacctgcagaatggggggatatgtacgtggaccag





gaactggacatcaaccggctgtccgactacgatgtggacgctatcgtg





cctcagagctttctgaaggacgactccatcgacaacaaggtgctgacc





agaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagag





gtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaag





ctgattacccagagaaagttcgacaatctgaccaaggccgagagaggc





ggcctgagcgaactggataaggccggcttcatcaagagacagctggtg





gaaacccggcagatcacaaagcacgtggcacagatactagattcccga





atgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaa





gtaatcactttaaagtcaaaattggtgtcggacttcagaaaggatttt





caattctataaagttagggagataaataactaccaccatgcgcacgac





gcttatcttaatgccgtcgtagggaccgcactcattaagaaatacccg





aagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtc





cgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcc





aaatacttcttttattctaacattatgaatttctttaagacggaaatc





actctggcaaacggagagatacgcaaacgacctttaattgaaaccaat





ggggagacaggtgaaatcgtatgggataagggccgggacttcgcgacg





gtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaact





gaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagg





aatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaag





tacggtggcttcgtgagccctacagttgcctattctgtcctagtagtg





gcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaa





ttattggggataacgattatggagcgctcgtcttttgaaaagaacccc





atcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctc





ataattaaactaccaaagtatagtctgtttgagttagaaaatggccga





aaacggatgttggctagcgccagagagcttcaaaaggggaacgaactc





gcactaccgtctaaatacgtgaatttcctgtatttagcgtcccattac





gagaagttgaaaggttcacctgaagataacgaacagaagcaacttttt





gttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcg





gaattcagtaagagagtcatcctagctgatgccaatctggacaaagta





ttaagcgcatacaacaagcacagggataaacccatacgtgagcaggcg





gaaaatattatccatttgtttactcttaccaacctcggcgctccagcc





gcattcaagtattttgacacaacgatagatcgcaaagagtacagatct





accaaggaggtgctagacgcgacactgattcaccaatccatcacggga





ttatatgaaactcggatagatttgtcacagcttgggggtgacggatcc





cccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatcc





ccctcccggctccagatgttcttcgctaataaccacgaccaggaattt





gaccctccaaaggtttacccacctgtcccagctgagaagaggaagccc





atccgggtgctgtctctctttgatggaatcgctacagggctcctggtg





ctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtg





tgtgaggactccatcacggtgggcatggtgcggcaccaggggaagatc





atgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggag





tggggcccattcgatctggtgattgggggcagtccctgcaatgacctc





tccatcgtcaaccctgctcgcaagggcctctacgagggcactggccgg





ctcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggag





ggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccct





gtgatgattgatgccaaagaagtgtcagctgcacacagggcccgctac





ttctggggtaaccttcccggtatgaacaggccgttggcatccactgtg





aatgataagctggagctgcaggagtgtctggagcatggcaggatagcc





aagttcagcaaagtgaggaccattactacgaggtcaaactccataaag





cagggcaaagaccagcattttcctgtgttcatgaatgagaaagaggac





atcttatggtgcactgaaatggaaagggtatttggtttcccagtccac





tatactgacgtgtccaacatgagccgcttggcgaggcagagactgctg





ggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctg





aaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaaca





aacttctctctgctgaaacaagccggagatgtcgaagagaatcctgga





ccgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtc





cccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgcc





acgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgag





ctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtg





tgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggag





agcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggcc





gagttgagcggttcccggctggccgcgcagcaacagatggaaggcctc





ctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtc





ggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtg





ctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctg





gagacctccgcgccccgcaacctccccttctacgagcggctcggcttc





accgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgc





atgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacct





ctggattacaaaatttgtgaaagattgactggtattcttaactatgtt





gctccttttacgctatgtggatacgctgctttaatgcctttgtatcat





gctattgcttcccgtatggctttcattttctcctccttgtataaatcc





tggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgt





ggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggc





attgccaccacctgtcagctcctttccgggactttcgctttccccctc





cctattgccacggcggaactcatcgccgcctgccttgcccgctgctgg





acaggggctcggctgttgggcactgacaattccgtggtgttgtcgggg





aaatcatcgtcctttccttggctgctcgcctgtgttgccacctggatt





ctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg





gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgt





cttcgccttcgccctcagacgagtcggatctccctttgggccgcctcc





ccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctta





gccactttttaaaagaaaaggggggactggaagggctaattcactccc





aacgaagacaagatctgctttttgcttgtactgggtctctctggttag





accagatctgagcctgggagctctctggctaactagggaacccactgc





ttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccc





gtctgttgtgtgactctggtaactagagatccctcagacccttttagt





cagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcc





tcgactgtgccttctagttgccagccatctgttgtttgcccctccccc





gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa





taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt





ctggggggggggtggggcaggacagcaagggggaggattgggaagaca





atagcaggcatgctggggatgcggtgggctctatggcttctgaggcgg





aaagaaccagctggggctctagggggtatccccacgcgccctgtagcg





gcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgcta





cacttgccagcgccctagcgcccgctcctttcgctttcttcccttcct





ttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggc





tccctttagggttccgatttagtgctttacggcacctcgaccccaaaa





aacttgattagggtgatggttcacgtagtgggccatcgccctgataga





cggtttttcgccctttgacgttggagtccacgttctttaatagtggac





tcttgttccaaactggaacaacactcaaccctatctcggtctattctt





ttgatttataagggattttgccgatttcggcctattggttaaaaaatg





agctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtg





tcagttagggtgtggaaagtccccaggctccccagcaggcagaagtat





gcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccc





aggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtc





agcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc





gcccagttccgcccattctccgccccatggctgactaattttttttat





ttatgcagaggccgaggccgcctctgcctctgagctattccagaagta





gtgaggaggcttttttggaggcctaggcttttgcaaaaagctccctac





cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttc





ctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg





gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactca





cattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgt





cgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtt





tgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgct





cggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaa





tacggttatccacagaatcaggggataacgcaggaaagaacatgtgag





caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg





cgtttttccataggctccgcccccctgacgagcatcacaaaaatcgac





gctcaagtcagaggtggcgaaacccgacaggactataaagataccagg





cgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgc





cgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgc





tttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttc





gctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgct





gcgccttatccggtaactatcgtcttgagtccaacccggtaagacacg





acttatcgccactggcagcagccactggtaacaggattagcagagcga





ggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacg





gctacactagaagaacagtatttggtatctgcgctctgctgaagccag





ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacca





ccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgca





gaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagat





tatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtt





ttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacc





aatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgtt





catccatagttgcctgactccccgtcgtgtagataactacgatacggg





agggcttaccatctggccccagtgctgcaatgataccgcgagacccac





gctcaccggctccagatttatcagcaataaaccagccagccggaaggg





ccgagcgcagaagtggtcctgcaactttatccgcctccatccagtcta





ttaattgttgccgggaagctagagtaagtagttcgccagttaatagtt





tgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgt





cgtttggtatggcttcattcagctccggttcccaacgatcaaggcgag





ttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtc





ctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatgg





ttatggcagcactgcataattctcttactgtcatgccatccgtaagat





gcttttctgtgactggtgagtactcaaccaagtcattctgagaatagt





gtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataata





ccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgtt





cttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt





cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactt





tcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa





aaaagggaataagggcgacacggaaatgttgaatactcatactcttcc





tttttcaatattattgaagcatttatcagggttattgtctcatgagcg





gatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1108 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 46)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cgtgtgaagggagaatgaggaagttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





ccccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatc





cccctcccggctccagatgttcttcgctaataaccacgaccaggaatt





tgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcc





catccgggtgctgtctctctttgatggaatcgctacagggctcctggt





gctgaaggacttgggcattcaggtggaccgctacattgcctcggaggt





gtgtgaggactccatcacggtgggcatggtgcggcaccaggggaagat





catgtacgtcggggacgtccgcagcgtcacacagaagcatatccagga





gtggggcccattcgatctggtgattgggggcagtccctgcaatgacct





ctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccg





gctcttctttgagttctaccgcctcctgcatgatgcgcggcccaagga





gggagatgatcgccccttcttctggctctttgagaatgtggtggccat





gggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccc





tgtgatgattgatgccaaagaagtgtcagctgcacacagggcccgcta





cttctggggtaaccttcccggtatgaacaggccgttggcatccactgt





gaatgataagctggagctgcaggagtgtctggagcatggcaggatagc





caagttcagcaaagtgaggaccattactacgaggtcaaactccataaa





gcagggcaaagaccagcattttcctgtgttcatgaatgagaaagagga





catcttatggtgcactgaaatggaaagggtatttggtttcccagtcca





ctatactgacgtgtccaacatgagccgcttggcgaggcagagactgct





gggccggtcatggagcgtgccagtcatccgccacctcttcgctccgct





gaaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaac





aaacttctctctgctgaaacaagccggagatgtcgaagagaatcctgg





accgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgt





ccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgc





cacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccga





gctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggt





gtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccgga





gagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggc





cgagttgagcggttcccggctggccgcgcagcaacagatggaaggcct





cctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgt





cggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgt





gctccccggagtggaggcggccgagcgcgccggggtgcccgccttcct





ggagacctccgcgccccgcaacctccccttctacgagcggctcggctt





caccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtg





catgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacc





tctggattacaaaatttgtgaaagattgactggtattcttaactatgt





tgctccttttacgctatgtggatacgctgctttaatgcctttgtatca





tgctattgcttcccgtatggctttcattttctcctccttgtataaatc





ctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacg





tggcgtggtgtgcactgtgtttgctgacgcaacccccactggttgggg





cattgccaccacctgtcagctcctttccgggactttcgctttccccct





ccctattgccacggcggaactcatcgccgcctgccttgcccgctgctg





gacaggggctcggctgttgggcactgacaattccgtggtgttgtcggg





gaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggat





tctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagc





ggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcg





tcttcgccttcgccctcagacgagtcggatctccctttgggccgcctc





cccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctt





agccactttttaaaagaaaaggggggactggaagggctaattcactcc





caacgaagacaagatctgctttttgcttgtactgggtctctctggtta





gaccagatctgagcctgggagctctctggctaactagggaacccactg





cttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcc





cgtctgttgtgtgactctggtaactagagatccctcagacccttttag





tcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagc





ctcgactgtgccttctagttgccagccatctgttgtttgcccctcccc





cgtgccttccttgaccctggaaggtgccactcccactgtcctttccta





ataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctat





tctggggggtggggggggcaggacagcaagggggaggattgggaagac





aatagcaggcatgctggggatgcggtgggctctatggcttctgaggcg





gaaagaaccagctggggctctagggggtatccccacgcgccctgtagc





ggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgct





acacttgccagcgccctagcgcccgctcctttcgctttcttcccttcc





tttctcgccacgttcgccggctttccccgtcaagctctaaatcggggg





ctccctttagggttccgatttagtgctttacggcacctcgaccccaaa





aaacttgattagggtgatggttcacgtagtgggccatcgccctgatag





acggtttttcgccctttgacgttggagtccacgttctttaatagtgga





ctcttgttccaaactggaacaacactcaaccctatctcggtctattct





tttgatttataagggattttgccgatttcggcctattggttaaaaaat





gagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgt





gtcagttagggtgtggaaagtccccaggctccccagcaggcagaagta





tgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccc





caggctccccagcaggcagaagtatgcaaagcatgcatctcaattagt





cagcaaccatagtcccgcccctaactccgcccatcccgcccctaactc





cgcccagttccgcccattctccgccccatggctgactaatttttttta





tttatgcagaggccgaggccgcctctgcctctgagctattccagaagt





agtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccta





ccgtcgacctctagctagagcttggcgtaatcatggtcatagctgttt





cctgtgtgaaattgttatccgctcacaattccacacaacatacgagcc





ggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactc





acattaattgcgttgcgctcactgcccgctttccagtcgggaaacctg





tcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggt





ttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgc





tcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggta





atacggttatccacagaatcaggggataacgcaggaaagaacatgtga





gcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctg





gcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga





cgctcaagtcagaggtggcgaaacccgacaggactataaagataccag





gcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctg





ccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcg





ctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgtt





cgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgc





tgcgccttatccggtaactatcgtcttgagtccaacccggtaagacac





gacttatcgccactggcagcagccactggtaacaggattagcagagcg





aggtatgtaggcggtgctacagagttcttgaagtggtggcctaactac





ggctacactagaagaacagtatttggtatctgcgctctgctgaagcca





gttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacc





accgctggtagcggtggtttttttgtttgcaagcagcagattacgcgc





agaaaaaaaggatctcaagaagatcctttgatcttttctacggggtct





gacgctcagtggaacgaaaactcacgttaagggattttggtcatgaga





ttatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagt





tttaaatcaatctaaagtatatatgagtaaacttggtctgacagttac





caatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgt





tcatccatagttgcctgactccccgtcgtgtagataactacgatacgg





gagggcttaccatctggccccagtgctgcaatgataccgcgagaccca





cgctcaccggctccagatttatcagcaataaaccagccagccggaagg





gccgagcgcagaagtggtcctgcaactttatccgcctccatccagtct





attaattgttgccgggaagctagagtaagtagttcgccagttaatagt





ttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcg





tcgtttggtatggcttcattcagctccggttcccaacgatcaaggcga





gttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggt





cctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatg





gttatggcagcactgcataattctcttactgtcatgccatccgtaaga





tgcttttctgtgactggtgagtactcaaccaagtcattctgagaatag





tgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataat





accgcgccacatagcagaactttaaaagtgctcatcattggaaaacgt





tcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagt





tcgatgtaacccactcgtgcacccaactgatcttcagcatcttttact





ttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgca





aaaaagggaataagggcgacacggaaatgttgaatactcatactcttc





ctttttcaatattattgaagcatttatcagggttattgtctcatgagc





ggatacatatttgaatgtatttagaaaaataaacaaataggggttccg





cgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1109 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 47)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacgggggaggtctatataagcag





cgcgttttgcctgtactgggtctctctggttagaccagatctgagcct





gggagctctctggctaactagggaacccactgcttaagcctcaataaa





gcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact





ctggtaactagagatccctcagacccttttagtcagtgtggaaaatct





ctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccaga





ggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag





aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcgg





aggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaa





gaaaaaatataaattaaaacatatagtatgggcaagcagggagctaga





acgattcgcagttaatcctggcctgttagaaacatcagaaggctgtag





acaaatactgggacagctacaaccatcccttcagacaggatcagaaga





acttagatcattatataatacagtagcaaccctctattgtgtgcatca





aaggatagagataaaagacaccaaggaagctttagacaagatagagga





agagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggcggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





ggccctatccctgggggaggggttttagagctagaaatagcaagttaa





aataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtg





cttttttgaattcgctagctaggtcttgaaaggagtgggaattggctc





cggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaa





gttggggggaggggtcggcaattgatccggtgcctagagaaggtggcg





cggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcc





cgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgtt





ctttttcgcaacgggtttgccgccagaacacaggaccggtgccaccat





ggactataaggaccacgacggagactacaaggatcatgatattgatta





caaagacgatgacgataagatggccccaaagaagaagcggaaggtcgg





tatccacggagtcccagcagccgacaagaagtacagcatcggcctggc





catcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaa





ggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacag





catcaagaagaacctgatcggagccctgctgttcgacagcggcgaaac





agccgaggccacccggctgaagagaaccgccagaagaagatacaccag





acggaagaaccggatctgctatctgcaagagatcttcagcaacgagat





ggccaaggtggacgacagcttcttccacagactggaagagtccttcct





ggtggaagaggataagaagcacgagcggcaccccatcttcggcaacat





cgtggacgaggtggcctaccacgagaagtaccccaccatctaccacct





gagaaagaaactggtggacagcaccgacaaggccgacctgcggctgat





ctatctggccctggcccacatgatcaagttccggggccacttcctgat





cgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcat





ccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaa





cgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaa





gagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaa





gaatggcctgttcggcaacctgattgccctgagcctgggcctgacccc





caacttcaagagcaacttcgacctggccgaggatgccaaactgcagct





gagcaaggacacctacgacgacgacctggacaacctgctggcccagat





cggcgaccagtacgccgacctgtttctggccgccaagaacctgtccga





cgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaa





ggcccccctgagcgcctctatgatcaagagatacgacgagcaccacca





ggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaa





gtacaaagagattttcttcgaccagagcaagaacggctacgccggcta





cattgacggcggagccagccaggaagagttctacaagttcatcaagcc





catcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaa





cagagaggacctgctgcggaagcagcggaccttcgacaacggcagcat





cccccaccagatccacctgggagagctgcacgccattctgcggcggca





ggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaa





gatcctgaccttccgcatcccctactacgtgggccctctggccagggg





aaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcac





cccctggaacttcgaggaagtggtggacaagggcgcttccgcccagag





cttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaa





ggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataa





cgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgc





cttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaa





gaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcg





gttcaacgcctccctgggcacataccacgatctgctgaaaattatcaa





ggacaaggacttcctggacaatgaggaaaacgaggacattctggaaga





tatcgtgctgaccctgacactgtttgaggacagagagatgatcgagga





acggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagca





gctgaagcggcggagatacaccggctggggcaggctgagccggaagct





gatcaacggcatccgggacaagcagtccggcaagacaatcctggattt





cctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcca





cgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtc





cggccagggcgatagcctgcacgagcacattgccaatctggccggcag





ccccgccattaagaagggcatcctgcagacagtgaaggtggtggacga





gctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcga





aatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcca





gatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaa





gctgtacctgtactacctgcagaatggggggatatgtacgtggaccag





gaactggacatcaaccggctgtccgactacgatgtggacgctatcgtg





cctcagagctttctgaaggacgactccatcgacaacaaggtgctgacc





agaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagag





gtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaag





ctgattacccagagaaagttcgacaatctgaccaaggccgagagaggc





ggcctgagcgaactggataaggccggcttcatcaagagacagctggtg





gaaacccggcagatcacaaagcacgtggcacagatactagattcccga





atgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaa





gtaatcactttaaagtcaaaattggtgtcggacttcagaaaggatttt





caattctataaagttagggagataaataactaccaccatgcgcacgac





gcttatcttaatgccgtcgtagggaccgcactcattaagaaatacccg





aagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtc





cgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcc





aaatacttcttttattctaacattatgaatttctttaagacggaaatc





actctggcaaacggagagatacgcaaacgacctttaattgaaaccaat





ggggagacaggtgaaatcgtatgggataagggccgggacttcgcgacg





gtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaact





gaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagg





aatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaag





tacggtggcttcgtgagccctacagttgcctattctgtcctagtagtg





gcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaa





ttattggggataacgattatggagcgctcgtcttttgaaaagaacccc





atcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctc





ataattaaactaccaaagtatagtctgtttgagttagaaaatggccga





aaacggatgttggctagcgccagagagcttcaaaaggggaacgaactc





gcactaccgtctaaatacgtgaatttcctgtatttagcgtcccattac





gagaagttgaaaggttcacctgaagataacgaacagaagcaacttttt





gttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcg





gaattcagtaagagagtcatcctagctgatgccaatctggacaaagta





ttaagcgcatacaacaagcacagggataaacccatacgtgagcaggcg





gaaaatattatccatttgtttactcttaccaacctcggcgctccagcc





gcattcaagtattttgacacaacgatagatcgcaaagagtacagatct





accaaggaggtgctagacgcgacactgattcaccaatccatcacggga





ttatatgaaactcggatagatttgtcacagcttgggggtgacggatcc





cccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatcc





ccctcccggctccagatgttcttcgctaataaccacgaccaggaattt





gaccctccaaaggtttacccacctgtcccagctgagaagaggaagccc





atccgggtgctgtctctctttgatggaatcgctacagggctcctggtg





ctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtg





tgtgaggactccatcacggtgggcatggtgcggcaccaggggaagatc





atgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggag





tggggcccattcgatctggtgattgggggcagtccctgcaatgacctc





tccatcgtcaaccctgctcgcaagggcctctacgagggcactggccgg





ctcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggag





ggagatgatcgccccttcttctggctctttgcgaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccct





gtgatgattgatgccaaagaagtgtcagctgcacacagggcccgctac





ttctggggtaaccttcccggtatgaacaggccgttggcatccactgtg





aatgataagctggagctgcaggagtgtctggagcatggcaggatagcc





aagttcagcaaagtgaggaccattactacgaggtcaaactccataaag





cagggcaaagaccagcattttcctgtgttcatgaatgagaaagaggac





atcttatggtgcactgaaatggaaagggtatttggtttcccagtccac





tatactgacgtgtccaacatgagccgcttggcgaggcagagactgctg





ggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctg





aaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaaca





aacttctctctgctgaaacaagccggagatgtcgaagagaatcctgga





ccgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtc





cccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgcc





acgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgag





ctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtg





tgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggag





agcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggcc





gagttgagcggttcccggctggccgcgcagcaacagatggaaggcctc





ctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtc





ggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtg





ctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctg





gagacctccgcgccccgcaacctccccttctacgagcggctcggcttc





accgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgc





atgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacct





ctggattacaaaatttgtgaaagattgactggtattcttaactatgtt





gctccttttacgctatgtggatacgctgctttaatgcctttgtatcat





gctattgcttcccgtatggctttcattttctcctccttgtataaatcc





tggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgt





ggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggc





attgccaccacctgtcagctcctttccgggactttcgctttccccctc





cctattgccacggcggaactcatcgccgcctgccttgcccgctgctgg





acaggggctcggctgttgggcactgacaattccgtggtgttgtcgggg





aaatcatcgtcctttccttggctgctcgcctgtgttgccacctggatt





ctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg





gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgt





cttcgccttcgccctcagacgagtcggatctccctttgggccgcctcc





ccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctta





gccactttttaaaagaaaaggggggactggaagggctaattcactccc





aacgaagacaagatctgctttttgcttgtactgggtctctctggttag





accagatctgagcctgggagctctctggctaactagggaacccactgc





ttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccc





gtctgttgtgtgactctggtaactagagatccctcagacccttttagt





cagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcc





tcgactgtgccttctagttgccagccatctgttgtttgcccctccccc





gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa





taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt





ctggggggtggggggggcaggacagcaagggggaggattgggaagaca





atagcaggcatgctggggatgcggtgggctctatggcttctgaggcgg





aaagaaccagctggggctctagggggtatccccacgcgccctgtagcg





gcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgcta





cacttgccagcgccctagcgcccgctcctttcgctttcttcccttcct





ttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggc





tccctttagggttccgatttagtgctttacggcacctcgaccccaaaa





aacttgattagggtgatggttcacgtagtgggccatcgccctgataga





cggtttttcgccctttgacgttggagtccacgttctttaatagtggac





tcttgttccaaactggaacaacactcaaccctatctcggtctattctt





ttgatttataagggattttgccgatttcggcctattggttaaaaaatg





agctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtg





tcagttagggtgtggaaagtccccaggctccccagcaggcagaagtat





gcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccc





aggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtc





agcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc





gcccagttccgcccattctccgccccatggctgactaattttttttat





ttatgcagaggccgaggccgcctctgcctctgagctattccagaagta





gtgaggaggcttttttggaggcctaggcttttgcaaaaagctccctac





cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttc





ctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg





gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactca





cattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgt





cgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtt





tgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgct





cggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaa





tacggttatccacagaatcaggggataacgcaggaaagaacatgtgag





caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg





cgtttttccataggctccgcccccctgacgagcatcacaaaaatcgac





gctcaagtcagaggtggcgaaacccgacaggactataaagataccagg





cgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgc





cgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgc





tttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttc





gctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgct





gcgccttatccggtaactatcgtcttgagtccaacccggtaagacacg





acttatcgccactggcagcagccactggtaacaggattagcagagcga





ggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacg





gctacactagaagaacagtatttggtatctgcgctctgctgaagccag





ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacca





ccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgca





gaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagat





tatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtt





ttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacc





aatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgtt





catccatagttgcctgactccccgtcgtgtagataactacgatacggg





agggcttaccatctggccccagtgctgcaatgataccgcgagacccac





gctcaccggctccagatttatcagcaataaaccagccagccggaaggg





ccgagcgcagaagtggtcctgcaactttatccgcctccatccagtcta





ttaattgttgccgggaagctagagtaagtagttcgccagttaatagtt





tgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgt





cgtttggtatggcttcattcagctccggttcccaacgatcaaggcgag





ttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtc





ctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatgg





ttatggcagcactgcataattctcttactgtcatgccatccgtaagat





gcttttctgtgactggtgagtactcaaccaagtcattctgagaatagt





gtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataata





ccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgtt





cttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt





cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactt





tcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa





aaaagggaataagggcgacacggaaatgttgaatactcatactcttcc





tttttcaatattattgaagcatttatcagggttattgtctcatgagcg





gatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1110 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 48)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cgtcgggcttggggagaggagggttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





ccccaagaagaagaggaaagtcctcgagggggaggcgggagcggatcc





ccctcccggctccagatgttcttcgctaataaccacgaccaggaattt





gaccctccaaaggtttacccacctgtcccagctgagaagaggaagccc





atccgggtgctgtctctctttgatggaatcgctacagggctcctggtg





ctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtg





tgtgaggactccatcacggtgggcatggtgcggcaccaggggaagatc





atgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggag





tggggcccattcgatctggtgattgggggcagtccctgcaatgacctc





tccatcgtcaaccctgctcgcaagggcctctacgagggcactggccgg





ctcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggag





ggagatgatcgccccttcttctggctctttgcgaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccct





gtgatgattgatgccaaagaagtgtcagctgcacacagggcccgctac





ttctggggtaaccttcccggtatgaacaggccgttggcatccactgtg





aatgataagctggagctgcaggagtgtctggagcatggcaggatagcc





aagttcagcaaagtgaggaccattactacgaggtcaaactccataaag





cagggcaaagaccagcattttcctgtgttcatgaatgagaaagaggac





atcttatggtgcactgaaatggaaagggtatttggtttcccagtccac





tatactgacgtgtccaacatgagccgcttggcgaggcagagactgctg





ggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctg





aaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaaca





aacttctctctgctgaaacaagccggagatgtcgaagagaatcctgga





ccgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtc





cccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgcc





acgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgag





ctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtg





tgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggag





agcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggcc





gagttgagcggttcccggctggccgcgcagcaacagatggaaggcctc





ctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtc





ggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtg





ctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctg





gagacctccgcgccccgcaacctccccttctacgagcggctcggcttc





accgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgc





atgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacct





ctggattacaaaatttgtgaaagattgactggtattcttaactatgtt





gctccttttacgctatgtggatacgctgctttaatgcctttgtatcat





gctattgcttcccgtatggctttcattttctcctccttgtataaatcc





tggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgt





ggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggc





attgccaccacctgtcagctcctttccgggactttcgctttccccctc





cctattgccacggcggaactcatcgccgcctgccttgcccgctgctgg





acaggggctcggctgttgggcactgacaattccgtggtgttgtcgggg





aaatcatcgtcctttccttggctgctcgcctgtgttgccacctggatt





ctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg





gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgt





cttcgccttcgccctcagacgagtcggatctccctttgggccgcctcc





ccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctta





gccactttttaaaagaaaaggggggactggaagggctaattcactccc





aacgaagacaagatctgctttttgcttgtactgggtctctctggttag





accagatctgagcctgggagctctctggctaactagggaacccactgc





ttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccc





gtctgttgtgtgactctggtaactagagatccctcagacccttttagt





cagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcc





tcgactgtgccttctagttgccagccatctgttgtttgcccctccccc





gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa





taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt





ctggggggtggggggggcaggacagcaagggggaggattgggaagaca





atagcaggcatgctggggatgcggtgggctctatggcttctgaggcgg





aaagaaccagctggggctctagggggtatccccacgcgccctgtagcg





gcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgcta





cacttgccagcgccctagcgcccgctcctttcgctttcttcccttcct





ttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggc





tccctttagggttccgatttagtgctttacggcacctcgaccccaaaa





aacttgattagggtgatggttcacgtagtgggccatcgccctgataga





cggtttttcgccctttgacgttggagtccacgttctttaatagtggac





tcttgttccaaactggaacaacactcaaccctatctcggtctattctt





ttgatttataagggattttgccgatttcggcctattggttaaaaaatg





agctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtg





tcagttagggtgtggaaagtccccaggctccccagcaggcagaagtat





gcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccc





aggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtc





agcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc





gcccagttccgcccattctccgccccatggctgactaattttttttat





ttatgcagaggccgaggccgcctctgcctctgagctattccagaagta





gtgaggaggcttttttggaggcctaggcttttgcaaaaagctccctac





cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttc





ctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg





gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactca





cattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgt





cgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtt





tgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgct





cggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaa





tacggttatccacagaatcaggggataacgcaggaaagaacatgtgag





caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg





cgtttttccataggctccgcccccctgacgagcatcacaaaaatcgac





gctcaagtcagaggtggcgaaacccgacaggactataaagataccagg





cgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgc





cgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgc





tttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttc





gctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgct





gcgccttatccggtaactatcgtcttgagtccaacccggtaagacacg





acttatcgccactggcagcagccactggtaacaggattagcagagcga





ggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacg





gctacactagaagaacagtatttggtatctgcgctctgctgaagccag





ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacca





ccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgca





gaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagat





tatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtt





ttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacc





aatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgtt





catccatagttgcctgactccccgtcgtgtagataactacgatacggg





agggcttaccatctggccccagtgctgcaatgataccgcgagacccac





gctcaccggctccagatttatcagcaataaaccagccagccggaaggg





ccgagcgcagaagtggtcctgcaactttatccgcctccatccagtcta





ttaattgttgccgggaagctagagtaagtagttcgccagttaatagtt





tgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgt





cgtttggtatggcttcattcagctccggttcccaacgatcaaggcgag





ttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtc





ctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatgg





ttatggcagcactgcataattctcttactgtcatgccatccgtaagat





gcttttctgtgactggtgagtactcaaccaagtcattctgagaatagt





gtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataata





ccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgtt





cttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt





cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactt





tcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa





aaaagggaataagggcgacacggaaatgttgaatactcatactcttcc





tttttcaatattattgaagcatttatcagggttattgtctcatgagcg





gatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1111 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 49)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





gctctccccaccccaccttctgttttagagctagaaatagcaagttaa





aataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtg





cttttttgaattcgctagctaggtcttgaaaggagtgggaattggctc





cggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaa





gttggggggaggggtcggcaattgatccggtgcctagagaaggtggcg





cggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcc





cgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgtt





ctttttcgcaacgggtttgccgccagaacacaggaccggtgccaccat





ggactataaggaccacgacggagactacaaggatcatgatattgatta





caaagacgatgacgataagatggccccaaagaagaagcggaaggtcgg





tatccacggagtcccagcagccgacaagaagtacagcatcggcctggc





catcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaa





ggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacag





catcaagaagaacctgatcggagccctgctgttcgacagcggcgaaac





agccgaggccacccggctgaagagaaccgccagaagaagatacaccag





acggaagaaccggatctgctatctgcaagagatcttcagcaacgagat





ggccaaggtggacgacagcttcttccacagactggaagagtccttcct





ggtggaagaggataagaagcacgagcggcaccccatcttcggcaacat





cgtggacgaggtggcctaccacgagaagtaccccaccatctaccacct





gagaaagaaactggtggacagcaccgacaaggccgacctgcggctgat





ctatctggccctggcccacatgatcaagttccggggccacttcctgat





cgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcat





ccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaa





cgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaa





gagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaa





gaatggcctgttcggcaacctgattgccctgagcctgggcctgacccc





caacttcaagagcaacttcgacctggccgaggatgccaaactgcagct





gagcaaggacacctacgacgacgacctggacaacctgctggcccagat





cggcgaccagtacgccgacctgtttctggccgccaagaacctgtccga





cgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaa





ggcccccctgagcgcctctatgatcaagagatacgacgagcaccacca





ggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaa





gtacaaagagattttcttcgaccagagcaagaacggctacgccggcta





cattgacggcggagccagccaggaagagttctacaagttcatcaagcc





catcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaa





cagagaggacctgctgcggaagcagcggaccttcgacaacggcagcat





cccccaccagatccacctgggagagctgcacgccattctgcggcggca





ggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaa





gatcctgaccttccgcatcccctactacgtgggccctctggccagggg





aaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcac





cccctggaacttcgaggaagtggtggacaagggcgcttccgcccagag





cttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaa





ggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataa





cgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgc





cttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaa





gaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcg





gttcaacgcctccctgggcacataccacgatctgctgaaaattatcaa





ggacaaggacttcctggacaatgaggaaaacgaggacattctggaaga





tatcgtgctgaccctgacactgtttgaggacagagagatgatcgagga





acggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagca





gctgaagcggcggagatacaccggctggggcaggctgagccggaagct





gatcaacggcatccgggacaagcagtccggcaagacaatcctggattt





cctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcca





cgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtc





cggccagggcgatagcctgcacgagcacattgccaatctggccggcag





ccccgccattaagaagggcatcctgcagacagtgaaggtggtggacga





gctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcga





aatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcca





gatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaa





gctgtacctgtactacctgcagaatgggcgggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





ccccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatc





cccctcccggctccagatgttcttcgctaataaccacgaccaggaatt





tgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcc





catccgggtgctgtctctctttgatggaatcgctacagggctcctggt





gctgaaggacttgggcattcaggtggaccgctacattgcctcggaggt





gtgtgaggactccatcacggtgggcatggtgcggcaccaggggaagat





catgtacgtcggggacgtccgcagcgtcacacagaagcatatccagga





gtggggcccattcgatctggtgattgggggcagtccctgcaatgacct





ctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccg





gctcttctttgagttctaccgcctcctgcatgatgcgcggcccaagga





gggagatgatcgccccttcttctggctctttgcgaatgtggtggccat





gggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccc





tgtgatgattgatgccaaagaagtgtcagctgcacacagggcccgcta





cttctggggtaaccttcccggtatgaacaggccgttggcatccactgt





gaatgataagctggagctgcaggagtgtctggagcatggcaggatagc





caagttcagcaaagtgaggaccattactacgaggtcaaactccataaa





gcagggcaaagaccagcattttcctgtgttcatgaatgagaaagagga





catcttatggtgcactgaaatggaaagggtatttggtttcccagtcca





ctatactgacgtgtccaacatgagccgcttggcgaggcagagactgct





gggccggtcatggagcgtgccagtcatccgccacctcttcgctccgct





gaaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaac





aaacttctctctgctgaaacaagccggagatgtcgaagagaatcctgg





accgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgt





ccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgc





cacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccga





gctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggt





gtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccgga





gagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggc





cgagttgagcggttcccggctggccgcgcagcaacagatggaaggcct





cctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgt





cggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgt





gctccccggagtggaggcggccgagcgcgccggggtgcccgccttcct





ggagacctccgcgccccgcaacctccccttctacgagcggctcggctt





caccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtg





catgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacc





tctggattacaaaatttgtgaaagattgactggtattcttaactatgt





tgctccttttacgctatgtggatacgctgctttaatgcctttgtatca





tgctattgcttcccgtatggctttcattttctcctccttgtataaatc





ctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacg





tggcgtggtgtgcactgtgtttgctgacgcaacccccactggttgggg





cattgccaccacctgtcagctcctttccgggactttcgctttccccct





ccctattgccacggcggaactcatcgccgcctgccttgcccgctgctg





gacaggggctcggctgttgggcactgacaattccgtggtgttgtcggg





gaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggat





tctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagc





ggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcg





tcttcgccttcgccctcagacgagtcggatctccctttgggccgcctc





cccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctt





agccactttttaaaagaaaaggggggactggaagggctaattcactcc





caacgaagacaagatctgctttttgcttgtactgggtctctctggtta





gaccagatctgagcctgggagctctctggctaactagggaacccactg





cttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcc





cgtctgttgtgtgactctggtaactagagatccctcagacccttttag





tcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagc





ctcgactgtgccttctagttgccagccatctgttgtttgcccctcccc





cgtgccttccttgaccctggaaggtgccactcccactgtcctttccta





ataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctat





tctggggggtggggggggcaggacagcaagggggaggattgggaagac





aatagcaggcatgctggggatgcggtgggctctatggcttctgaggcg





gaaagaaccagctggggctctagggggtatccccacgcgccctgtagc





ggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgct





acacttgccagcgccctagcgcccgctcctttcgctttcttcccttcc





tttctcgccacgttcgccggctttccccgtcaagctctaaatcggggg





ctccctttagggttccgatttagtgctttacggcacctcgaccccaaa





aaacttgattagggtgatggttcacgtagtgggccatcgccctgatag





acggtttttcgccctttgacgttggagtccacgttctttaatagtgga





ctcttgttccaaactggaacaacactcaaccctatctcggtctattct





tttgatttataagggattttgccgatttcggcctattggttaaaaaat





gagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgt





gtcagttagggtgtggaaagtccccaggctccccagcaggcagaagta





tgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccc





caggctccccagcaggcagaagtatgcaaagcatgcatctcaattagt





cagcaaccatagtcccgcccctaactccgcccatcccgcccctaactc





cgcccagttccgcccattctccgccccatggctgactaatttttttta





tttatgcagaggccgaggccgcctctgcctctgagctattccagaagt





agtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccta





ccgtcgacctctagctagagcttggcgtaatcatggtcatagctgttt





cctgtgtgaaattgttatccgctcacaattccacacaacatacgagcc





ggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactc





acattaattgcgttgcgctcactgcccgctttccagtcgggaaacctg





tcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggt





ttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgc





tcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggta





atacggttatccacagaatcaggggataacgcaggaaagaacatgtga





gcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctg





gcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga





cgctcaagtcagaggtggcgaaacccgacaggactataaagataccag





gcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctg





ccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcg





ctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgtt





cgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgc





tgcgccttatccggtaactatcgtcttgagtccaacccggtaagacac





gacttatcgccactggcagcagccactggtaacaggattagcagagcg





aggtatgtaggcggtgctacagagttcttgaagtggtggcctaactac





ggctacactagaagaacagtatttggtatctgcgctctgctgaagcca





gttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacc





accgctggtagcggtggtttttttgtttgcaagcagcagattacgcgc





agaaaaaaaggatctcaagaagatcctttgatcttttctacggggtct





gacgctcagtggaacgaaaactcacgttaagggattttggtcatgaga





ttatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagt





tttaaatcaatctaaagtatatatgagtaaacttggtctgacagttac





caatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgt





tcatccatagttgcctgactccccgtcgtgtagataactacgatacgg





gagggcttaccatctggccccagtgctgcaatgataccgcgagaccca





cgctcaccggctccagatttatcagcaataaaccagccagccggaagg





gccgagcgcagaagtggtcctgcaactttatccgcctccatccagtct





attaattgttgccgggaagctagagtaagtagttcgccagttaatagt





ttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcg





tcgtttggtatggcttcattcagctccggttcccaacgatcaaggcga





gttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggt





cctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatg





gttatggcagcactgcataattctcttactgtcatgccatccgtaaga





tgcttttctgtgactggtgagtactcaaccaagtcattctgagaatag





tgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataat





accgcgccacatagcagaactttaaaagtgctcatcattggaaaacgt





tcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagt





tcgatgtaacccactcgtgcacccaactgatcttcagcatcttttact





ttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgca





aaaaagggaataagggcgacacggaaatgttgaatactcatactcttc





ctttttcaatattattgaagcatttatcagggttattgtctcatgagc





ggatacatatttgaatgtatttagaaaaataaacaaataggggttccg





cgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1112 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 50)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cgtgtgaagggagaatgaggaagttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





ccccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatc





cccctcccggctccagatgttcttcgctaataaccacgaccaggaatt





tgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcc





catccgggtgctgtctctctttgatggaatcgctacagggctcctggt





gctgaaggacttgggcattcaggtggaccgctacattgcctcggaggt





gtgtgaggactccatcacggtgggcatggtgcggcaccaggggaagat





catgtacgtcggggacgtccgcagcgtcacacagaagcatatccagga





gtggggcccattcgatctggtgattgggggcagtccctgcaatgacct





ctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccg





gctcttctttgagttctaccgcctcctgcatgatgcgcggcccaagga





gggagatgatcgccccttcttctggctctttgcgaatgtggtggccat





gggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccc





tgtgatgattgatgccaaagaagtgtcagctgcacacagggcccgcta





cttctggggtaaccttcccggtatgaacaggccgttggcatccactgt





gaatgataagctggagctgcaggagtgtctggagcatggcaggatagc





caagttcagcaaagtgaggaccattactacgaggtcaaactccataaa





gcagggcaaagaccagcattttcctgtgttcatgaatgagaaagagga





catcttatggtgcactgaaatggaaagggtatttggtttcccagtcca





ctatactgacgtgtccaacatgagccgcttggcgaggcagagactgct





gggccggtcatggagcgtgccagtcatccgccacctcttcgctccgct





gaaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaac





aaacttctctctgctgaaacaagccggagatgtcgaagagaatcctgg





accgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgt





ccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgc





cacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccga





gctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggt





gtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccgga





gagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggc





cgagttgagcggttcccggctggccgcgcagcaacagatggaaggcct





cctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgt





cggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgt





gctccccggagtggaggcggccgagcgcgccggggtgcccgccttcct





ggagacctccgcgccccgcaacctccccttctacgagcggctcggctt





caccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtg





catgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacc





tctggattacaaaatttgtgaaagattgactggtattcttaactatgt





tgctccttttacgctatgtggatacgctgctttaatgcctttgtatca





tgctattgcttcccgtatggctttcattttctcctccttgtataaatc





ctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacg





tggcgtggtgtgcactgtgtttgctgacgcaacccccactggttgggg





cattgccaccacctgtcagctcctttccgggactttcgctttccccct





ccctattgccacggcggaactcatcgccgcctgccttgcccgctgctg





gacaggggctcggctgttgggcactgacaattccgtggtgttgtcggg





gaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggat





tctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagc





ggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcg





tcttcgccttcgccctcagacgagtcggatctccctttgggccgcctc





cccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctt





agccactttttaaaagaaaaggggggactggaagggctaattcactcc





caacgaagacaagatctgctttttgcttgtactgggtctctctggtta





gaccagatctgagcctgggagctctctggctaactagggaacccactg





cttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcc





cgtctgttgtgtgactctggtaactagagatccctcagacccttttag





tcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagc





ctcgactgtgccttctagttgccagccatctgttgtttgcccctcccc





cgtgccttccttgaccctggaaggtgccactcccactgtcctttccta





ataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctat





tctggggggtggggggggcaggacagcaagggggaggattgggaagac





aatagcaggcatgctggggatgcggtgggctctatggcttctgaggcg





gaaagaaccagctggggctctagggggtatccccacgcgccctgtagc





ggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgct





acacttgccagcgccctagcgcccgctcctttcgctttcttcccttcc





tttctcgccacgttcgccggctttccccgtcaagctctaaatcggggg





ctccctttagggttccgatttagtgctttacggcacctcgaccccaaa





aaacttgattagggtgatggttcacgtagtgggccatcgccctgatag





acggtttttcgccctttgacgttggagtccacgttctttaatagtgga





ctcttgttccaaactggaacaacactcaaccctatctcggtctattct





tttgatttataagggattttgccgatttcggcctattggttaaaaaat





gagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgt





gtcagttagggtgtggaaagtccccaggctccccagcaggcagaagta





tgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccc





caggctccccagcaggcagaagtatgcaaagcatgcatctcaattagt





cagcaaccatagtcccgcccctaactccgcccatcccgcccctaactc





cgcccagttccgcccattctccgccccatggctgactaatttttttta





tttatgcagaggccgaggccgcctctgcctctgagctattccagaagt





agtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccta





ccgtcgacctctagctagagcttggcgtaatcatggtcatagctgttt





cctgtgtgaaattgttatccgctcacaattccacacaacatacgagcc





ggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactc





acattaattgcgttgcgctcactgcccgctttccagtcgggaaacctg





tcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggt





ttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgc





tcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggta





atacggttatccacagaatcaggggataacgcaggaaagaacatgtga





gcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctg





gcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga





cgctcaagtcagaggtggcgaaacccgacaggactataaagataccag





gcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctg





ccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcg





ctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgtt





cgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgc





tgcgccttatccggtaactatcgtcttgagtccaacccggtaagacac





gacttatcgccactggcagcagccactggtaacaggattagcagagcg





aggtatgtaggcggtgctacagagttcttgaagtggtggcctaactac





ggctacactagaagaacagtatttggtatctgcgctctgctgaagcca





gttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacc





accgctggtagcggtggtttttttgtttgcaagcagcagattacgcgc





agaaaaaaaggatctcaagaagatcctttgatcttttctacggggtct





gacgctcagtggaacgaaaactcacgttaagggattttggtcatgaga





ttatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagt





tttaaatcaatctaaagtatatatgagtaaacttggtctgacagttac





caatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgt





tcatccatagttgcctgactccccgtcgtgtagataactacgatacgg





gagggcttaccatctggccccagtgctgcaatgataccgcgagaccca





cgctcaccggctccagatttatcagcaataaaccagccagccggaagg





gccgagcgcagaagtggtcctgcaactttatccgcctccatccagtct





attaattgttgccgggaagctagagtaagtagttcgccagttaatagt





ttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcg





tcgtttggtatggcttcattcagctccggttcccaacgatcaaggcga





gttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggt





cctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatg





gttatggcagcactgcataattctcttactgtcatgccatccgtaaga





tgcttttctgtgactggtgagtactcaaccaagtcattctgagaatag





tgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataat





accgcgccacatagcagaactttaaaagtgctcatcattggaaaacgt





tcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagt





tcgatgtaacccactcgtgcacccaactgatcttcagcatcttttact





ttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgca





aaaaagggaataagggcgacacggaaatgttgaatactcatactcttc





ctttttcaatattattgaagcatttatcagggttattgtctcatgagc





ggatacatatttgaatgtatttagaaaaataaacaaataggggttccg





cgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1426 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 53)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cggcggtactgcaccaggcggcgttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





ccccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatc





cccctcccggctccagatgttcttcgctaataaccacgaccaggaatt





tgaccctccaaaggtttacccacctgtcccagctgagaagaggaagcc





catccgggtgctgtctctctttgatggaatcgctacagggctcctggt





gctgaaggacttgggcattcaggtggaccgctacattgcctcggaggt





gtgtgaggactccatcacggtgggcatggtgcggcaccaggggaagat





catgtacgtcggggacgtccgcagcgtcacacagaagcatatccagga





gtggggcccattcgatctggtgattgggggcagtccctgcaatgacct





ctccatcgtcaaccctgctcgcaagggcctctacgagggcactggccg





gctcttctttgagttctaccgcctcctgcatgatgcgcggcccaagga





gggagatgatcgccccttcttctggctctttgagaatgtggtggccat





gggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccc





tgtgatgattgatgccaaagaagtgtcagctgcacacagggcccgcta





cttctggggtaaccttcccggtatgaacaggccgttggcatccactgt





gaatgataagctggagctgcaggagtgtctggagcatggcaggatagc





caagttcagcaaagtgaggaccattactacgaggtcaaactccataaa





gcagggcaaagaccagcattttcctgtgttcatgaatgagaaagagga





catcttatggtgcactgaaatggaaagggtatttggtttcccagtcca





ctatactgacgtgtccaacatgagccgcttggcgaggcagagactgct





gggccggtcatggagcgtgccagtcatccgccacctcttcgctccgct





gaaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaac





aaacttctctctgctgaaacaagccggagatgtcgaagagaatcctgg





accgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgt





ccccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgc





cacgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccga





gctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggt





gtgggtcgcggacgacggcgccgcggtggcggtctggaccacgccgga





gagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggc





cgagttgagcggttcccggctggccgcgcagcaacagatggaaggcct





cctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgt





cggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgt





gctccccggagtggaggcggccgagcgcgccggggtgcccgccttcct





ggagacctccgcgccccgcaacctccccttctacgagcggctcggctt





caccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtg





catgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacc





tctggattacaaaatttgtgaaagattgactggtattcttaactatgt





tgctccttttacgctatgtggatacgctgctttaatgcctttgtatca





tgctattgcttcccgtatggctttcattttctcctccttgtataaatc





ctggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacg





tggcgtggtgtgcactgtgtttgctgacgcaacccccactggttgggg





cattgccaccacctgtcagctcctttccgggactttcgctttccccct





ccctattgccacggcggaactcatcgccgcctgccttgcccgctgctg





gacaggggctcggctgttgggcactgacaattccgtggtgttgtcggg





gaaatcatcgtcctttccttggctgctcgcctgtgttgccacctggat





tctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagc





ggaccttccttcccgcggcctgctgccggctctgcggcctcttccgcg





tcttcgccttcgccctcagacgagtcggatctccctttgggccgcctc





cccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctt





agccactttttaaaagaaaaggggggactggaagggctaattcactcc





caacgaagacaagatctgctttttgcttgtactgggtctctctggtta





gaccagatctgagcctgggagctctctggctaactagggaacccactg





cttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcc





cgtctgttgtgtgactctggtaactagagatccctcagacccttttag





tcagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagc





ctcgactgtgccttctagttgccagccatctgttgtttgcccctcccc





cgtgccttccttgaccctggaaggtgccactcccactgtcctttccta





ataaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctat





tctggggggtggggggggcaggacagcaagggggaggattgggaagac





aatagcaggcatgctggggatgcggtgggctctatggcttctgaggcg





gaaagaaccagctggggctctagggggtatccccacgcgccctgtagc





ggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgct





acacttgccagcgccctagcgcccgctcctttcgctttcttcccttcc





tttctcgccacgttcgccggctttccccgtcaagctctaaatcggggg





ctccctttagggttccgatttagtgctttacggcacctcgaccccaaa





aaacttgattagggtgatggttcacgtagtgggccatcgccctgatag





acggtttttcgccctttgacgttggagtccacgttctttaatagtgga





ctcttgttccaaactggaacaacactcaaccctatctcggtctattct





tttgatttataagggattttgccgatttcggcctattggttaaaaaat





gagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgt





gtcagttagggtgtggaaagtccccaggctccccagcaggcagaagta





tgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtccc





caggctccccagcaggcagaagtatgcaaagcatgcatctcaattagt





cagcaaccatagtcccgcccctaactccgcccatcccgcccctaactc





cgcccagttccgcccattctccgccccatggctgactaatttttttta





tttatgcagaggccgaggccgcctctgcctctgagctattccagaagt





agtgaggaggcttttttggaggcctaggcttttgcaaaaagctcccta





ccgtcgacctctagctagagcttggcgtaatcatggtcatagctgttt





cctgtgtgaaattgttatccgctcacaattccacacaacatacgagcc





ggaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactc





acattaattgcgttgcgctcactgcccgctttccagtcgggaaacctg





tcgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggt





ttgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgc





tcggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggta





atacggttatccacagaatcaggggataacgcaggaaagaacatgtga





gcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctg





gcgtttttccataggctccgcccccctgacgagcatcacaaaaatcga





cgctcaagtcagaggtggcgaaacccgacaggactataaagataccag





gcgtttccccctggaagctccctcgtgcgctctcctgttccgaccctg





ccgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcg





ctttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgtt





cgctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgc





tgcgccttatccggtaactatcgtcttgagtccaacccggtaagacac





gacttatcgccactggcagcagccactggtaacaggattagcagagcg





aggtatgtaggcggtgctacagagttcttgaagtggtggcctaactac





ggctacactagaagaacagtatttggtatctgcgctctgctgaagcca





gttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacc





accgctggtagcggtggtttttttgtttgcaagcagcagattacgcgc





agaaaaaaaggatctcaagaagatcctttgatcttttctacggggtct





gacgctcagtggaacgaaaactcacgttaagggattttggtcatgaga





ttatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagt





tttaaatcaatctaaagtatatatgagtaaacttggtctgacagttac





caatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgt





tcatccatagttgcctgactccccgtcgtgtagataactacgatacgg





gagggcttaccatctggccccagtgctgcaatgataccgcgagaccca





cgctcaccggctccagatttatcagcaataaaccagccagccggaagg





gccgagcgcagaagtggtcctgcaactttatccgcctccatccagtct





attaattgttgccgggaagctagagtaagtagttcgccagttaatagt





ttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcg





tcgtttggtatggcttcattcagctccggttcccaacgatcaaggcga





gttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggt





cctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatg





gttatggcagcactgcataattctcttactgtcatgccatccgtaaga





tgcttttctgtgactggtgagtactcaaccaagtcattctgagaatag





tgtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataat





accgcgccacatagcagaactttaaaagtgctcatcattggaaaacgt





tcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagt





tcgatgtaacccactcgtgcacccaactgatcttcagcatcttttact





ttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgca





aaaaagggaataagggcgacacggaaatgttgaatactcatactcttc





ctttttcaatattattgaagcatttatcagggttattgtctcatgagc





ggatacatatttgaatgtatttagaaaaataaacaaataggggttccg





cgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1427 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 54)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaaaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggcggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





ggggcgcggacatggaggacggttttagagctagaaatagcaagttaa





aataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtg





cttttttgaattcgctagctaggtcttgaaaggagtgggaattggctc





cggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaa





gttggggggaggggtcggcaattgatccggtgcctagagaaggtggcg





cggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcc





cgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgtt





ctttttcgcaacgggtttgccgccagaacacaggaccggtgccaccat





ggactataaggaccacgacggagactacaaggatcatgatattgatta





caaagacgatgacgataagatggccccaaagaagaagcggaaggtcgg





tatccacggagtcccagcagccgacaagaagtacagcatcggcctggc





catcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaa





ggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacag





catcaagaagaacctgatcggagccctgctgttcgacagcggcgaaac





agccgaggccacccggctgaagagaaccgccagaagaagatacaccag





acggaagaaccggatctgctatctgcaagagatcttcagcaacgagat





ggccaaggtggacgacagcttcttccacagactggaagagtccttcct





ggtggaagaggataagaagcacgagcggcaccccatcttcggcaacat





cgtggacgaggtggcctaccacgagaagtaccccaccatctaccacct





gagaaagaaactggtggacagcaccgacaaggccgacctgcggctgat





ctatctggccctggcccacatgatcaagttccggggccacttcctgat





cgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcat





ccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaa





cgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaa





gagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaa





gaatggcctgttcggcaacctgattgccctgagcctgggcctgacccc





caacttcaagagcaacttcgacctggccgaggatgccaaactgcagct





gagcaaggacacctacgacgacgacctggacaacctgctggcccagat





cggcgaccagtacgccgacctgtttctggccgccaagaacctgtccga





cgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaa





ggcccccctgagcgcctctatgatcaagagatacgacgagcaccacca





ggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaa





gtacaaagagattttcttcgaccagagcaagaacggctacgccggcta





cattgacggcggagccagccaggaagagttctacaagttcatcaagcc





catcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaa





cagagaggacctgctgcggaagcagcggaccttcgacaacggcagcat





cccccaccagatccacctgggagagctgcacgccattctgcggcggca





ggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaa





gatcctgaccttccgcatcccctactacgtgggccctctggccagggg





aaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcac





cccctggaacttcgaggaagtggtggacaagggcgcttccgcccagag





cttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaa





ggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataa





cgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgc





cttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaa





gaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcg





gttcaacgcctccctgggcacataccacgatctgctgaaaattatcaa





ggacaaggacttcctggacaatgaggaaaacgaggacattctggaaga





tatcgtgctgaccctgacactgtttgaggacagagagatgatcgagga





acggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagca





gctgaagcggcggagatacaccggctggggcaggctgagccggaagct





gatcaacggcatccgggacaagcagtccggcaagacaatcctggattt





cctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcca





cgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtc





cggccagggcgatagcctgcacgagcacattgccaatctggccggcag





ccccgccattaagaagggcatcctgcagacagtgaaggtggtggacga





gctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcga





aatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcca





gatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaa





gctgtacctgtactacctgcagaatggggggatatgtacgtggaccag





gaactggacatcaaccggctgtccgactacgatgtggacgctatcgtg





cctcagagctttctgaaggacgactccatcgacaacaaggtgctgacc





agaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagag





gtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaag





ctgattacccagagaaagttcgacaatctgaccaaggccgagagaggc





ggcctgagcgaactggataaggccggcttcatcaagagacagctggtg





gaaacccggcagatcacaaagcacgtggcacagatactagattcccga





atgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaa





gtaatcactttaaagtcaaaattggtgtcggacttcagaaaggatttt





caattctataaagttagggagataaataactaccaccatgcgcacgac





gcttatcttaatgccgtcgtagggaccgcactcattaagaaatacccg





aagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtc





cgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcc





aaatacttcttttattctaacattatgaatttctttaagacggaaatc





actctggcaaacggagagatacgcaaacgacctttaattgaaaccaat





ggggagacaggtgaaatcgtatgggataagggccgggacttcgcgacg





gtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaact





gaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagg





aatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaag





tacggtggcttcgtgagccctacagttgcctattctgtcctagtagtg





gcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaa





ttattggggataacgattatggagcgctcgtcttttgaaaagaacccc





atcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctc





ataattaaactaccaaagtatagtctgtttgagttagaaaatggccga





aaacggatgttggctagcgccagagagcttcaaaaggggaacgaactc





gcactaccgtctaaatacgtgaatttcctgtatttagcgtcccattac





gagaagttgaaaggttcacctgaagataacgaacagaagcaacttttt





gttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcg





gaattcagtaagagagtcatcctagctgatgccaatctggacaaagta





ttaagcgcatacaacaagcacagggataaacccatacgtgagcaggcg





gaaaatattatccatttgtttactcttaccaacctcggcgctccagcc





gcattcaagtattttgacacaacgatagatcgcaaagagtacagatct





accaaggaggtgctagacgcgacactgattcaccaatccatcacggga





ttatatgaaactcggatagatttgtcacagcttgggggtgacggatcc





cccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatcc





ccctcccggctccagatgttcttcgctaataaccacgaccaggaattt





gaccctccaaaggtttacccacctgtcccagctgagaagaggaagccc





atccgggtgctgtctctctttgatggaatcgctacagggctcctggtg





ctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtg





tgtgaggactccatcacggtgggcatggtgcggcaccaggggaagatc





atgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggag





tggggcccattcgatctggtgattgggggcagtccctgcaatgacctc





tccatcgtcaaccctgctcgcaagggcctctacgagggcactggccgg





ctcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggag





ggagatgatcgccccttcttctggctctttgagaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccct





gtgatgattgatgccaaagaagtgtcagctgcacacagggcccgctac





ttctggggtaaccttcccggtatgaacaggccgttggcatccactgtg





aatgataagctggagctgcaggagtgtctggagcatggcaggatagcc





aagttcagcaaagtgaggaccattactacgaggtcaaactccataaag





cagggcaaagaccagcattttcctgtgttcatgaatgagaaagaggac





atcttatggtgcactgaaatggaaagggtatttggtttcccagtccac





tatactgacgtgtccaacatgagccgcttggcgaggcagagactgctg





ggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctg





aaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaaca





aacttctctctgctgaaacaagccggagatgtcgaagagaatcctgga





ccgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtc





cccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgcc





acgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgag





ctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtg





tgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggag





agcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggcc





gagttgagcggttcccggctggccgcgcagcaacagatggaaggcctc





ctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtc





ggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtg





ctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctg





gagacctccgcgccccgcaacctccccttctacgagcggctcggcttc





accgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgc





atgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacct





ctggattacaaaatttgtgaaagattgactggtattcttaactatgtt





gctccttttacgctatgtggatacgctgctttaatgcctttgtatcat





gctattgcttcccgtatggctttcattttctcctccttgtataaatcc





tggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgt





ggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggc





attgccaccacctgtcagctcctttccgggactttcgctttccccctc





cctattgccacggcggaactcatcgccgcctgccttgcccgctgctgg





acaggggctcggctgttgggcactgacaattccgtggtgttgtcgggg





aaatcatcgtcctttccttggctgctcgcctgtgttgccacctggatt





ctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg





gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgt





cttcgccttcgccctcagacgagtcggatctccctttgggccgcctcc





ccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctta





gccactttttaaaagaaaaggggggactggaagggctaattcactccc





aacgaagacaagatctgctttttgcttgtactgggtctctctggttag





accagatctgagcctgggagctctctggctaactagggaacccactgc





ttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccc





gtctgttgtgtgactctggtaactagagatccctcagacccttttagt





cagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcc





tcgactgtgccttctagttgccagccatctgttgtttgcccctccccc





gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa





taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt





ctggggggtggggggggcaggacagcaagggggaggattgggaagaca





atagcaggcatgctggggatgcggtgggctctatggcttctgaggcgg





aaagaaccagctggggctctagggggtatccccacgcgccctgtagcg





gcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgcta





cacttgccagcgccctagcgcccgctcctttcgctttcttcccttcct





ttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggc





tccctttagggttccgatttagtgctttacggcacctcgaccccaaaa





aacttgattagggtgatggttcacgtagtgggccatcgccctgataga





cggtttttcgccctttgacgttggagtccacgttctttaatagtggac





tcttgttccaaactggaacaacactcaaccctatctcggtctattctt





ttgatttataagggattttgccgatttcggcctattggttaaaaaatg





agctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtg





tcagttagggtgtggaaagtccccaggctccccagcaggcagaagtat





gcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccc





aggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtc





agcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc





gcccagttccgcccattctccgccccatggctgactaattttttttat





ttatgcagaggccgaggccgcctctgcctctgagctattccagaagta





gtgaggaggcttttttggaggcctaggcttttgcaaaaagctccctac





cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttc





ctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg





gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactca





cattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgt





cgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtt





tgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgct





cggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaa





tacggttatccacagaatcaggggataacgcaggaaagaacatgtgag





caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg





cgtttttccataggctccgcccccctgacgagcatcacaaaaatcgac





gctcaagtcagaggtggcgaaacccgacaggactataaagataccagg





cgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgc





cgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgc





tttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttc





gctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgct





gcgccttatccggtaactatcgtcttgagtccaacccggtaagacacg





acttatcgccactggcagcagccactggtaacaggattagcagagcga





ggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacg





gctacactagaagaacagtatttggtatctgcgctctgctgaagccag





ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacca





ccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgca





gaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagat





tatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtt





ttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacc





aatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgtt





catccatagttgcctgactccccgtcgtgtagataactacgatacggg





agggcttaccatctggccccagtgctgcaatgataccgcgagacccac





gctcaccggctccagatttatcagcaataaaccagccagccggaaggg





ccgagcgcagaagtggtcctgcaactttatccgcctccatccagtcta





ttaattgttgccgggaagctagagtaagtagttcgccagttaatagtt





tgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgt





cgtttggtatggcttcattcagctccggttcccaacgatcaaggcgag





ttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtc





ctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatgg





ttatggcagcactgcataattctcttactgtcatgccatccgtaagat





gcttttctgtgactggtgagtactcaaccaagtcattctgagaatagt





gtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataata





ccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgtt





cttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt





cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactt





tcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa





aaaagggaataagggcgacacggaaatgttgaatactcatactcttcc





tttttcaatattattgaagcatttatcagggttattgtctcatgagcg





gatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1428 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 55)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacgggggaggtctatataagcag





cgcgttttgcctgtactgggtctctctggttagaccagatctgagcct





gggagctctctggctaactagggaacccactgcttaagcctcaataaa





gcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgact





ctggtaactagagatccctcagacccttttagtcagtgtggaaaatct





ctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccaga





ggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaag





aggcgaggggcggcgactggtgagtacgccaaaaattttgactagcgg





aggctagaaggagagagatgggtgcgagagcgtcagtattaagcgggg





gagaattagatcgcgatgggaaaaaattcggttaaggccagggggaaa





gaaaaaatataaattaaaacatatagtatgggcaagcagggagctaga





acgattcgcagttaatcctggcctgttagaaacatcagaaggctgtag





acaaatactgggacagctacaaccatcccttcagacaggatcagaaga





acttagatcattatataatacagtagcaaccctctattgtgtgcatca





aaggatagagataaaagacaccaaggaagctttagacaagatagagga





agagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggggaacggtaccgagggcctat





ttcccatgattccttcatatttgcatatacgatacaaggctgttagag





agataattagaattaatttgactgtaaacacaaagatattagtacaaa





atacgtgacgtagaaagtaataatttcttgggtagtttgcagttttaa





aattatgttttaaaatggactatcatatgcttaccgtaacttgaaagt





atttcgatttcttggctttatatatcttgtggaaaggacgaaacaccg





gcggtactgcaccaggcggcgttttagagctagaaatagcaagttaaa





ataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc





ttttttgaattcgctagctaggtcttgaaaggagtgggaattggctcc





ggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaag





ttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgc





ggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttccc





gaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttc





tttttcgcaacgggtttgccgccagaacacaggaccggtgccaccatg





gactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggt





atccacggagtcccagcagccgacaagaagtacagcatcggcctggcc





atcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaag





gtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacagc





atcaagaagaacctgatcggagccctgctgttcgacagcggcgaaaca





gccgaggccacccggctgaagagaaccgccagaagaagatacaccaga





cggaagaaccggatctgctatctgcaagagatcttcagcaacgagatg





gccaaggtggacgacagcttcttccacagactggaagagtccttcctg





gtggaagaggataagaagcacgagcggcaccccatcttcggcaacatc





gtggacgaggtggcctaccacgagaagtaccccaccatctaccacctg





agaaagaaactggtggacagcaccgacaaggccgacctgcggctgatc





tatctggccctggcccacatgatcaagttccggggccacttcctgatc





gagggcgacctgaaccccgacaacagcgacgtggacaagctgttcatc





cagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaac





gccagcggcgtggacgccaaggccatcctgtctgccagactgagcaag





agcagacggctggaaaatctgatcgcccagctgcccggcgagaagaag





aatggcctgttcggcaacctgattgccctgagcctgggcctgaccccc





aacttcaagagcaacttcgacctggccgaggatgccaaactgcagctg





agcaaggacacctacgacgacgacctggacaacctgctggcccagatc





ggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgac





gccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaag





gcccccctgagcgcctctatgatcaagagatacgacgagcaccaccag





gacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaag





tacaaagagattttcttcgaccagagcaagaacggctacgccggctac





attgacggcggagccagccaggaagagttctacaagttcatcaagccc





atcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaac





agagaggacctgctgcggaagcagcggaccttcgacaacggcagcatc





ccccaccagatccacctgggagagctgcacgccattctgcggcggcag





gaagatttttacccattcctgaaggacaaccgggaaaagatcgagaag





atcctgaccttccgcatcccctactacgtgggccctctggccagggga





aacagcagattcgcctggatgaccagaaagagcgaggaaaccatcacc





ccctggaacttcgaggaagtggtggacaagggcgcttccgcccagagc





ttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaag





gtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataac





gagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgcc





ttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaag





accaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaag





aaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcgg





ttcaacgcctccctgggcacataccacgatctgctgaaaattatcaag





gacaaggacttcctggacaatgaggaaaacgaggacattctggaagat





atcgtgctgaccctgacactgtttgaggacagagagatgatcgaggaa





cggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcag





ctgaagcggcggagatacaccggctggggcaggctgagccggaagctg





atcaacggcatccgggacaagcagtccggcaagacaatcctggatttc





ctgaagtccgacggcttcgccaacagaaacttcatgcagctgatccac





gacgacagcctgacctttaaagaggacatccagaaagcccaggtgtcc





ggccagggcgatagcctgcacgagcacattgccaatctggccggcagc





cccgccattaagaagggcatcctgcagacagtgaaggtggtggacgag





ctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcgaa





atggccagagagaaccagaccacccagaagggacagaagaacagccgc





gagagaatgaagcggatcgaagagggcatcaaagagctgggcagccag





atcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaag





ctgtacctgtactacctgcagaatggggggatatgtacgtggaccagg





aactggacatcaaccggctgtccgactacgatgtggacgctatcgtgc





ctcagagctttctgaaggacgactccatcgacaacaaggtgctgacca





gaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagagg





tcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagc





tgattacccagagaaagttcgacaatctgaccaaggccgagagaggcg





gcctgagcgaactggataaggccggcttcatcaagagacagctggtgg





aaacccggcagatcacaaagcacgtggcacagatactagattcccgaa





tgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaag





taatcactttaaagtcaaaattggtgtcggacttcagaaaggattttc





aattctataaagttagggagataaataactaccaccatgcgcacgacg





cttatcttaatgccgtcgtagggaccgcactcattaagaaatacccga





agctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtcc





gtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcca





aatacttcttttattctaacattatgaatttctttaagacggaaatca





ctctggcaaacggagagatacgcaaacgacctttaattgaaaccaatg





gggagacaggtgaaatcgtatgggataagggccgggacttcgcgacgg





tgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaactg





aggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagga





atagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaagt





acggtggcttcgtgagccctacagttgcctattctgtcctagtagtgg





caaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaat





tattggggataacgattatggagcgctcgtcttttgaaaagaacccca





tcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctca





taattaaactaccaaagtatagtctgtttgagttagaaaatggccgaa





aacggatgttggctagcgccagagagcttcaaaaggggaacgaactcg





cactaccgtctaaatacgtgaatttcctgtatttagcgtcccattacg





agaagttgaaaggttcacctgaagataacgaacagaagcaactttttg





ttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcgg





aattcagtaagagagtcatcctagctgatgccaatctggacaaagtat





taagcgcatacaacaagcacagggataaacccatacgtgagcaggcgg





aaaatattatccatttgtttactcttaccaacctcggcgctccagccg





cattcaagtattttgacacaacgatagatcgcaaagagtacagatcta





ccaaggaggtgctagacgcgacactgattcaccaatccatcacgggat





tatatgaaactcggatagatttgtcacagcttgggggtgacggatccc





ccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatccc





cctcccggctccagatgttcttcgctaataaccacgaccaggaatttg





accctccaaaggtttacccacctgtcccagctgagaagaggaagccca





tccgggtgctgtctctctttgatggaatcgctacagggctcctggtgc





tgaaggacttgggcattcaggtggaccgctacattgcctcggaggtgt





gtgaggactccatcacggtgggcatggtgcggcaccaggggaagatca





tgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggagt





ggggcccattcgatctggtgattgggggcagtccctgcaatgacctct





ccatcgtcaaccctgctcgcaagggcctctacgagggcactggccggc





tcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggagg





gagatgatcgccccttcttctggctctttgcgaatgtggtggccatgg





gcgttagtgacaagagggacatctcgcgatttctcgagtccaaccctg





tgatgattgatgccaaagaagtgtcagctgcacacagggcccgctact





tctggggtaaccttcccggtatgaacaggccgttggcatccactgtga





atgataagctggagctgcaggagtgtctggagcatggcaggatagcca





agttcagcaaagtgaggaccattactacgaggtcaaactccataaagc





agggcaaagaccagcattttcctgtgttcatgaatgagaaagaggaca





tcttatggtgcactgaaatggaaagggtatttggtttcccagtccact





atactgacgtgtccaacatgagccgcttggcgaggcagagactgctgg





gccggtcatggagcgtgccagtcatccgccacctcttcgctccgctga





aggagtattttgcgtgtgtgtccggccggcccggatccggcgcaacaa





acttctctctgctgaaacaagccggagatgtcgaagagaatcctggac





cgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtcc





ccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgcca





cgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgagc





tgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtgt





gggtcgcggacgacggcgccgcggtggcggtctggaccacgccggaga





gcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggccg





agttgagcggttcccggctggccgcgcagcaacagatggaaggcctcc





tggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtcg





gagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtgc





tccccggagtggaggcggccgagcgcgccggggtgcccgccttcctgg





agacctccgcgccccgcaacctccccttctacgagcggctcggcttca





ccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgca





tgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacctc





tggattacaaaatttgtgaaagattgactggtattcttaactatgttg





ctccttttacgctatgtggatacgctgctttaatgcctttgtatcatg





ctattgcttcccgtatggctttcattttctcctccttgtataaatcct





ggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgtg





gcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggca





ttgccaccacctgtcagctcctttccgggactttcgctttccccctcc





ctattgccacggcggaactcatcgccgcctgccttgcccgctgctgga





caggggctcggctgttgggcactgacaattccgtggtgttgtcgggga





aatcatcgtcctttccttggctgctcgcctgtgttgccacctggattc





tgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcgg





accttccttcccgcggcctgctgccggctctgcggcctcttccgcgtc





ttcgccttcgccctcagacgagtcggatctccctttgggccgcctccc





cgcgtcgactttaagaccaatgacttacaaggcagctgtagatcttag





ccactttttaaaagaaaaggggggactggaagggctaattcactccca





acgaagacaagatctgctttttgcttgtactgggtctctctggttaga





ccagatctgagcctgggagctctctggctaactagggaacccactgct





taagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgcccg





tctgttgtgtgactctggtaactagagatccctcagacccttttagtc





agtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcct





cgactgtgccttctagttgccagccatctgttgtttgcccctcccccg





tgccttccttgaccctggaaggtgccactcccactgtcctttcctaat





aaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctattc





tggggggtggggggggcaggacagcaagggggaggattgggaagacaa





tagcaggcatgctggggatgcggtgggctctatggcttctgaggcgga





aagaaccagctggggctctagggggtatccccacgcgccctgtagcgg





cgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctac





acttgccagcgccctagcgcccgctcctttcgctttcttcccttcctt





tctcgccacgttcgccggctttccccgtcaagctctaaatcgggggct





ccctttagggttccgatttagtgctttacggcacctcgaccccaaaaa





acttgattagggtgatggttcacgtagtgggccatcgccctgatagac





ggtttttcgccctttgacgttggagtccacgttctttaatagtggact





cttgttccaaactggaacaacactcaaccctatctcggtctattcttt





tgatttataagggattttgccgatttcggcctattggttaaaaaatga





gctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtgt





cagttagggtgtggaaagtccccaggctccccagcaggcagaagtatg





caaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccca





ggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtca





gcaaccatagtcccgcccctaactccgcccatcccgcccctaactccg





cccagttccgcccattctccgccccatggctgactaattttttttatt





tatgcagaggccgaggccgcctctgcctctgagctattccagaagtag





tgaggaggcttttttggaggcctaggcttttgcaaaaagctccctacc





gtcgacctctagctagagcttggcgtaatcatggtcatagctgtttcc





tgtgtgaaattgttatccgctcacaattccacacaacatacgagccgg





aagcataaagtgtaaagcctggggtgcctaatgagtgagctaactcac





attaattgcgttgcgctcactgcccgctttccagtcgggaaacctgtc





gtgccagctgcattaatgaatcggccaacgcgcggggagaggcggttt





gcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgctc





ggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaat





acggttatccacagaatcaggggataacgcaggaaagaacatgtgagc





aaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggc





gtttttccataggctccgcccccctgacgagcatcacaaaaatcgacg





ctcaagtcagaggtggcgaaacccgacaggactataaagataccaggc





gtttccccctggaagctccctcgtgcgctctcctgttccgaccctgcc





gcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgct





ttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttcg





ctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctg





cgccttatccggtaactatcgtcttgagtccaacccggtaagacacga





cttatcgccactggcagcagccactggtaacaggattagcagagcgag





gtatgtaggcggtgctacagagttcttgaagtggtggcctaactacgg





ctacactagaagaacagtatttggtatctgcgctctgctgaagccagt





taccttcggaaaaagagttggtagctcttgatccggcaaacaaaccac





cgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcag





aaaaaaaggatctcaagaagatcctttgatcttttctacggggtctga





cgctcagtggaacgaaaactcacgttaagggattttggtcatgagatt





atcaaaaaggatcttcacctagatccttttaaattaaaaatgaagttt





taaatcaatctaaagtatatatgagtaaacttggtctgacagttacca





atgcttaatcagtgaggcacctatctcagcgatctgtctatttcgttc





atccatagttgcctgactccccgtcgtgtagataactacgatacggga





gggcttaccatctggccccagtgctgcaatgataccgcgagacccacg





ctcaccggctccagatttatcagcaataaaccagccagccggaagggc





cgagcgcagaagtggtcctgcaactttatccgcctccatccagtctat





taattgttgccgggaagctagagtaagtagttcgccagttaatagttt





gcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgtc





gtttggtatggcttcattcagctccggttcccaacgatcaaggcgagt





tacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcc





tccgatcgttgtcagaagtaagttggccgcagtgttatcactcatggt





tatggcagcactgcataattctcttactgtcatgccatccgtaagatg





cttttctgtgactggtgagtactcaaccaagtcattctgagaatagtg





tatgcggcgaccgagttgctcttgcccggcgtcaatacgggataatac





cgcgccacatagcagaactttaaaagtgctcatcattggaaaacgttc





ttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttc





gatgtaacccactcgtgcacccaactgatcttcagcatcttttacttt





caccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaaa





aaagggaataagggcgacacggaaatgttgaatactcatactcttcct





ttttcaatattattgaagcatttatcagggttattgtctcatgagcgg





atacatatttgaatgtatttagaaaaataaacaaataggggttccgcg





cacatttccccgaaaagtgccacct.






In an aspect, a disclosed pBK1428 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 56)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





ggggcgcggacatggaggacggttttagagctagaaatagcaagttaa





aataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtg





cttttttgaattcgctagctaggtcttgaaaggagtgggaattggctc





cggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaa





gttggggggaggggtcggcaattgatccggtgcctagagaaggtggcg





cggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttcc





cgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgtt





ctttttcgcaacgggtttgccgccagaacacaggaccggtgccaccat





ggactataaggaccacgacggagactacaaggatcatgatattgatta





caaagacgatgacgataagatggccccaaagaagaagcggaaggtcgg





tatccacggagtcccagcagccgacaagaagtacagcatcggcctggc





catcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaa





ggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacag





catcaagaagaacctgatcggagccctgctgttcgacagcggcgaaac





agccgaggccacccggctgaagagaaccgccagaagaagatacaccag





acggaagaaccggatctgctatctgcaagagatcttcagcaacgagat





ggccaaggtggacgacagcttcttccacagactggaagagtccttcct





ggtggaagaggataagaagcacgagcggcaccccatcttcggcaacat





cgtggacgaggtggcctaccacgagaagtaccccaccatctaccacct





gagaaagaaactggtggacagcaccgacaaggccgacctgcggctgat





ctatctggccctggcccacatgatcaagttccggggccacttcctgat





cgagggcgacctgaaccccgacaacagcgacgtggacaagctgttcat





ccagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaa





cgccagcggcgtggacgccaaggccatcctgtctgccagactgagcaa





gagcagacggctggaaaatctgatcgcccagctgcccggcgagaagaa





gaatggcctgttcggcaacctgattgccctgagcctgggcctgacccc





caacttcaagagcaacttcgacctggccgaggatgccaaactgcagct





gagcaaggacacctacgacgacgacctggacaacctgctggcccagat





cggcgaccagtacgccgacctgtttctggccgccaagaacctgtccga





cgccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaa





ggcccccctgagcgcctctatgatcaagagatacgacgagcaccacca





ggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaa





gtacaaagagattttcttcgaccagagcaagaacggctacgccggcta





cattgacggcggagccagccaggaagagttctacaagttcatcaagcc





catcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaa





cagagaggacctgctgcggaagcagcggaccttcgacaacggcagcat





cccccaccagatccacctgggagagctgcacgccattctgcggcggca





ggaagatttttacccattcctgaaggacaaccgggaaaagatcgagaa





gatcctgaccttccgcatcccctactacgtgggccctctggccagggg





aaacagcagattcgcctggatgaccagaaagagcgaggaaaccatcac





cccctggaacttcgaggaagtggtggacaagggcgcttccgcccagag





cttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaa





ggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataa





cgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgc





cttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaa





gaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaa





gaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcg





gttcaacgcctccctgggcacataccacgatctgctgaaaattatcaa





ggacaaggacttcctggacaatgaggaaaacgaggacattctggaaga





tatcgtgctgaccctgacactgtttgaggacagagagatgatcgagga





acggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagca





gctgaagcggcggagatacaccggctggggcaggctgagccggaagct





gatcaacggcatccgggacaagcagtccggcaagacaatcctggattt





cctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcca





cgacgacagcctgacctttaaagaggacatccagaaagcccaggtgtc





cggccagggcgatagcctgcacgagcacattgccaatctggccggcag





ccccgccattaagaagggcatcctgcagacagtgaaggtggtggacga





gctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcga





aatggccagagagaaccagaccacccagaagggacagaagaacagccg





cgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcca





gatcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaa





gctgtacctgtactacctgcagaatggggggatatgtacgtggaccag





gaactggacatcaaccggctgtccgactacgatgtggacgctatcgtg





cctcagagctttctgaaggacgactccatcgacaacaaggtgctgacc





agaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagag





gtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaag





ctgattacccagagaaagttcgacaatctgaccaaggccgagagaggc





ggcctgagcgaactggataaggccggcttcatcaagagacagctggtg





gaaacccggcagatcacaaagcacgtggcacagatactagattcccga





atgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaa





gtaatcactttaaagtcaaaattggtgtcggacttcagaaaggatttt





caattctataaagttagggagataaataactaccaccatgcgcacgac





gcttatcttaatgccgtcgtagggaccgcactcattaagaaatacccg





aagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtc





cgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcc





aaatacttcttttattctaacattatgaatttctttaagacggaaatc





actctggcaaacggagagatacgcaaacgacctttaattgaaaccaat





ggggagacaggtgaaatcgtatgggataagggccgggacttcgcgacg





gtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaact





gaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagg





aatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaag





tacggtggcttcgtgagccctacagttgcctattctgtcctagtagtg





gcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaa





ttattggggataacgattatggagcgctcgtcttttgaaaagaacccc





atcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctc





ataattaaactaccaaagtatagtctgtttgagttagaaaatggccga





aaacggatgttggctagcgccagagagcttcaaaaggggaacgaactc





gcactaccgtctaaatacgtgaatttcctgtatttagcgtcccattac





gagaagttgaaaggttcacctgaagataacgaacagaagcaacttttt





gttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcg





gaattcagtaagagagtcatcctagctgatgccaatctggacaaagta





ttaagcgcatacaacaagcacagggataaacccatacgtgagcaggcg





gaaaatattatccatttgtttactcttaccaacctcggcgctccagcc





gcattcaagtattttgacacaacgatagatcgcaaagagtacagatct





accaaggaggtgctagacgcgacactgattcaccaatccatcacggga





ttatatgaaactcggatagatttgtcacagcttgggggtgacggatcc





cccaagaagaagaggaaagtcctcgagggcggaggcgggagcggatcc





ccctcccggctccagatgttcttcgctaataaccacgaccaggaattt





gaccctccaaaggtttacccacctgtcccagctgagaagaggaagccc





atccgggtgctgtctctctttgatggaatcgctacagggctcctggtg





ctgaaggacttgggcattcaggtggaccgctacattgcctcggaggtg





tgtgaggactccatcacggtgggcatggtgcggcaccaggggaagatc





atgtacgtcggggacgtccgcagcgtcacacagaagcatatccaggag





tggggcccattcgatctggtgattgggggcagtccctgcaatgacctc





tccatcgtcaaccctgctcgcaagggcctctacgagggcactggccgg





ctcttctttgagttctaccgcctcctgcatgatgcgcggcccaaggag





ggagatgatcgccccttcttctggctctttgcgaatgtggtggccatg





ggcgttagtgacaagagggacatctcgcgatttctcgagtccaaccct





gtgatgattgatgccaaagaagtgtcagctgcacacagggcccgctac





ttctggggtaaccttcccggtatgaacaggccgttggcatccactgtg





aatgataagctggagctgcaggagtgtctggagcatggcaggatagcc





aagttcagcaaagtgaggaccattactacgaggtcaaactccataaag





cagggcaaagaccagcattttcctgtgttcatgaatgagaaagaggac





atcttatggtgcactgaaatggaaagggtatttggtttcccagtccac





tatactgacgtgtccaacatgagccgcttggcgaggcagagactgctg





ggccggtcatggagcgtgccagtcatccgccacctcttcgctccgctg





aaggagtattttgcgtgtgtgtccggccggcccggatccggcgcaaca





aacttctctctgctgaaacaagccggagatgtcgaagagaatcctgga





ccgaccgagtacaagcccacggtgcgcctcgccacccgcgacgacgtc





cccagggccgtacgcaccctcgccgccgcgttcgccgactaccccgcc





acgcgccacaccgtcgatccggaccgccacatcgagcgggtcaccgag





ctgcaagaactcttcctcacgcgcgtcgggctcgacatcggcaaggtg





tgggtcgcggacgacggcgccgcggtggcggtctggaccacgccggag





agcgtcgaagcgggggcggtgttcgccgagatcggcccgcgcatggcc





gagttgagcggttcccggctggccgcgcagcaacagatggaaggcctc





ctggcgccgcaccggcccaaggagcccgcgtggttcctggccaccgtc





ggagtctcgcccgaccaccagggcaagggtctgggcagcgccgtcgtg





ctccccggagtggaggcggccgagcgcgccggggtgcccgccttcctg





gagacctccgcgccccgcaacctccccttctacgagcggctcggcttc





accgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacctggtgc





atgacccgcaagcccggtgcctgaacgcgttaagtcgacaatcaacct





ctggattacaaaatttgtgaaagattgactggtattcttaactatgtt





gctccttttacgctatgtggatacgctgctttaatgcctttgtatcat





gctattgcttcccgtatggctttcattttctcctccttgtataaatcc





tggttgctgtctctttatgaggagttgtggcccgttgtcaggcaacgt





ggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggc





attgccaccacctgtcagctcctttccgggactttcgctttccccctc





cctattgccacggcggaactcatcgccgcctgccttgcccgctgctgg





acaggggctcggctgttgggcactgacaattccgtggtgttgtcgggg





aaatcatcgtcctttccttggctgctcgcctgtgttgccacctggatt





ctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcg





gaccttccttcccgcggcctgctgccggctctgcggcctcttccgcgt





cttcgccttcgccctcagacgagtcggatctccctttgggccgcctcc





ccgcgtcgactttaagaccaatgacttacaaggcagctgtagatctta





gccactttttaaaagaaaaggggggactggaagggctaattcactccc





aacgaagacaagatctgctttttgcttgtactgggtctctctggttag





accagatctgagcctgggagctctctggctaactagggaacccactgc





ttaagcctcaataaagcttgccttgagtgcttcaagtagtgtgtgccc





gtctgttgtgtgactctggtaactagagatccctcagacccttttagt





cagtgtggaaaatctctagcagggcccgtttaaacccgctgatcagcc





tcgactgtgccttctagttgccagccatctgttgtttgcccctccccc





gtgccttccttgaccctggaaggtgccactcccactgtcctttcctaa





taaaatgaggaaattgcatcgcattgtctgagtaggtgtcattctatt





ctggggggtggggggggcaggacagcaagggggaggattgggaagaca





atagcaggcatgctggggatgcggtgggctctatggcttctgaggcgg





aaagaaccagctggggctctagggggtatccccacgcgccctgtagcg





gcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgcta





cacttgccagcgccctagcgcccgctcctttcgctttcttcccttcct





ttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggc





tccctttagggttccgatttagtgctttacggcacctcgaccccaaaa





aacttgattagggtgatggttcacgtagtgggccatcgccctgataga





cggtttttcgccctttgacgttggagtccacgttctttaatagtggac





tcttgttccaaactggaacaacactcaaccctatctcggtctattctt





ttgatttataagggattttgccgatttcggcctattggttaaaaaatg





agctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtg





tcagttagggtgtggaaagtccccaggctccccagcaggcagaagtat





gcaaagcatgcatctcaattagtcagcaaccaggtgtggaaagtcccc





aggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtc





agcaaccatagtcccgcccctaactccgcccatcccgcccctaactcc





gcccagttccgcccattctccgccccatggctgactaattttttttat





ttatgcagaggccgaggccgcctctgcctctgagctattccagaagta





gtgaggaggcttttttggaggcctaggcttttgcaaaaagctccctac





cgtcgacctctagctagagcttggcgtaatcatggtcatagctgtttc





ctgtgtgaaattgttatccgctcacaattccacacaacatacgagccg





gaagcataaagtgtaaagcctggggtgcctaatgagtgagctaactca





cattaattgcgttgcgctcactgcccgctttccagtcgggaaacctgt





cgtgccagctgcattaatgaatcggccaacgcgcggggagaggcggtt





tgcgtattgggcgctcttccgcttcctcgctcactgactcgctgcgct





cggtcgttcggctgcggcgagcggtatcagctcactcaaaggcggtaa





tacggttatccacagaatcaggggataacgcaggaaagaacatgtgag





caaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctgg





cgtttttccataggctccgcccccctgacgagcatcacaaaaatcgac





gctcaagtcagaggtggcgaaacccgacaggactataaagataccagg





cgtttccccctggaagctccctcgtgcgctctcctgttccgaccctgc





cgcttaccggatacctgtccgcctttctcccttcgggaagcgtggcgc





tttctcatagctcacgctgtaggtatctcagttcggtgtaggtcgttc





gctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgct





gcgccttatccggtaactatcgtcttgagtccaacccggtaagacacg





acttatcgccactggcagcagccactggtaacaggattagcagagcga





ggtatgtaggcggtgctacagagttcttgaagtggtggcctaactacg





gctacactagaagaacagtatttggtatctgcgctctgctgaagccag





ttaccttcggaaaaagagttggtagctcttgatccggcaaacaaacca





ccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgca





gaaaaaaaggatctcaagaagatcctttgatcttttctacggggtctg





acgctcagtggaacgaaaactcacgttaagggattttggtcatgagat





tatcaaaaaggatcttcacctagatccttttaaattaaaaatgaagtt





ttaaatcaatctaaagtatatatgagtaaacttggtctgacagttacc





aatgcttaatcagtgaggcacctatctcagcgatctgtctatttcgtt





catccatagttgcctgactccccgtcgtgtagataactacgatacggg





agggcttaccatctggccccagtgctgcaatgataccgcgagacccac





gctcaccggctccagatttatcagcaataaaccagccagccggaaggg





ccgagcgcagaagtggtcctgcaactttatccgcctccatccagtcta





ttaattgttgccgggaagctagagtaagtagttcgccagttaatagtt





tgcgcaacgttgttgccattgctacaggcatcgtggtgtcacgctcgt





cgtttggtatggcttcattcagctccggttcccaacgatcaaggcgag





ttacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtc





ctccgatcgttgtcagaagtaagttggccgcagtgttatcactcatgg





ttatggcagcactgcataattctcttactgtcatgccatccgtaagat





gcttttctgtgactggtgagtactcaaccaagtcattctgagaatagt





gtatgcggcgaccgagttgctcttgcccggcgtcaatacgggataata





ccgcgccacatagcagaactttaaaagtgctcatcattggaaaacgtt





cttcggggcgaaaactctcaaggatcttaccgctgttgagatccagtt





cgatgtaacccactcgtgcacccaactgatcttcagcatcttttactt





tcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgccgcaa





aaaagggaataagggcgacacggaaatgttgaatactcatactcttcc





tttttcaatattattgaagcatttatcagggttattgtctcatgagcg





gatacatatttgaatgtatttagaaaaataaacaaataggggttccgc





gcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1531 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 59)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cggcggtactgcaccaggcggcgttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





cccaaagaagaaacggaaggtgggtggaggaagtggcgggtcaggtgg





ctctagacggacactggtgaccttcaaggatgtatttgtggacttcac





cagggaggagtggaagctgctggacactgctcagcagatcgtgtacag





aaatgtgatgctggagaactataagaacctggtttccttgggttatca





gcttactaagccagatgtgatcctccggttggagaagggagaagagcc





ctcgggaggtggttcgggaggtggttcggagggtgtgcaggtgaaaag





ggtcctggagaaaagtcctgggaagctccttgtcaagatgccttttca





aacttcgccagggggcaaggctgaggggggtggggccaccacatccac





ccaggtcatggtgatcaaacgccccggcaggaagcgaaaagctgaggc





cgaccctcaggccattcccaagaaacggggccgaaagccggggagtgt





ggtggcagccgctgccgccgaggccaaaaagaaagccgtgaaggagtc





ttctatccgatctgtgcaggagacagtactccccatcaagaagcgcaa





gacccgggagggcgcgcccaagaagaagaggaaagtctccggatccgg





cgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaa





tcctggaccgaccgagtacaagcccacggtgcgcctcgccacccgcga





cgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgacta





ccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggt





caccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcgg





caaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccac





gccggagagcgtcgaagcgggggcggtgttcgccgagatcggcccgcg





catggccgagttgagcggttcccggctggccgcgcagcaacagatgga





aggcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggc





caccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgc





cgtcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgc





cttcctggagacctccgcgccccgcaacctccccttctacgagcggct





cggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcac





ctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaa





tcaacctctggattacaaaatttgtgaaagattgactggtattcttaa





ctatgttgctccttttacgctatgtggatacgctgctttaatgccttt





gtatcatgctattgcttcccgtatggctttcattttctcctccttgta





taaatcctggttgctgtctctttatgaggagttgtggcccgttgtcag





gcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactgg





ttggggcattgccaccacctgtcagctcctttccgggactttcgcttt





ccccctccctattgccacggcggaactcatcgccgcctgccttgcccg





ctgctggacaggggctcggctgttgggcactgacaattccgtggtgtt





gtcggggaaatcatcgtcctttccttggctgctcgcctgtgttgccac





ctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaa





tccagcggaccttccttcccgcggcctgctgccggctctgcggcctct





tccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggc





cgcctccccgcgtcgactttaagaccaatgacttacaaggcagctgta





gatcttagccactttttaaaagaaaaggggggactggaagggctaatt





cactcccaacgaagacaagatctgctttttgcttgtactgggtctctc





tggttagaccagatctgagcctgggagctctctggctaactagggaac





ccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtg





tgtgcccgtctgttgtgtgactctggtaactagagatccctcagaccc





ttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctg





atcagcctcgactgtgccttctagttgccagccatctgttgtttgccc





ctcccccgtgccttccttgaccctggaaggtgccactcccactgtcct





ttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtca





ttctattctggggggtggggggggcaggacagcaagggggaggattgg





gaagacaatagcaggcatgctggggatgcggtgggctctatggcttct





gaggcggaaagaaccagctggggctctagggggtatccccacgcgccc





tgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtg





accgctacacttgccagcgccctagcgcccgctcctttcgctttcttc





ccttcctttctcgccacgttcgccggctttccccgtcaagctctaaat





cgggggctccctttagggttccgatttagtgctttacggcacctcgac





cccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccc





tgatagacggtttttcgccctttgacgttggagtccacgttctttaat





agtggactcttgttccaaactggaacaacactcaaccctatctcggtc





tattcttttgatttataagggattttgccgatttcggcctattggtta





aaaaatgagctgatttaacaaaaatttaacgcgaattaattctgtgga





atgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggca





gaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaa





agtccccaggctccccagcaggcagaagtatgcaaagcatgcatctca





attagtcagcaaccatagtcccgcccctaactccgcccatcccgcccc





taactccgcccagttccgcccattctccgccccatggctgactaattt





tttttatttatgcagaggccgaggccgcctctgcctctgagctattcc





agaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagc





tccctaccgtcgacctctagctagagcttggcgtaatcatggtcatag





ctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagc





taactcacattaattgcgttgcgctcactgcccgctttccagtcggga





aacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggaga





ggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcg





ctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaag





gcggtaatacggttatccacagaatcaggggataacgcaggaaagaac





atgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcg





ttgctggcgtttttccataggctccgcccccctgacgagcatcacaaa





aatcgacgctcaagtcagaggtggcgaaacccgacaggactataaaga





taccaggcgtttccccctggaagctccctcgtgcgctctcctgttccg





accctgccgcttaccggatacctgtccgcctttctcccttcgggaagc





gtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtag





gtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagccc





gaccgctgcgccttatccggtaactatcgtcttgagtccaacccggta





agacacgacttatcgccactggcagcagccactggtaacaggattagc





agagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcct





aactacggctacactagaagaacagtatttggtatctgcgctctgctg





aagccagttaccttcggaaaaagagttggtagctcttgatccggcaaa





caaaccaccgctggtagcggtggtttttttgtttgcaagcagcagatt





acgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacg





gggtctgacgctcagtggaacgaaaactcacgttaagggattttggtc





atgagattatcaaaaaggatcttcacctagatccttttaaattaaaaa





tgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtcta





tttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcga





gacccacgctcaccggctccagatttatcagcaataaaccagccagcc





ggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatc





cagtctattaattgttgccgggaagctagagtaagtagttcgccagtt





aatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtca





cgctcgtcgtttggtatggcttcattcagctccggttcccaacgatca





aggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctcc





ttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatca





ctcatggttatggcagcactgcataattctcttactgtcatgccatcc





gtaagatgcttttctgtgactggtgagtactcaaccaagtcattctga





gaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgg





gataataccgcgccacatagcagaactttaaaagtgctcatcattgga





aaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgaga





tccagttcgatgtaacccactcgtgcacccaactgatcttcagcatct





tttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaat





gccgcaaaaaagggaataagggcgacacggaaatgttgaatactcata





ctcttcctttttcaatattattgaagcatttatcagggttattgtctc





atgagcggatacatatttgaatgtatttagaaaaataaacaaataggg





gttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1532 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth









(SEQ ID NO: 60)


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaacaaaagtaagaccaccgcacagcaagcggccgctgatc





ttcagacctggaggaggagatatgagggacaattggagaagtgaatta





tataaatataaagtagtaaaaattgaaccattaggagtagcacccacc





aaggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaata





ggagctttgttccttgggttcttgggagcagcaggaagcactatgggc





gcagcgtcaatgacgctgacggtacaggccagacaattattgtctggt





atagtgcagcagcagaacaatttgctgagggctattgaggcgcaacag





catctgttgcaactcacagtctggggcatcaagcagctccaggcaaga





atcctggctgtggaaagatacctaaaggatcaacagctcctggggatt





tggggttgctctggaaaactcatttgcaccactgctgtgccttggaat





gctagttggagtaataaatctctggaacagatttggaatcacacgacc





tggatggagtgggacagagaaattaacaattacacaagcttaatacac





tccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaa





ttattggaattagataaatgggcaagtttgtggaattggtttaacata





acaaattggctgtggtatataaaattattcataatgatagtaggaggc





ttggtaggtttaagaatagtttttgctgtactttctatagtgaataga





gttaggcagggatattcaccattatcgtttcagacccacctcccaacc





ccgaggggacccgacaggcccgaaggaatagaagaagaaggtggagag





agagacagagacagatccattcgattagtgaacggatcggcactgcgt





gcgccaattctgcagacaaatggcagtattcatccacaattttaaaag





aaaaggggggattggggggtacagtgcaggggaaagaatagtagacat





aatagcaacagacatacaaactaaagaattacaaaaacaaattacaaa





aattcaaaattttcgggtttattacagggacagcagagatccagtttg





gttaattaatggggggacgttaacggggcggaacggtaccgagggcct





atttcccatgattccttcatatttgcatatacgatacaaggctgttag





agagataattagaattaatttgactgtaaacacaaagatattagtaca





aaatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttt





aaaattatgttttaaaatggactatcatatgcttaccgtaacttgaaa





gtatttcgatttcttggctttatatatcttgtggaaaggacgaaacac





cggggcgcggacatggaggacggttttagagctagaaatagcaagtta





aaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggt





gcttttttgaattcgctagctaggtcttgaaaggagtgggaattggct





ccggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgaga





agttggggggaggggtcggcaattgatccggtgcctagagaaggtggc





gcggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttc





ccgaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgt





tctttttcgcaacgggtttgccgccagaacacaggaccggtgccacca





tggactataaggaccacgacggagactacaaggatcatgatattgatt





acaaagacgatgacgataagatggccccaaagaagaagcggaaggtcg





gtatccacggagtcccagcagccgacaagaagtacagcatcggcctgg





ccatcggcaccaactctgtgggctgggccgtgatcaccgacgagtaca





aggtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcaca





gcatcaagaagaacctgatcggagccctgctgttcgacagcggcgaaa





cagccgaggccacccggctgaagagaaccgccagaagaagatacacca





gacggaagaaccggatctgctatctgcaagagatcttcagcaacgaga





tggccaaggtggacgacagcttcttccacagactggaagagtccttcc





tggtggaagaggataagaagcacgagcggcaccccatcttcggcaaca





tcgtggacgaggtggcctaccacgagaagtaccccaccatctaccacc





tgagaaagaaactggtggacagcaccgacaaggccgacctgcggctga





tctatctggccctggcccacatgatcaagttccggggccacttcctga





tcgagggcgacctgaaccccgacaacagcgacgtggacaagctgttca





tccagctggtgcagacctacaaccagctgttcgaggaaaaccccatca





acgccagcggcgtggacgccaaggccatcctgtctgccagactgagca





agagcagacggctggaaaatctgatcgcccagctgcccggcgagaaga





agaatggcctgttcggcaacctgattgccctgagcctgggcctgaccc





ccaacttcaagagcaacttcgacctggccgaggatgccaaactgcagc





tgagcaaggacacctacgacgacgacctggacaacctgctggcccaga





tcggcgaccagtacgccgacctgtttctggccgccaagaacctgtccg





acgccatcctgctgagcgacatcctgagagtgaacaccgagatcacca





aggcccccctgagcgcctctatgatcaagagatacgacgagcaccacc





aggacctgaccctgctgaaagctctcgtgcggcagcagctgcctgaga





agtacaaagagattttcttcgaccagagcaagaacggctacgccggct





acattgacggcggagccagccaggaagagttctacaagttcatcaagc





ccatcctggaaaagatggacggcaccgaggaactgctcgtgaagctga





acagagaggacctgctgcggaagcagcggaccttcgacaacggcagca





tcccccaccagatccacctgggagagctgcacgccattctgcggcggc





aggaagatttttacccattcctgaaggacaaccgggaaaagatcgaga





agatcctgaccttccgcatcccctactacgtgggccctctggccaggg





gaaacagcagattcgcctggatgaccagaaagagcgaggaaaccatca





ccccctggaacttcgaggaagtggtggacaagggcgcttccgcccaga





gcttcatcgagcggatgaccaacttcgataagaacctgcccaacgaga





aggtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtata





acgagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccg





ccttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttca





agaccaaccggaaagtgaccgtgaagcagctgaaagaggactacttca





agaaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatc





ggttcaacgcctccctgggcacataccacgatctgctgaaaattatca





aggacaaggacttcctggacaatgaggaaaacgaggacattctggaag





atatcgtgctgaccctgacactgtttgaggacagagagatgatcgagg





aacggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagc





agctgaagcggcggagatacaccggctggggcaggctgagccggaagc





tgatcaacggcatccgggacaagcagtccggcaagacaatcctggatt





tcctgaagtccgacggcttcgccaacagaaacttcatgcagctgatcc





acgacgacagcctgacctttaaagaggacatccagaaagcccaggtgt





ccggccagggcgatagcctgcacgagcacattgccaatctggccggca





gccccgccattaagaagggcatcctgcagacagtgaaggtggtggacg





agctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcg





aaatggccagagagaaccagaccacccagaagggacagaagaacagcc





gcgagagaatgaagcggatcgaagagggcatcaaagagctgggcagcc





agatcctgaaagaacaccccgtggaaaacacccagctgcagaacgaga





agctgtacctgtactacctgcagaatggggggatatgtacgtggacca





ggaactggacatcaaccggctgtccgactacgatgtggacgctatcgt





gcctcagagctttctgaaggacgactccatcgacaacaaggtgctgac





cagaagcgacaagaaccggggcaagagcgacaacgtgccctccgaaga





ggtcgtgaagaagatgaagaactactggcggcagctgctgaacgccaa





gctgattacccagagaaagttcgacaatctgaccaaggccgagagagg





cggcctgagcgaactggataaggccggcttcatcaagagacagctggt





ggaaacccggcagatcacaaagcacgtggcacagatactagattcccg





aatgaatacgaaatacgacgagaacgataagctgattcgggaagtcaa





agtaatcactttaaagtcaaaattggtgtcggacttcagaaaggattt





tcaattctataaagttagggagataaataactaccaccatgcgcacga





cgcttatcttaatgccgtcgtagggaccgcactcattaagaaataccc





gaagctagaaagtgagtttgtgtatggtgattacaaagtttatgacgt





ccgtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagc





caaatacttcttttattctaacattatgaatttctttaagacggaaat





cactctggcaaacggagagatacgcaaacgacctttaattgaaaccaa





tggggagacaggtgaaatcgtatgggataagggccgggacttcgcgac





ggtgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaac





tgaggtgcagaccggagggttttcaaaggaatcgattcttccaaaaag





gaatagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaa





gtacggtggcttcgtgagccctacagttgcctattctgtcctagtagt





ggcaaaagttgagaagggaaaatccaagaaactgaagtcagtcaaaga





attattggggataacgattatggagcgctcgtcttttgaaaagaaccc





catcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatct





cataattaaactaccaaagtatagtctgtttgagttagaaaatggccg





aaaacggatgttggctagcgccagagagcttcaaaaggggaacgaact





cgcactaccgtctaaatacgtgaatttcctgtatttagcgtcccatta





cgagaagttgaaaggttcacctgaagataacgaacagaagcaactttt





tgttgagcagcacaaacattatctcgacgaaatcatagagcaaatttc





ggaattcagtaagagagtcatcctagctgatgccaatctggacaaagt





attaagcgcatacaacaagcacagggataaacccatacgtgagcaggc





ggaaaatattatccatttgtttactcttaccaacctcggcgctccagc





cgcattcaagtattttgacacaacgatagatcgcaaagagtacagatc





taccaaggaggtgctagacgcgacactgattcaccaatccatcacggg





attatatgaaactcggatagatttgtcacagcttgggggtgacggatc





cccaaagaagaaacggaaggtgggtggaggaagtggcgggtcaggtgg





ctctagacggacactggtgaccttcaaggatgtatttgtggacttcac





cagggaggagtggaagctgctggacactgctcagcagatcgtgtacag





aaatgtgatgctggagaactataagaacctggtttccttgggttatca





gcttactaagccagatgtgatcctccggttggagaagggagaagagcc





ctcgggaggtggttcgggaggtggttcggagggtgtgcaggtgaaaag





ggtcctggagaaaagtcctgggaagctccttgtcaagatgccttttca





aacttcgccagggggcaaggctgaggggggtggggccaccacatccac





ccaggtcatggtgatcaaacgccccggcaggaagcgaaaagctgaggc





cgaccctcaggccattcccaagaaacggggccgaaagccggggagtgt





ggtggcagccgctgccgccgaggccaaaaagaaagccgtgaaggagtc





ttctatccgatctgtgcaggagacagtactccccatcaagaagcgcaa





gacccgggagggcgcgcccaagaagaagaggaaagtctccggatccgg





cgcaacaaacttctctctgctgaaacaagccggagatgtcgaagagaa





tcctggaccgaccgagtacaagcccacggtgcgcctcgccacccgcga





cgacgtccccagggccgtacgcaccctcgccgccgcgttcgccgacta





ccccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggt





caccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcgg





caaggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccac





gccggagagcgtcgaagcgggggcggtgttcgccgagatcggcccgcg





catggccgagttgagcggttcccggctggccgcgcagcaacagatgga





aggcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggc





caccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgc





cgtcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgc





cttcctggagacctccgcgccccgcaacctccccttctacgagcggct





cggcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcac





ctggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaa





tcaacctctggattacaaaatttgtgaaagattgactggtattcttaa





ctatgttgctccttttacgctatgtggatacgctgctttaatgccttt





gtatcatgctattgcttcccgtatggctttcattttctcctccttgta





taaatcctggttgctgtctctttatgaggagttgtggcccgttgtcag





gcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactgg





ttggggcattgccaccacctgtcagctcctttccgggactttcgcttt





ccccctccctattgccacggcggaactcatcgccgcctgccttgcccg





ctgctggacaggggctcggctgttgggcactgacaattccgtggtgtt





gtcggggaaatcatcgtcctttccttggctgctcgcctgtgttgccac





ctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaa





tccagcggaccttccttcccgcggcctgctgccggctctgcggcctct





tccgcgtcttcgccttcgccctcagacgagtcggatctccctttgggc





cgcctccccgcgtcgactttaagaccaatgacttacaaggcagctgta





gatcttagccactttttaaaagaaaaggggggactggaagggctaatt





cactcccaacgaagacaagatctgctttttgcttgtactgggtctctc





tggttagaccagatctgagcctgggagctctctggctaactagggaac





ccactgcttaagcctcaataaagcttgccttgagtgcttcaagtagtg





tgtgcccgtctgttgtgtgactctggtaactagagatccctcagaccc





ttttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctg





atcagcctcgactgtgccttctagttgccagccatctgttgtttgccc





ctcccccgtgccttccttgaccctggaaggtgccactcccactgtcct





ttcctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtca





ttctattctggggggtggggggggcaggacagcaagggggaggattgg





gaagacaatagcaggcatgctggggatgcggtgggctctatggcttct





gaggcggaaagaaccagctggggctctagggggtatccccacgcgccc





tgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtg





accgctacacttgccagcgccctagcgcccgctcctttcgctttcttc





ccttcctttctcgccacgttcgccggctttccccgtcaagctctaaat





cgggggctccctttagggttccgatttagtgctttacggcacctcgac





cccaaaaaacttgattagggtgatggttcacgtagtgggccatcgccc





tgatagacggtttttcgccctttgacgttggagtccacgttctttaat





agtggactcttgttccaaactggaacaacactcaaccctatctcggtc





tattcttttgatttataagggattttgccgatttcggcctattggtta





aaaaatgagctgatttaacaaaaatttaacgcgaattaattctgtgga





atgtgtgtcagttagggtgtggaaagtccccaggctccccagcaggca





gaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaa





agtccccaggctccccagcaggcagaagtatgcaaagcatgcatctca





attagtcagcaaccatagtcccgcccctaactccgcccatcccgcccc





taactccgcccagttccgcccattctccgccccatggctgactaattt





tttttatttatgcagaggccgaggccgcctctgcctctgagctattcc





agaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagc





tccctaccgtcgacctctagctagagcttggcgtaatcatggtcatag





ctgtttcctgtgtgaaattgttatccgctcacaattccacacaacata





cgagccggaagcataaagtgtaaagcctggggtgcctaatgagtgagc





taactcacattaattgcgttgcgctcactgcccgctttccagtcggga





aacctgtcgtgccagctgcattaatgaatcggccaacgcgcggggaga





ggcggtttgcgtattgggcgctcttccgcttcctcgctcactgactcg





ctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaag





gcggtaatacggttatccacagaatcaggggataacgcaggaaagaac





atgtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcg





ttgctggcgtttttccataggctccgcccccctgacgagcatcacaaa





aatcgacgctcaagtcagaggtggcgaaacccgacaggactataaaga





taccaggcgtttccccctggaagctccctcgtgcgctctcctgttccg





accctgccgcttaccggatacctgtccgcctttctcccttcgggaagc





gtggcgctttctcatagctcacgctgtaggtatctcagttcggtgtag





gtcgttcgctccaagctgggctgtgtgcacgaaccccccgttcagccc





gaccgctgcgccttatccggtaactatcgtcttgagtccaacccggta





agacacgacttatcgccactggcagcagccactggtaacaggattagc





agagcgaggtatgtaggcggtgctacagagttcttgaagtggtggcct





aactacggctacactagaagaacagtatttggtatctgcgctctgctg





aagccagttaccttcggaaaaagagttggtagctcttgatccggcaaa





caaaccaccgctggtagcggtggtttttttgtttgcaagcagcagatt





acgcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacg





gggtctgacgctcagtggaacgaaaactcacgttaagggattttggtc





atgagattatcaaaaaggatcttcacctagatccttttaaattaaaaa





tgaagttttaaatcaatctaaagtatatatgagtaaacttggtctgac





agttaccaatgcttaatcagtgaggcacctatctcagcgatctgtcta





tttcgttcatccatagttgcctgactccccgtcgtgtagataactacg





atacgggagggcttaccatctggccccagtgctgcaatgataccgcga





gacccacgctcaccggctccagatttatcagcaataaaccagccagcc





ggaagggccgagcgcagaagtggtcctgcaactttatccgcctccatc





cagtctattaattgttgccgggaagctagagtaagtagttcgccagtt





aatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtca





cgctcgtcgtttggtatggcttcattcagctccggttcccaacgatca





aggcgagttacatgatcccccatgttgtgcaaaaaagcggttagctcc





ttcggtcctccgatcgttgtcagaagtaagttggccgcagtgttatca





ctcatggttatggcagcactgcataattctcttactgtcatgccatcc





gtaagatgcttttctgtgactggtgagtactcaaccaagtcattctga





gaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacgg





gataataccgcgccacatagcagaactttaaaagtgctcatcattgga





aaacgttcttcggggcgaaaactctcaaggatcttaccgctgttgaga





tccagttcgatgtaacccactcgtgcacccaactgatcttcagcatct





tttactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaat





gccgcaaaaaagggaataagggcgacacggaaatgttgaatactcata





ctcttcctttttcaatattattgaagcatttatcagggttattgtctc





atgagcggatacatatttgaatgtatttagaaaaataaacaaataggg





gttccgcgcacatttccccgaaaagtgccacctgac.






In an aspect, a disclosed pBK1536 plasmid can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:









(SEQ ID NO: 61) 


gtcgacggatcgggagatctcccgatcccctatggtgcactctcagta





caatctgctctgatgccgcatagttaagccagtatctgctccctgctt





gtgtgttggaggtcgctgagtagtgcgcgagcaaaatttaagctacaa





caaggcaaggcttgaccgacaattgcatgaagaatctgcttagggtta





ggcgttttgcgctgcttcgcgatgtacgggccagatatacgcgttgac





attgattattgactagttattaatagtaatcaattacggggtcattag





ttcatagcccatatatggagttccgcgttacataacttacggtaaatg





gcccgcctggctgaccgcccaacgacccccgcccattgacgtcaataa





tgacgtatgttcccatagtaacgccaatagggactttccattgacgtc





aatgggtggagtatttacggtaaactgcccacttggcagtacatcaag





tgtatcatatgccaagtacgccccctattgacgtcaatgacggtaaat





ggcccgcctggcattatgcccagtacatgaccttatgggactttccta





cttggcagtacatctacgtattagtcatcgctattaccatggtgatgc





ggttttggcagtacatcaatgggcgtggatagcggtttgactcacggg





gatttccaagtctccaccccattgacgtcaatgggagtttgttttggc





accaaaatcaacgggactttccaaaatgtcgtaacaactccgccccat





tgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagca





gcgcgttttgcctgtactgggtctctctggttagaccagatctgagcc





tgggagctctctggctaactagggaacccactgcttaagcctcaataa





agcttgccttgagtgcttcaagtagtgtgtgcccgtctgttgtgtgac





tctggtaactagagatccctcagacccttttagtcagtgtggaaaatc





tctagcagtggcgcccgaacagggacttgaaagcgaaagggaaaccag





aggagctctctcgacgcaggactcggcttgctgaagcgcgcacggcaa





gaggcgaggggcggcgactggtgagtacgccaaaaattttgactagcg





gaggctagaaggagagagatgggtgcgagagcgtcagtattaagcggg





ggagaattagatcgcgatgggaaaaaattcggttaaggccagggggaa





agaaaaaatataaattaaaacatatagtatgggcaagcagggagctag





aacgattcgcagttaatcctggcctgttagaaacatcagaaggctgta





gacaaatactgggacagctacaaccatcccttcagacaggatcagaag





aacttagatcattatataatacagtagcaaccctctattgtgtgcatc





aaaggatagagataaaagacaccaaggaagctttagacaagatagagg





aagagcaaaaaaaagtaagaccaccgcacagcaagcggccgctgatct





tcagacctggaggaggagatatgagggacaattggagaagtgaattat





ataaatataaagtagtaaaaattgaaccattaggagtagcacccacca





aggcaaagagaagagtggtgcagagagaaaaaagagcagtgggaatag





gagctttgttccttgggttcttgggagcagcaggaagcactatgggcg





cagcgtcaatgacgctgacggtacaggccagacaattattgtctggta





tagtgcagcagcagaacaatttgctgagggctattgaggcgcaacagc





atctgttgcaactcacagtctggggcatcaagcagctccaggcaagaa





tcctggctgtggaaagatacctaaaggatcaacagctcctggggattt





ggggttgctctggaaaactcatttgcaccactgctgtgccttggaatg





ctagttggagtaataaatctctggaacagatttggaatcacacgacct





ggatggagtgggacagagaaattaacaattacacaagcttaatacact





ccttaattgaagaatcgcaaaaccagcaagaaaagaatgaacaagaat





tattggaattagataaatgggcaagtttgtggaattggtttaacataa





caaattggctgtggtatataaaattattcataatgatagtaggaggct





tggtaggtttaagaatagtttttgctgtactttctatagtgaatagag





ttaggcagggatattcaccattatcgtttcagacccacctcccaaccc





cgaggggacccgacaggcccgaaggaatagaagaagaaggtggagaga





gagacagagacagatccattcgattagtgaacggatcggcactgcgtg





cgccaattctgcagacaaatggcagtattcatccacaattttaaaaga





aaaggggggattggggggtacagtgcaggggaaagaatagtagacata





atagcaacagacatacaaactaaagaattacaaaaacaaattacaaaa





attcaaaattttcgggtttattacagggacagcagagatccagtttgg





ttaattaatggggggacgttaacggggcggaacggtaccgagggccta





tttcccatgattccttcatatttgcatatacgatacaaggctgttaga





gagataattagaattaatttgactgtaaacacaaagatattagtacaa





aatacgtgacgtagaaagtaataatttcttgggtagtttgcagtttta





aaattatgttttaaaatggactatcatatgcttaccgtaacttgaaag





tatttcgatttcttggctttatatatcttgtggaaaggacgaaacacc





ggagacgtgtacacgtctctgttttagagctagaaatagcaagttaaa





ataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtgc





ttttttgaattcgctagctaggtcttgaaaggagtgggaattggctcc





ggtgcccgtcagtgggcagagcgcacatcgcccacagtccccgagaag





ttggggggaggggtcggcaattgatccggtgcctagagaaggtggcgc





ggggtaaactgggaaagtgatgtcgtgtactggctccgcctttttccc





gaggggggggagaaccgtatataagtgcagtagtcgccgtgaacgttc





tttttcgcaacgggtttgccgccagaacacaggaccggtgccaccatg





gactataaggaccacgacggagactacaaggatcatgatattgattac





aaagacgatgacgataagatggccccaaagaagaagcggaaggtcggt





atccacggagtcccagcagccgacaagaagtacagcatcggcctggcc





atcggcaccaactctgtgggctgggccgtgatcaccgacgagtacaag





gtgcccagcaagaaattcaaggtgctgggcaacaccgaccggcacagc





atcaagaagaacctgatcggagccctgctgttcgacagcggcgaaaca





gccgaggccacccggctgaagagaaccgccagaagaagatacaccaga





cggaagaaccggatctgctatctgcaagagatcttcagcaacgagatg





gccaaggtggacgacagcttcttccacagactggaagagtccttcctg





gtggaagaggataagaagcacgagcggcaccccatcttcggcaacatc





gtggacgaggtggcctaccacgagaagtaccccaccatctaccacctg





agaaagaaactggtggacagcaccgacaaggccgacctgcggctgatc





tatctggccctggcccacatgatcaagttccggggccacttcctgatc





gagggcgacctgaaccccgacaacagcgacgtggacaagctgttcatc





cagctggtgcagacctacaaccagctgttcgaggaaaaccccatcaac





gccagcggcgtggacgccaaggccatcctgtctgccagactgagcaag





agcagacggctggaaaatctgatcgcccagctgcccggcgagaagaag





aatggcctgttcggcaacctgattgccctgagcctgggcctgaccccc





aacttcaagagcaacttcgacctggccgaggatgccaaactgcagctg





agcaaggacacctacgacgacgacctggacaacctgctggcccagatc





ggcgaccagtacgccgacctgtttctggccgccaagaacctgtccgac





gccatcctgctgagcgacatcctgagagtgaacaccgagatcaccaag





gcccccctgagcgcctctatgatcaagagatacgacgagcaccaccag





gacctgaccctgctgaaagctctcgtgcggcagcagctgcctgagaag





tacaaagagattttcttcgaccagagcaagaacggctacgccggctac





attgacggcggagccagccaggaagagttctacaagttcatcaagccc





atcctggaaaagatggacggcaccgaggaactgctcgtgaagctgaac





agagaggacctgctgcggaagcagcggaccttcgacaacggcagcatc





ccccaccagatccacctgggagagctgcacgccattctgcggcggcag





gaagatttttacccattcctgaaggacaaccgggaaaagatcgagaag





atcctgaccttccgcatcccctactacgtgggccctctggccagggga





aacagcagattcgcctggatgaccagaaagagcgaggaaaccatcacc





ccctggaacttcgaggaagtggtggacaagggcgcttccgcccagagc





ttcatcgagcggatgaccaacttcgataagaacctgcccaacgagaag





gtgctgcccaagcacagcctgctgtacgagtacttcaccgtgtataac





gagctgaccaaagtgaaatacgtgaccgagggaatgagaaagcccgcc





ttcctgagcggcgagcagaaaaaggccatcgtggacctgctgttcaag





accaaccggaaagtgaccgtgaagcagctgaaagaggactacttcaag





aaaatcgagtgcttcgactccgtggaaatctccggcgtggaagatcgg





ttcaacgcctccctgggcacataccacgatctgctgaaaattatcaag





gacaaggacttcctggacaatgaggaaaacgaggacattctggaagat





atcgtgctgaccctgacactgtttgaggacagagagatgatcgaggaa





cggctgaaaacctatgcccacctgttcgacgacaaagtgatgaagcag





ctgaagcggcggagatacaccggctggggcaggctgagccggaagctg





atcaacggcatccgggacaagcagtccggcaagacaatcctggatttc





ctgaagtccgacggcttcgccaacagaaacttcatgcagctgatccac





gacgacagcctgacctttaaagaggacatccagaaagcccaggtgtcc





ggccagggcgatagcctgcacgagcacattgccaatctggccggcagc





cccgccattaagaagggcatcctgcagacagtgaaggtggtggacgag





ctcgtgaaagtgatgggccggcacaagcccgagaacatcgtgatcgaa





atggccagagagaaccagaccacccagaagggacagaagaacagccgc





gagagaatgaagcggatcgaagagggcatcaaagagctgggcagccag





atcctgaaagaacaccccgtggaaaacacccagctgcagaacgagaag





ctgtacctgtactacctgcagaatggggggatatgtacgtggaccagg





aactggacatcaaccggctgtccgactacgatgtggacgctatcgtgc





ctcagagctttctgaaggacgactccatcgacaacaaggtgctgacca





gaagcgacaagaaccggggcaagagcgacaacgtgccctccgaagagg





tcgtgaagaagatgaagaactactggcggcagctgctgaacgccaagc





tgattacccagagaaagttcgacaatctgaccaaggccgagagaggcg





gcctgagcgaactggataaggccggcttcatcaagagacagctggtgg





aaacccggcagatcacaaagcacgtggcacagatactagattcccgaa





tgaatacgaaatacgacgagaacgataagctgattcgggaagtcaaag





taatcactttaaagtcaaaattggtgtcggacttcagaaaggattttc





aattctataaagttagggagataaataactaccaccatgcgcacgacg





cttatcttaatgccgtcgtagggaccgcactcattaagaaatacccga





agctagaaagtgagtttgtgtatggtgattacaaagtttatgacgtcc





gtaagatgatcgcgaaaagcgaacaggagataggcaaggctacagcca





aatacttcttttattctaacattatgaatttctttaagacggaaatca





ctctggcaaacggagagatacgcaaacgacctttaattgaaaccaatg





gggagacaggtgaaatcgtatgggataagggccgggacttcgcgacgg





tgagaaaagttttgtccatgccccaagtcaacatagtaaagaaaactg





aggtgcagaccggagggttttcaaaggaatcgattcttccaaaaagga





atagtgataagctcatcgctcgtaaaaaggactgggacccgaaaaagt





acggtggcttcgtgagccctacagttgcctattctgtcctagtagtgg





caaaagttgagaagggaaaatccaagaaactgaagtcagtcaaagaat





tattggggataacgattatggagcgctcgtcttttgaaaagaacccca





tcgacttccttgaggcgaaaggttacaaggaagtaaaaaaggatctca





taattaaactaccaaagtatagtctgtttgagttagaaaatggccgaa





aacggatgttggctagcgccagagagcttcaaaaggggaacgaactcg





cactaccgtctaaatacgtgaatttcctgtatttagcgtcccattacg





agaagttgaaaggttcacctgaagataacgaacagaagcaactttttg





ttgagcagcacaaacattatctcgacgaaatcatagagcaaatttcgg





aattcagtaagagagtcatcctagctgatgccaatctggacaaagtat





taagcgcatacaacaagcacagggataaacccatacgtgagcaggcgg





aaaatattatccatttgtttactcttaccaacctcggcgctccagccg





cattcaagtattttgacacaacgatagatcgcaaagagtacagatcta





ccaaggaggtgctagacgcgacactgattcaccaatccatcacgggat





tatatgaaactcggatagatttgtcacagcttgggggtgacggatccc





caaagaagaaacggaaggtgggtggaggaagtggcgggtcaggtggct





ctagacggacactggtgaccttcaaggatgtatttgtggacttcacca





gggaggagtggaagctgctggacactgctcagcagatcgtgtacagaa





atgtgatgctggagaactataagaacctggtttccttgggttatcagc





ttactaagccagatgtgatcctccggttggagaagggagaagagccct





cgggaggtggttcgggaggtggttcggagggtgtgcaggtgaaaaggg





tcctggagaaaagtcctgggaagctccttgtcaagatgccttttcaaa





cttcgccagggggcaaggctgaggggggtggggccaccacatccaccc





aggtcatggtgatcaaacgccccggcaggaagcgaaaagctgaggccg





accctcaggccattcccaagaaacggggccgaaagccggggagtgtgg





tggcagccgctgccgccgaggccaaaaagaaagccgtgaaggagtctt





ctatccgatctgtgcaggagacagtactccccatcaagaagcgcaaga





cccgggagggcgcgcccaagaagaagaggaaagtctccggatccggcg





caacaaacttctctctgctgaaacaagccggagatgtcgaagagaatc





ctggaccgaccgagtacaagcccacggtgcgcctcgccacccgcgacg





acgtccccagggccgtacgcaccctcgccgccgcgttcgccgactacc





ccgccacgcgccacaccgtcgatccggaccgccacatcgagcgggtca





ccgagctgcaagaactcttcctcacgcgcgtcgggctcgacatcggca





aggtgtgggtcgcggacgacggcgccgcggtggcggtctggaccacgc





cggagagcgtcgaagcgggggcggtgttcgccgagatcggcccgcgca





tggccgagttgagcggttcccggctggccgcgcagcaacagatggaag





gcctcctggcgccgcaccggcccaaggagcccgcgtggttcctggcca





ccgtcggagtctcgcccgaccaccagggcaagggtctgggcagcgccg





tcgtgctccccggagtggaggcggccgagcgcgccggggtgcccgcct





tcctggagacctccgcgccccgcaacctccccttctacgagcggctcg





gcttcaccgtcaccgccgacgtcgaggtgcccgaaggaccgcgcacct





ggtgcatgacccgcaagcccggtgcctgaacgcgttaagtcgacaatc





aacctctggattacaaaatttgtgaaagattgactggtattcttaact





atgttgctccttttacgctatgtggatacgctgctttaatgcctttgt





atcatgctattgcttcccgtatggctttcattttctcctccttgtata





aatcctggttgctgtctctttatgaggagttgtggcccgttgtcaggc





aacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggtt





ggggcattgccaccacctgtcagctcctttccgggactttcgctttcc





ccctccctattgccacggcggaactcatcgccgcctgccttgcccgct





gctggacaggggctcggctgttgggcactgacaattccgtggtgttgt





cggggaaatcatcgtcctttccttggctgctcgcctgtgttgccacct





ggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatc





cagcggaccttccttcccgcggcctgctgccggctctgcggcctcttc





cgcgtcttcgccttcgccctcagacgagtcggatctccctttgggccg





cctccccgcgtcgactttaagaccaatgacttacaaggcagctgtaga





tcttagccactttttaaaagaaaaggggggactggaagggctaattca





ctcccaacgaagacaagatctgctttttgcttgtactgggtctctctg





gttagaccagatctgagcctgggagctctctggctaactagggaaccc





actgcttaagcctcaataaagcttgccttgagtgcttcaagtagtgtg





tgcccgtctgttgtgtgactctggtaactagagatccctcagaccctt





ttagtcagtgtggaaaatctctagcagggcccgtttaaacccgctgat





cagcctcgactgtgccttctagttgccagccatctgttgtttgcccct





cccccgtgccttccttgaccctggaaggtgccactcccactgtccttt





cctaataaaatgaggaaattgcatcgcattgtctgagtaggtgtcatt





ctattctggggggtggggggggcaggacagcaagggggaggattggga





agacaatagcaggcatgctggggatgcggtgggctctatggcttctga





ggcggaaagaaccagctggggctctagggggtatccccacgcgccctg





tagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgac





cgctacacttgccagcgccctagcgcccgctcctttcgctttcttccc





ttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcg





ggggctccctttagggttccgatttagtgctttacggcacctcgaccc





caaaaaacttgattagggtgatggttcacgtagtgggccatcgccctg





atagacggtttttcgccctttgacgttggagtccacgttctttaatag





tggactcttgttccaaactggaacaacactcaaccctatctcggtcta





ttcttttgatttataagggattttgccgatttcggcctattggttaaa





aaatgagctgatttaacaaaaatttaacgcgaattaattctgtggaat





gtgtgtcagttagggtgtggaaagtccccaggctccccagcaggcaga





agtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaag





tccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaat





tagtcagcaaccatagtcccgcccctaactccgcccatcccgccccta





actccgcccagttccgcccattctccgccccatggctgactaattttt





tttatttatgcagaggccgaggccgcctctgcctctgagctattccag





aagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagctc





cctaccgtcgacctctagctagagcttggcgtaatcatggtcatagct





gtttcctgtgtgaaattgttatccgctcacaattccacacaacatacg





agccggaagcataaagtgtaaagcctggggtgcctaatgagtgagcta





actcacattaattgcgttgcgctcactgcccgctttccagtcgggaaa





cctgtcgtgccagctgcattaatgaatcggccaacgcgcggggagagg





cggtttgcgtattgggcgctcttccgcttcctcgctcactgactcgct





gcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggc





ggtaatacggttatccacagaatcaggggataacgcaggaaagaacat





gtgagcaaaaggccagcaaaaggccaggaaccgtaaaaaggccgcgtt





gctggcgtttttccataggctccgcccccctgacgagcatcacaaaaa





tcgacgctcaagtcagaggtggcgaaacccgacaggactataaagata





ccaggcgtttccccctggaagctccctcgtgcgctctcctgttccgac





cctgccgcttaccggatacctgtccgcctttctcccttcgggaagcgt





ggcgctttctcatagctcacgctgtaggtatctcagttcggtgtaggt





cgttcgctccaagctgggctgtgtgcacgaaccccccgttcagcccga





ccgctgcgccttatccggtaactatcgtcttgagtccaacccggtaag





acacgacttatcgccactggcagcagccactggtaacaggattagcag





agcgaggtatgtaggcggtgctacagagttcttgaagtggtggcctaa





ctacggctacactagaagaacagtatttggtatctgcgctctgctgaa





gccagttaccttcggaaaaagagttggtagctcttgatccggcaaaca





aaccaccgctggtagcggtggtttttttgtttgcaagcagcagattac





gcgcagaaaaaaaggatctcaagaagatcctttgatcttttctacggg





gtctgacgctcagtggaacgaaaactcacgttaagggattttggtcat





gagattatcaaaaaggatcttcacctagatccttttaaattaaaaatg





aagttttaaatcaatctaaagtatatatgagtaaacttggtctgacag





ttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatt





tcgttcatccatagttgcctgactccccgtcgtgtagataactacgat





acgggagggcttaccatctggccccagtgctgcaatgataccgcgaga





cccacgctcaccggctccagatttatcagcaataaaccagccagccgg





aagggccgagcgcagaagtggtcctgcaactttatccgcctccatcca





gtctattaattgttgccgggaagctagagtaagtagttcgccagttaa





tagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtcacg





ctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaag





gcgagttacatgatcccccatgttgtgcaaaaaagcggttagctcctt





cggtcctccgatcgttgtcagaagtaagttggccgcagtgttatcact





catggttatggcagcactgcataattctcttactgtcatgccatccgt





aagatgcttttctgtgactggtgagtactcaaccaagtcattctgaga





atagtgtatgcggcgaccgagttgctcttgcccggcgtcaatacggga





taataccgcgccacatagcagaactttaaaagtgctcatcattggaaa





acgttcttcggggcgaaaactctcaaggatcttaccgctgttgagatc





cagttcgatgtaacccactcgtgcacccaactgatcttcagcatcttt





tactttcaccagcgtttctgggtgagcaaaaacaggaaggcaaaatgc





cgcaaaaaagggaataagggcgacacggaaatgttgaatactcatact





cttcctttttcaatattattgaagcatttatcagggttattgtctcat





gagcggatacatatttgaatgtatttagaaaaataaacaaataggggt





tccgcgcacatttccccgaaaagtgccacctgac.






C. Methods of Administering Precision Gene Therapy

Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a disclosed isolated nucleic acid molecule, and reducing the activity and/or expression of APOE in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a disclosed isolated nucleic acid molecule, and reducing the activity and/or expression of APOE e4 in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, wherein the fusion protein comprises a Cas endonuclease and a polypeptide having an enzymatic activity, and reducing the activity and/or expression of APOE in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing the activity and/or expression of APOE in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, wherein the fusion protein comprises a Cas endonuclease and a polypeptide having an enzymatic activity, and reducing the activity and/or expression of the APOE e4 allele in one or more cells.


Disclosed herein is a method of administering precision gene therapy, the method comprising contacting one or more cells with a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing the activity and/or expression of the APOE e4 allele in one or more cells.


In an aspect of a disclosed method, increased APOE expression and/or activity can be mediated by a coding mutation in exon 4, gene dysregulation, or a combination thereof.


In an aspect, a disclosed method can reduce expression and/or activity of APOE regardless of the subject's genotype.


In an aspect, the disclosed cells can be neurons such as, for example, cholinergic neurons. In an aspect, the disclosed cells can be in a subject.


In an aspect, a disclosed viral vector can be a lentiviral vector. In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule and one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO: 19 or SEQ ID NO:20 or a fragment thereof. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect of a disclosed method, a subject can be a human. In an aspect, a subject can be suspected of having or can be diagnosed with having Alzheimer's disease (such as, for example, LOAD). In an aspect, a disclosed subject can be symptomatic or asymptomatic.


In an aspect, a disclosed method can comprise reducing the pathological phenotype associated with Alzheimer's disease. In an aspect, reducing the pathological phenotype associated with Alzheimer's disease can comprise reducing the A042/40 ratio and reducing the level of Tau. In an aspect, a disclosed method can comprise diagnosing the subject with Alzheimer's disease.


In an aspect, a disclosed method can comprise repeating one or more steps of the method and/or modifying one or more steps of the method.


In an aspect of a disclosed method, administering a disclosed viral vector can comprise intravenous administration, intracerebral administration, intra-CSF administration, intracerebroventricular (ICV) administration, intraventricular administration, intra-cistema magna (ICM) administration, intraparenchymal administration, intrathecal (lumbar, cistemal, or both) administration, or any combination thereof.


In an aspect, a disclosed method can comprise administering to the subject a therapeutically effective amount of a therapeutic agent, an effective amount of an immune modulator, or a combination thereof.


Disclosed herein is a method of administering precision gene therapy, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein and (ii) at least one guide RNA, wherein the fusion protein comprises a Cas endonuclease and a polypeptide having an enzymatic activity, and reducing expression of the APOE e4 allele.


Disclosed herein is a method of administering precision gene therapy, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele.


In an aspect, the disclosed cells can be neurons such as, for example, cholinergic neurons. In an aspect, the disclosed cells can be in a subject.


In an aspect, a disclosed viral vector can be a lentiviral vector. In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a disclosed promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule and one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed dCas9-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO: 19 or SEQ ID NO:20 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dVRER and a disclosed polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect of a disclosed method, a subject can be a human. In an aspect, a subject can be suspected of having or can be diagnosed with having Alzheimer's disease (such as, for example, LOAD). In an aspect, a disclosed subject can be symptomatic or asymptomatic.


In an aspect, a disclosed method can comprise reducing the pathological phenotype associated with Alzheimer's disease. In an aspect, reducing the pathological phenotype associated with Alzheimer's disease can comprise reducing the A042/40 ratio and reducing the level of Tau. In an aspect, a disclosed method can comprise diagnosing the subject with Alzheimer's disease.


In an aspect, a disclosed method can comprise repeating one or more steps of the method and/or modifying one or more steps of the method.


In an aspect of a disclosed method, administering a disclosed vector can comprise intravenous administration, intracerebral administration, intra-CSF administration, intracerebroventricular (ICV) administration, intraventricular administration, intra-cistema magna (ICM) administration, intraparenchymal administration, intrathecal (lumbar, cistemal, or both) administration, or any combination thereof.


In an aspect, a disclosed method can comprise administering to the subject a therapeutically effective amount of a therapeutic agent, an effective amount of an immune modulator, or a combination thereof.


D. Methods of Treating and/or Preventing Alzheimer's Disease Progression

Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of APOE, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of APOE.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of APOE, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of APOE.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of the APOE e4 allele, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, and reducing expression of the APOE e4 allele.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele, thereby reducing the pathological phenotype associated with Alzheimer's disease.


Disclosed herein is a method of treating and/or preventing Alzheimer's disease progression in a subject, the method comprising reducing the pathological phenotype associated with Alzheimer's disease by administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, and reducing expression of the APOE e4 allele.


In an aspect of a disclosed method, increased APOE expression and/or activity can be mediated by a coding mutation in exon 4, gene dysregulation, or a combination thereof.


In an aspect, a disclosed method can reduce expression and/or activity of APOE regardless of the subject's genotype.


In an aspect, a disclosed viral vector can be a lentiviral vector. In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a disclosed promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule and one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect of a disclosed method, a subject can be a human. In an aspect, a subject can be suspected of having or can be diagnosed with having Alzheimer's disease (such as, for example, LOAD). In an aspect, a disclosed subject can be symptomatic or asymptomatic. In an aspect, a disclosed method can comprise reducing the pathological phenotype associated with Alzheimer's disease. In an aspect, reducing the pathological phenotype associated with Alzheimer's disease can comprise reducing the A042/40 ratio and reducing the level of Tau. In an aspect, a disclosed method can comprise diagnosing the subject with Alzheimer's disease.


In an aspect, a disclosed method can comprise repeating one or more steps of the method and/or modifying one or more steps of the method.


In an aspect of a disclosed method, administering a disclosed vector can comprise intravenous administration, intracerebral administration, intra-CSF administration, intracerebroventricular (ICV) administration, intraventricular administration, intra-cistema magna (ICM) administration, intraparenchymal administration, intrathecal (lumbar, cistemal, or both) administration, or any combination thereof.


In an aspect, a disclosed method can comprise administering to the subject a therapeutically effective amount of a therapeutic agent, an effective amount of an immune modulator, or a combination thereof.


In an aspect, a disclosed method can comprise administering one or more additional therapeutic agents. Additional therapeutic agents can comprise any disclosed therapeutic agents. A therapeutic agent can be any that effects a desired clinical outcome in a subject having a Alzheimer's disease, suspected of having Alzheimer's disease, and/or likely to develop or acquire Alzheimer's disease. In an aspect, a disclosed therapeutic agent can be an oligonucleotide therapeutic agent. A disclosed oligonucleotide therapeutic agent can comprise a single-stranded or double-stranded DNA, iRNA, shRNA, siRNA, mRNA, non-coding RNA (ncRNA), an antisense molecule, miRNA, a morpholino, a peptide-nucleic acid (PNA), or an analog or conjugate thereof. In an aspect, a disclosed oligonucleotide therapeutic agent can be an ASO or an RNAi. In an aspect, a disclosed oligonucleotide therapeutic agent can comprise one or more modifications at any position applicable. In an aspect, a disclosed therapeutic agent can comprise an isolated nucleic acid molecule encoding a protein that is deficient or absent in the subject. In an aspect, a disclosed therapeutic agent can be a biologically active agent, a pharmaceutically active agent, an anti-bacterial agent, an anti-fungal agent, a corticosteroid, an analgesic, an immunostimulant, an immune-based product, or any combination thereof.


E. Methods of Reducing Activity and/or Expression of APOE

Disclosed herein is a method of reducing expression of APOE, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, thereby reducing expression of APOE.


Disclosed herein is a method of reducing expression of APOE, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, thereby reducing expression of APOE.


In an aspect of a disclosed method, increased APOE expression and/or activity can be mediated by a coding mutation in exon 4, gene dysregulation, or a combination thereof.


In an aspect, a disclosed viral vector can be a lentiviral vector. In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a disclosed promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule and one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect of a disclosed method, a subject can be a human. In an aspect, a subject can be suspected of having or can be diagnosed with having Alzheimer's disease (such as, for example, LOAD). In an aspect, a disclosed subject can be symptomatic or asymptomatic. In an aspect, a disclosed method can comprise reducing the pathological phenotype associated with Alzheimer's disease. In an aspect, reducing the pathological phenotype associated with Alzheimer's disease can comprise reducing the A042/40 ratio and reducing the level of Tau. In an aspect, a disclosed method can comprise diagnosing the subject with Alzheimer's disease.


In an aspect, a disclosed method can comprise repeating one or more steps of the method and/or modifying one or more steps of the method.


In an aspect of a disclosed method, administering a disclosed vector can comprise intravenous administration, intracerebral administration, intra-CSF administration, intracerebroventricular (ICV) administration, intraventricular administration, intra-cistema magna (ICM) administration, intraparenchymal administration, intrathecal (lumbar, cisternal, or both) administration, or any combination thereof.


In an aspect, a disclosed method can comprise administering to the subject a therapeutically effective amount of a therapeutic agent, an effective amount of an immune modulator, or a combination thereof.


F. Methods of Reducing Activity and/or Expression of APOE e4

Disclosed herein is a method of reducing expression of APOE e4, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a fusion protein comprising a Cas endonuclease and a polypeptide having an enzymatic activity and (ii) at least one guide RNA, thereby reducing expression of the APOE e4 allele.


Disclosed herein is a method of reducing expression of APOE e4, the method comprising administering to a subject in need thereof a therapeutically effective amount of a viral vector, wherein the viral vector comprises an isolated nucleic acid molecule comprising a nucleic acid sequence encoding (i) a Cas endonuclease, (ii) at least one polypeptide having an enzymatic activity, and (iii) at least one guide RNA, thereby reducing expression of the APOE e4 allele.


In an aspect of a disclosed method, increased APOE expression and/or activity can be mediated by a coding mutation in exon 4, gene dysregulation, or a combination thereof.


In an aspect, a disclosed viral vector can be a lentiviral vector. In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule. In an aspect, a disclosed promoter can drive the expression of a gRNA, the Cas9 endonuclease, a polypeptide, or a combination thereof. In an aspect, a disclosed promoter can be a hU6 promoter and a disclosed hU6 promoter can drive expression of a gRNA. In an aspect, a disclosed promoter can be an EFS-NC promoter and a disclosed EFS-NC promoter can drive expression of the Cas endonuclease. In an aspect, a disclosed promoter can comprise a hU6 promoter, an EFS-NC promoter, or a combination thereof.


In an aspect of a disclosed method, a disclosed viral vector can comprise one or more promoters operably linked to the isolated nucleic acid molecule and one or more regulatory elements. Regulatory elements are known in the art and can comprise one or more of the following: a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR. In an aspect, a disclosed viral vector can comprise two Sp1 response elements, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.


In an aspect, a disclosed Cas endonuclease can comprise Cas9, SpCas9, SaCas9, a variant Cas9, a dCas, or a dCas9. In an aspect, a disclosed Cas9 can comprise the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In an aspect, a disclosed Cas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65 or a fragment thereof.


In an aspect, a disclosed variant Cas9 can comprise VQR, EQR, or VRER. In an aspect a disclosed VRER can comprise the sequence set forth in SEQ ID NO:15. In an aspect, a disclosed VRER can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15 or a fragment thereof. In an aspect, a disclosed dCas can comprise dVQR, dEQR, or dVRER. In an aspect, a disclosed dCas can comprise the sequence set forth in SEQ ID NO:16. In an aspect, a disclosed dCas9 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:16 or a fragment thereof. A SpCas9 (3′NGG-PAM sequence) can comprise SpCas9 VQR (3′NGAN or 3′NGNG), SpCas9 EQR (3′NGAG), or SpCas9 VRER (3′NGCG).


In an aspect, a disclosed encoded polypeptide can comprise transcription activation activity, transcription repression activity, transcription release factor activity, histone modification activity, nucleic acid association activity, methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, or any combination thereof. In an aspect, a disclosed encoded polypeptide can be histone deacetylase or heterochromatin protein 1. In an aspect, a disclosed encoded polypeptide can comprise transcription repression activity. In an aspect, a disclosed DNMT3A can have the amino acid sequence set forth in SEQ ID NO:17 or the nucleotide sequence set forth in SEQ ID NO:18. In an aspect, a disclosed DNMT3A can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:17 or SEQ ID NO:18 or a fragment thereof.


In an aspect, at least one encoded polypeptide can comprise Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed TRD of MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:57 or the amino acid sequence set forth in SEQ ID NO:58. In an aspect, a disclosed TRD of MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:57 or SEQ ID NO:58 or a fragment thereof. In an aspect, a disclosed KRAB-MeCP2 can comprise the nucleotide sequence set forth in SEQ ID NO:62 or the amino acid sequence set forth in SEQ ID NO:63. In an aspect, a disclosed KRAB-MeCP2 can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:62 or SEQ ID NO:63 or a fragment thereof.


In an aspect, a disclosed gRNA can be designed to target exon 4 of the APOE gene or designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene. In an aspect, a disclosed gRNA can have the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14, SEQ ID NO:25-SEQ ID NO:28, SEQ ID NO:39-SEQ ID NO:42, and SEQ ID NO:51-SEQ ID NO:52.


In an aspect, a disclosed Cas endonuclease can be fused to a disclosed polypeptide having an enzymatic activity. In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be DNMT3A. In an aspect, a dCas9-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:19. In an aspect, a dCas9-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:20. In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be DNMT3A. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have the amino acid sequence set forth SEQ ID NO:38. In an aspect, a disclosed dVRER-DNMT3A fusion protein can be encoded by the sequence set forth in SEQ ID NO:37. In an aspect, a disclosed dVRER-DNMT3A fusion protein can have a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:38 or SEQ ID NO:37 or a fragment thereof.


In an aspect, a disclosed Cas endonuclease can be dCas9 and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2). In an aspect, a disclosed Cas endonuclease can be dVRER and the polypeptide can be Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).


In an aspect of a disclosed method, a subject can be a human. In an aspect, a subject can be suspected of having or can be diagnosed with having Alzheimer's disease (such as, for example, LOAD). In an aspect, a disclosed subject can be symptomatic or asymptomatic. In an aspect, a disclosed method can comprise reducing the pathological phenotype associated with Alzheimer's disease. In an aspect, reducing the pathological phenotype associated with Alzheimer's disease can comprise reducing the A042/40 ratio and reducing the level of Tau. In an aspect, a disclosed method can comprise diagnosing the subject with Alzheimer's disease.


In an aspect, a disclosed method can comprise repeating one or more steps of the method and/or modifying one or more steps of the method.


In an aspect of a disclosed method, administering a disclosed vector can comprise intravenous administration, intracerebral administration, intra-CSF administration, intracerebroventricular (ICV) administration, intraventricular administration, intra-cistema magna (ICM) administration, intraparenchymal administration, intrathecal (lumbar, cistemal, or both) administration, or any combination thereof.


In an aspect, a disclosed method can comprise administering to the subject a therapeutically effective amount of a therapeutic agent, an effective amount of an immune modulator, or a combination thereof.


G. Kits

Disclosed herein is a kit comprising one or more disclosed isolated nucleic acid molecules, disclosed vectors, disclosed lentiviral vectors, disclosed pharmaceutical formulations, disclosed host cells, disclosed guide RNAs, disclosed plasmids, or any combination thereof with or without additional therapeutic agents to treat, prevent, inhibit, and/or ameliorate one or more symptoms or complications associated AD or LOAD. In an aspect, a disclosed kit can be used in a disclosed method to reduce expression and/or activity of APOE regardless of the subject's genotype.


In an aspect, a disclosed kit can comprise at least two components constituting the kit. Together, the components constitute a functional unit for a given purpose (such as, for example, treating a subject diagnosed with or suspected of having A or LOAD). Individual member components may be physically packaged together or separately. For example, a kit comprising an instruction for using the kit may or may not physically include the instruction with other individual member components. Instead, the instruction can be supplied as a separate member component, either in a paper form or an electronic form which may be supplied on computer readable memory device or downloaded from an internet website, or as recorded presentation. In an aspect, a kit for use in a disclosed method can comprise one or more containers holding a disclosed pharmaceutical formulation, a disclosed therapeutic agent, a disclosed reagent, or a combination thereof, and a label or package insert with instructions for use. In an aspect, suitable containers include, for example, bottles, vials, syringes, blister pack, etc. The containers can be formed from a variety of materials such as glass or plastic. The container can hold, for example, a disclosed pharmaceutical formulation and/or a disclosed therapeutic agent and can have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The label or package insert can indicate that a disclosed pharmaceutical formulation and/or a disclosed therapeutic agent can be used for treating, preventing, inhibiting, and/or ameliorating Alzheimer's disease (such as, for example, LOAD) or complications and/or symptoms associated with Alzheimer's disease. In an aspect, a disclosed kit can comprise additional components necessary for administration such as, for example, other buffers, diluents, filters, needles, and syringes.


VI. EXAMPLES

Apolipoprotein E (ApoE) is encoded by the APOE gene (SEQ ID NO:01) positioned on chromosome 19q13.32 (GRCh 38: chr19:44,905,795-44,909,392). Two common coding SNPs in exon 4 of the gene give rise to three allelic variants, APOEe2 (SEQ ID NO:02), APOEe3 (SEQ ID NO:03), and APOEe4 (SEQ ID NO:04), encoding three corresponding protein isoforms that differ at two amino acid positions 112 and 158. The e4 allele of the apolipoprotein E gene (APOE e4) is the first, strongest, and most firmly established genetic risk factor for LOAD (Corder E H, et al. (1993) Science 261:921-923; Liu N, et al. (2008) Adv Genet. 60:335-405; Schmechel D E, et al. (1993) Proc Natl Acad Sci USA. 90:9649-9653; Saunders A M, et al. (1993) Neurology. 43:1467-1472). The initial discovery was made nearly 30 years ago by linkage analysis of pedigrees (Corder et al., 1993) and over the ensuing years it has become the most highly replicated genetic risk factor for LOAD (Corder et al., 1993; Liu et al. 2008; Schmechel et al., 1993; Saunders et al., 1993). Subsequent LOAD genome-wide association studies (GWAS) have confirmed strong associations with the APOE genomic region, and no other LOAD-association remotely approached the same level of significance (Harold D, et al. (2009) Nat Genet. 41:1088-1093; Lambert J C, et al. (2009) Nat Genet. 41:1094-1090; Heinzen E L, et al. (2009) J Alzheimers Dis. 19(1):69-77; Kamboh M I, et al. (2012) Mol Psychiatry. 17:1340-1346; Kamboh M I, et al. (2012) Transl Psychiatry. 2:e117; Seshadri, S. et al. (2010) JAMA. 303:1832-1840; Kunkle B W, et al. (2019) Nat Genet. 51:414-430; Lambert J C, et al. (2013) Nat Genet. 45:1452-1458; Coon K D, et al. (2007) J Clin Psychiatry. 68:613-618).


Carrying the APOE e4 variant significantly increases the lifetime risk for LOAD, whereas the number of e4 copies affects the level of risk and is associated with lower age of clinical disease onset (Corder et al., 1993; Farrer L A, et al. (1997) JAMA. 278:1349-1356), while APOE e3 is natural and APOE e2 conferred a protective effect (Saunders A M, et al. (1993) Neurology. 43:1467-1472; Reiman E M, et al. (2020) Nat Commun. 11:667). 40-65% of LOAD patients carry the e4 allele compared to 10-15% in the general population. Although, the precise molecular mechanisms underlying ApoE e4-mediated risk effects have not been fully elucidated, it was suggested that ApoE e4 acquired hyperfunction (gain of toxic effects) (Gottschalk W K, et al. (2016) J Alzheimers Dis Parkinsonism. 6(1):209) and increasing data indicate several cellular pathways through which ApoE e4 may exert toxicity associated with LOAD pathologic phenotypes (Huang Y A, et al. (2017) Cell. 168:427-441 e21; Sen A, et al. (2015) J Neurosci. 35:7538-7551; Theendakara V, et al. (2013) Proc Natl Acad Sci USA. 110:18303-18308; Theendakara V, et al. (2016) J Neurosci. 36:685-700; Min S W, et al. (2010) Neuron. 67:953-966; Tambini M D, et al. (2016) EMBO Rep. 17:27-36; Hatters D M, et al. (2006) J Mol Biol. 361:932-944). Collectively, these studies provide strong support to the concept that decreasing the levels of ApoE e4 specifically will have a therapeutic implication.


However, ApoE e4 as a target for LOAD remains significantly understudied, despite the few recent studies that have begun to pave the way. Another study utilized an antibody that specifically recognized the ApoE4 isoform and showed inhibition of A3 accumulation in the hippocampus and reversed the cognitive impairments compared to the control APOE4 mice (Luz I, et al. (2016) Curr Alzheimer Res. 13:918-929). Additional study applied the anti-human ApoE4 antibody and also found a reduction in A3 pathology characteristic of the APPS1-21/humanAPOE4 mice (Liao F, et al. (2018) J Clin Invest. 128:2144-2155). Collectively, these observations (Yang A, et al. (2021) Int J Mol Sci. 22(3):1244) demonstrated the beneficial effects of reducing the expression levels of ApoE, thus, supporting APOE as a promising therapeutics target for LOAD.


Moreover, accumulating evidence indicates that the increased overall expression of APOE plays an important role in the etiology of LOAD. Significant higher levels of APOE-mRNA in brain tissues obtained from e3/3 LOAD patients compared to 3/3 healthy donors, consistently with other reports showing elevated levels of APOE-mRNA in LOAD brains (Linnertz C, et al. (2014) Alzheimers Dement. 10:541-551; Zarow C, et al. (1998) Exp. Neurol. 149:79-86; Matsui T, et al. (2007) Brain Res. 1161:116-123; Akram A, et al. (2012) Neurobiol. Aging. 33:628e1). Further, studies using the APP/PS1 transgenic mice showed that lowering the ApoE protein levels ameliorated cognitive dysfunctions and AR pathology (Huynh T V, et al. (2017) Neuron. 96:1013-1023.e1014: Zheng J Y, et al. (2017) Neurobiol. Aging 2017, 54:112-132) independent of the APOE allele (Bien-Ly N, et al. (2012) J. Neurosci. 32:4803-4811; Kim J, et al. (2011) J. Neurosci. 31:18007-18012). While ApoE4 has received much attention for its LOAD-risk effect, there are clear changes in APOE expression associated with LOAD and independent of the e4 allele.


This means that the regulation of APOE expression can impact the risk to develop LOAD, making the modulation of the overall ApoE protein levels useful as a therapeutic target. To this end, reduction in APOE expression had beneficial effects, specifically a decrease in AR pathology. Antisense oligonucleotide (ASO) treatment lowered the APOE-mRNA and protein levels in the brains of APP/PS1-21 mouse model by at least 50%, leading to a significant decrease in AR pathology (Huynh T V, et al. (2017) Neuron 96:1013-1023 e4). Administration of anti-ApoE antibody have consistent effects on reducing A3 pathology and improved brain function and cognitive abilities (Kim J, et al. (2012) Annu Rev Neurosci. 31:75-93; Liao F, et al. (2014) J Neurosci. 34:7281-7292)).


Thus, as described below, methods of modifying the e4 isoform and reducing APOE expression and/or activity levels provide a promising avenue towards precision medicine in AD and especially LOAD.


Example 1

Determining the Effect of APOE Genotypes of APOE-mRNA Levels



FIG. 1A shows a schematic model describing the mechanisms that lead to increased ApoE activity and by that mediate the pathogenic effect of APOE e4 and APOE e3 (differ in amino acid at position 112 Arg and Cys, respectively) on LOAD. FIG. 1B shows a diagram of the different technologies to target ApoE, including antisense oligonucleotide (ASO), monoclonal antibody (mAbs), and CRISPR/Cas9 gene editing technologies. Total RNA was extracted from brain samples (100 mg) using TRIzol reagent (Invitrogen, Carlsbad, CA) followed by purification with a RNeasy kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. RNA concentration was determined spectrophotometrically at 260 nm, while the quality of the purified RNA was determined by 260 nm/280 nm ratio. All the RNA samples were of acceptable quality having ratios between 1.9 and 2.1. Sample quality and the absence of significant degradation products were confirmed by establishing that every sample had a RNA Integrity Number (RIN), as measured on an Agilent Bioanalyzer, of greater than 7. cDNA was synthesized using MultiScribe RT enzyme (Applied Biosystems, Foster City, CA) under these conditions: 10 min at 25° C. and 120 min at 37° C.


Real-time PCR was then used to quantify the levels of human TOMM40 mRNA and APOE mRNA. Duplicates of each sample were assayed by relative quantitative real-time PCR using the ABI 7900HT to determine the level of TOMM40 and APOE messages relative to the mRNAs for the housekeeping genes glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and cyclophilin A (PPIA). ABI MGB probe and primer set assays were used to amplify APOE cDNA (ID Hs00171168_ml, 108 bp); and the two RNA reference controls, GAPDH (ID Hs99999905_ml, 122 bp) and PPIA (ID Hs99999904_ml, 98 bp) (Applied Biosystems, Foster City, CA). Each cDNA (10 ng) was amplified in duplicate in at least two independent runs (overall >4 repeats), using TaqMan Universal PCR master mix reagent (Applied Biosystems, Foster City, CA) and the following conditions: 2 min at 50° C., 10 min at 95° C., 40 cycles; 15 sec at 95° C.; 1 min at 60° C. As a negative control for the specificity of the amplification, RNA control samples that were not converted to cDNA (no-RT) and no-cDNA/RNA samples (no-template) were used in each plate. No amplification product was detected in control reactions. Data were analyzed with a threshold set in the linear range of amplification. The cycle number at which any particular sample crossed that threshold (Ct) was then used to determine fold difference, whereas the geometric mean of the two control genes served as a reference for normalization. Fold difference was calculated as 2−DDCt; where DCt=[Ct(target)−Ct (reference)] and DDCt=[DCt(sample)]−[DCt(calibrator)].


The calibrator was a particular brain RNA sample used in every plate for normalization within and across runs. The variation of the DCt values among the calibrator replicates was less than 10%. For assay validation, standard curves for TOMAM40, APOE and each reference assay, GAPDH and PPIA using different amounts of human brain total RNA (0.1 ng-100 ng) were generated. In addition, the slope of the relative efficiency plot for TOMM40 and APOE with each internal control (GAPDH and PPIA) was determined to validate the assays. The slope in the relative efficiency plot for APOE and the reference genes were <0.1, showing a standard value required for the validation of the relative quantitative method. This methodology was published in Linnertz C, et al. (2014) Alzheimer's Dement. 10:541-551. FIG. 1C-FIG. 1E show the effect of APOE genotypes on APOE-mRNA levels. The fold levels of human APOE mRNA were assayed using qRT-PCR in temporal tissues (FIG. 1C) and in occipital tissues (FIG. 1D). FIG. 1E shows the level of human APOE-mRNA in whole brain tissues from humanized mice assayed by qRT-PCR.


Example 2
Schematic Representation of APOE Gene


FIG. 2 shows a schematic representation of APOE gene, which is located at chromosome 19q13.2. The SNP rs429358 changes amino acid in position 112 and defines APOE e4 allele. The SNP rs7412 changes amino acid in position 158 and defines the APOE e2 allele. The CpG island in exon 4 is highlighted. DMRI and DMR2 regions are defined by two CGIs, which are marked in a yellow box. Exons 1-4 are designated in boxes. The translated exons are highlighted in dark blue. 5′-UTR and 3′-UTR of the gene are highlighted in light blue.


Example 3
Determining the DNA-Methylation Profile of the APOE Linkage Disequilibrium Region

The manufacturer's instructions were followed for the Infinium MethylationEPIC BeadChip Kit, which determined the profile of over 850,000 methylation sites quantitatively across the genome. Initial processing and quality control assessment of the methyl-array data were carried out using the minfi72 package from the R statistical programming environment (R Foundation for Statistical Computing, 2018). Normalization of the data was carried out separately within each of the three datasets using the ‘preprocessSWAN’ function to remove systematic differences across arrays. (Maksimovic J, et al. (2012) Genome Biol. 13:R44). Probes that have a detection p-value >0.05 in any sample were removed from subsequent analysis. A standard linear model was deployed for each analysis to identify differentially methylated probes. Probes were annotated with their genomic coordinates in the hg19 version of the human genome and the nearest gene to the probe was listed using the gene models provided by Ensembl (version 74).



FIG. 3 shows the DNA-methylation profile of the APOE linkage disequilibrium (LD) region in FANS-sorted neuronal and non-neuronal nuclei. FIG. 3A shows a map of MethylEPIC array probes in the chr19: 45,393,000-45,424,000; hg19. The red circles represent probes with >0.5 methylation levels while the blue circles represent probes with <0.5 methylation levels. The APOE promoter region is hypomethylated and is an excellent target region for enhancement of DNA-methylation. FIG. 3B shows that probes showed significant differences in methylation levels between NeuN+ (n=16), NeuN sorted nuclei (n=16), or LOAD (n=8) vs. Normal (n=8). Solid bars represent neuronal population while the hatched bars represent the non-neuronal population. The accompanying table summarizes the p-values for each of the significant probes in FIG. 3B.


















Probe
p-value
Probe
p-value









16
4.14E−11
31
9.67E−23



17
6.04E−15
32
1.88E−30



18
8.63E−15
33
2.24E−12



19
1.06E−16
37
1.09E−16



20
1.04E−09
38
8.72E−16



25
8.49E−26
39
9.21E−20



26
4.60E−10
11
0.000423



27
1.60E−08










Example 4
Targeting the Promoter Region of APOE Gene


FIG. 4 shows the structure of human APOE gene and spCas9 gRNA design to target promoter region of the APOE gene. Genomic organization of the gene outlined in the lower panel while two SNPs within exon 4 are highlighted. The gRNA targeting promoter region of the gene is outlined. The 5′ UTR and 3′ UTR of the gene are indicated in boxes.


Example 5
Designing a Lentiviral Vector Carrying DNMT3A to Target the APOE Gene


FIG. 5 shows the schematic representation of lentiviral vector system carrying DNMT3A to target the promoter and exon 4 regions of APOE gene. The 5′-LTR and the 3′-LTR represent long terminal repeats. Phi represents the packaging signal of the vector. RRE represents the rev responsive element responsible for binding REV protein of the virus. The Sp1 responsive element inclusion (Ortiniski et al., 2017; Kantor et al., 2018) demonstrated high production yield. The hU6 promoter drives expression of the gRNA and the EFS-NC promoter drives the expression of dCAS9 (to target promoter of APOE) or dVRER to target SNP (112) at the exon 4 region. The p2A signal separates the effector molecule from GFP/Puro reporters. WPRE is the Woodchuck Hepatitis Virus (WHP) Post-Transcriptional Regulatory Element (WPRE), which is a DNA sequence that when transcribed creates a tertiary structure enhancing expression. The arrow pointing to the promoter region highlights the binding of the dCas9-DNMT3A-gRNA to the promoter region or the SNP region that results in the DNA methylation (red lollipops) and downregulation of gene expression (represented with the red cross sign).


Example 6
Targeting the APOE Promoter Region with a gRNA-dCas9-DNMT3A Lentiviral Vector


FIG. 6 shows the targeting of the promoter region of APOE with gRNA-dCas9-DNMT3A lentiviral vector system. Human hepatocytes HEPG2 cells were stably transduced with lentiviral vector carrying 4 different gRNA paired with dCas9-DNMT3A or dCAS9-DNMT3A null vectors. The table below shows the selection of gRNA to target APOE promoter region. The APOE promoter region was targeted by SpCas9-DNMT3A fusion protein via a set of gRNAs. Viral constructs 1026-1029 have an active version of DNMT3A while viral constructs 1030-1033 have an inactive version of DNMT3A (null). The sequences for the gRNAs targeting the promoter region of APOE for each construct are shown.
















Construct #
Guide
SEQ ID

DNMT3A


(SEQ ID NO)
RNA
NO
Sequence
Activity







1026
gRNA1
SEQ ID
gacaggggga
active


(SEQ ID

NO: 25
gccctataat



NO: 29)









1027
gRNA2
SEQ ID
tcaggagagc
active


(SEQ ID

NO: 26
tactcggggt



NO: 30)









1028
gRNA3
SEQ ID
actgggatgt
active


(SEQ ID

NO: 27
aagccatagc



NO: 31)









1029
gRNA4
SEQ ID
gttggagctt
active


(SEQ ID

NO: 28
agaatgtgaa



NO: 32)









1030
gRNA1
SEQ ID
gacaggggga
not active


(SEQ ID

NO: 25
gccctataat



NO: 33)









1031
gRNA2
SEQ ID
tcaggagagc
not active


(SEQ ID

NO: 26
tactcggggt



NO: 34)









1032
gRNA3
SEQ ID
actgggatgt
not active


(SEQ ID

NO: 27
aagccatagc



NO: 35)









1033
gRNA4
SEQ ID
gttggagctt
not active


SEQ ID

NO: 28
agaatgtgaa



NO: 36)









In FIG. 6A-FIG. 6B, the levels of the mRNA and protein downregulation were compared to untransduced naïve HEPG2 cells. The vectors delivering the active version of DNMT3A represented in white bars while the null mutants are shown in black bars. The experiments were repeated three time and the SD bars are highlighted. FIG. 6A shows the levels of RNA knockdown following the transduction with a lentiviral vector as assessed by real-time PCR (as described above). gRNA1 showed the most robust reduction in APOE-mRNA. FIG. 6B shows the levels of ApoE protein knockdown following the transduction with a lentivirval vector as assessed by western blot. The effects on the protein levels were comparable with the effects on the mRNA shown in FIG. 6A, demonstrating the most robust decrease in protein levels was driven by gRNA1. The levels of the mRNA and protein downregulation were compared to untransduced, naïve HEPG2 cells. In FIG. 6A-FIG. 6B, the vectors delivering the active version of DNMT3A were represented with white bars while null mutants were represented with black bars. The experiments were repeated three time and the SD bars are highlighted.


Example 7
Identifying the Location of VRER gRNAs and SpCas9 gRNAs Targeting the APOE Gene Promoter


FIG. 7 shows the structure of human APOE gene and the position of the VRER gRNAs relative to positions of the spCas9 gRNAs, all of which targeted the promoter region of the APOE gene. Genomic organization of the gene outlined in the lower panel highlighting the 2 SNPs within exon 4. gRNA targeting promoter region of the gene are outlined. spCas9 gRNAs (in green) and VRER gRNAs (in yellow) positions. The 5′-UTR and the 3′-UTR of the gene are indicated in boxes.


Example 8
Validating the VRER System Using GFP-Reporter Cells


FIG. 8A-FIG. 8B show the validation of the VRER system using GFP-reporter cells. Here, an all-in-one lentiviral vector harboring catalytically active SpCas9 and VRER-Cas9 and gRNA targeting different regions of the eGFP was created. Two gRNAs targeting eGFP sequences adjunct to NGG or NGCG PAMs were selected. In FIG. 8, the two gRNA targeting GFP-ORF are highlighted in green (SEQ ID NO: 13-ggcgaggagctgttcaccg) and light-blue (SEQ ID NO:14-gccacaagttcagcgtgtcc). The NGG motif recognized by dCas9 is highlighted in pink. The NGCG motif recognized by VRER protein is highlighted in yellow. A GFP-reporter 293T cell line was created by stable transduction using lentiviral vector. The HEK293T cell lines expressed the WT version of GFP and the mutated version (C-to-G) are 201A GFP (FIG. 8A) and 1003 (FIG. 8B). GFP was subjected to site-directed mutagenesis to change the PAM motif for VRER enzyme NGCG to GGG, which is recognized by SpCas9. To preserve the amino acid composition, all modifications were made at the third-base positions. The target cells were transduced with SpCas9-gRNA-to-GFP vector VRER-gRNA-to-GFP vector to assess the specificity and efficacy of the corresponding enzymes. The efficiency and the specificity of the Cas9 and VRER toward NGG and NGCG PAMs was assessed by measuring GFP-depletion in the cells transduced with the respective viruses. This was recorded with a +/− score with +++++ (i.e., 5 “+”) having the maximal cleavage activity while −−−−− (i.e., 5 “−”) indicated minimal cleavage activity. The methods described in Ortinski P I, et al. (2017) Mol Ther Methods Clin Dev. 5:153-164, are incorporated by reference in its entirety for teaching of these methods. The specificity of VRER was found to be comparable to that of Cas9 while the efficacy was demonstrated to be significantly lower. In other words, VRER-dCas9 was capable of efficiently discriminating between NGG and NGCG PAM motifs. No detectable cleavage of the enzyme was observed in the context of NGG.


Example 9
Targeting the APOE Promoter Region with a dVRER-DNMT3A Lentiviral Vector


FIG. 9 shows the effect of targeting the promoter region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. Human hepatocytes HEPG2 cells were stably transduced with lentiviral vector carrying 4 different gRNA targeting the APOE promoter region and paired with dVRER-DNMT3A or dVRER-DNMT3A null vectors. gRNA1 was gccctatccctgggggaggg (SEQ ID NO:39). gRNA2 was tcgggcttggggagaggagg (SEQ ID NO:40). gRNA3 was ctctccccaccccaccttct (SEQ ID NO:41). gRNA4 was tgtgaagggagaatgaggaa (SEQ ID NO:42). FIG. 9 shows the level of RNA knockdown following the transduction using real-time PCR. The levels of the mRNA downregulation was compared to untransduced, naïve HEPG2 cells. The vectors delivering the active version of DNMT3A are represented with white bars while the null mutants are represented with black bars. The experiments were repeated three times and the SD bars are highlighted. The gRNAs in this example are provided below.

















Construct #
Guide
gRNA Sequence
DNMT3A



SEQ ID NO
RNA
SEQ ID NO
Activity








1105
gRNA1
gccctatccc
active



SEQ ID

tgggggaggg




NO: 43

SEQ ID






NO: 39







1106
gRNA2
tcgggcttgg
active



SEQ ID

ggagaggagg




NO: 44

SEQ ID






NO: 40







1107
gRNA3
ctctccccac
active



SEQ ID

cccaccttct




NO: 45

SEQ ID






NO: 41







1108
gRNA4
tgtgaaggga
active



SEQ ID

gaatgaggaa




NO: 46

SEQ ID






NO: 42







1109
gRNA1
gccctatccc
not active



SEQ ID

tgggggaggg




NO: 47

SEQ ID






NO: 39







1110
gRNA2
tcgggcttgg
not active



SEQ ID

ggagaggagg




NO: 48

SEQ ID






NO: 40







1111
gRNA3
ctctccccac
not active



SEQ ID

cccaccttct




NO: 49

SEQ ID






NO: 41







1112
gRNA4
tgtgaaggga
not active



SEQ ID

gaatgaggaa




NO: 50

SEQ ID






NO: 42









Example 10
Differentiating and Characterizing hiPSC-Derived Neurons

hiPSCs lines were differentiated into cholinergic neurons (the primary LOAD-affected neurons) as described by Tagliafierro L, et al. (2018) Hum Mol Genet. 28(3):407-421 and Tagliafierro L, et al. (2017) Alzheimer's Dement. 13(11):1237-1250. FIG. 10A shows the timeline of differentiation. FIG. 10B shows the representative immunocytochemistry of hiPSC-derived neurons. FACS-analysis shows co-expression of TUBB3 and VachT (36.4%) and absence of GFAP signal (FIG. 10C-FIG. 10D). FIG. 10E shows relative expression levels of neuronal-(TUBB3 and CHAT) and astrocytes (GFAP) specific markers; and FIG. 10F illustrate APOE-mRNA expression in isogenic APOE 3/3 and 4/4 hiPSC-derived neurons. APOE-mRNA expression in isogenic APOE 3/3 was greater than in isogenic APOE 4/4, which is consistent with the observation in human brain as shown in FIG. 10A-FIG. 10D.


Furthermore, isogenic cell lines having APOE 3/3, APOE 3/4, and APOE 4/4 genotypes were cultured. Using CRISPR/Cas9 genome editing, isogenic lines were created such that the only difference is the SNP that defines the e4 allele. FIG. 11A-FIG. 11C show expression levels and immunohistochemical staining of isogenic APOE-hiPSC. FIG. 11A shows the fold levels of human APOE mRNA assayed by qRT-PCR using TaqMan assay. FIG. 11B (APOE 3/3) and FIG. 11C (APOE 4/4) show hiPSC shows cells stained with pluripotency markers OCT 4 and NANOG. (FROM GRANT)


Example 11
Evaluating Nuclear Envelope Markers in hiPSC-Derived Neurons

Loss of the integrity of the nuclear envelope has been associated with aging (Miller, et al., Cell Stem Cell 13, 691-705 (2013); Liu et al., Nature 491, 603-607 (2012)). To evaluate the nuclear architecture of the hiPSC-derived cells, nuclear envelope markers in isogenic APOE 3/3 and APOE 4/4 hiPSC-derived neurons were analyzed according to the methods described in Tagliafierro, et al., Hum Mol Genet (2018). In particular, the nuclear envelope integrity was assessed by using two specific nuclear envelope markers. First, Lamin A C (Miller, et al., Cell Stem Cell 13, 691-705 (2013); Tagliafierro, et al., Hum Mol Genet (2018)), wherein folded nuclei were counted as abnormal. Second, Lamin B1 (Liu et al., Nature 491, 603-607 (2012); Tagliafierro, et al., Hum Mol Genet (2018)), wherein nuclear circularity was quantified using the built-in ImageJ circularity plugin and assessed based on the Lamin B1 marker. 400 cells per staining were analyzed for two independent experiments.



FIG. 12A-FIG. 12M show the results of the analysis of nuclear envelope markers in isogenic APOE 3/3 and APOE 4/4 hiPSC-derived neurons. FIG. 12A shows the immunocytochemistry for lamin B1 in APOE 3/3 hiPSC-derived neurons while FIG. 12B shows lamin B1 staining in APOE 4/4 hiPSC-derived neurons. As demonstrated in FIG. 12C, the quantification of the nuclear envelope circularity showed loss circularity in the APOE 4/4 hiPSC-derived neurons vs. the APOE 3/3 hiPSC-derived neurons before heat treatment while FIG. 12D shows the same comparison after heat treatment (i.e., heat-shock treatment as described by Vigouroux, et al., J. Cell Sci. 114, 4459-4468 (2001)). FIG. 12E shows the immunocytochemistry for lamin AC in APOE 3/3 hiPSC-derived neurons while FIG. 12F shows lamin B1 staining in APOE 4/4 hiPSC-derived neurons. FIG. 12G shows the proportion of cells with abnormal nuclear morphology in the APOE 4/4 hiPSC-derived neurons vs. the APOE 3/3 hiPSC-derived neurons before heat treatment while FIG. 12H shows the same comparison after heat treatment (described by Vigouroux et al., 2001).


As shown in FIG. 12I, osmotic stress was applied by incubating the cells with an increasing concentration of NaCl2 (Czubryt, et al., Mol. Cell. Biochem. 172, 97-102 (1997)), which resulted in an increased sensitivity of the nuclear envelope in the APOE 4/4 neurons compared to the APOE 3/3 neurons. Using a commercially available kit, the percentage of the 5 methylcytosine (5 mC %) was measured (Jones M J, et al. (2015) Aging Cell. 14(6):924-932). FIG. 12J shows the decrease in global 5-mC % in APOE 4/4 hiPSC-derived neurons as compared to APOE 3/3 hiPSC-derived neurons.


For the nuclear dextran size exclusion assay (described by Eftekharzadeh B, et al. (2019) Neuron. 101(2):349; D'Angelo M A, et al. (2009) Cell. 136:284-295), low-molecular-weight (<25 kDa) dextran was expected to freely traverse nuclear pore complexes and fill the nucleus, whereas higher molecular weight (e.g., 70-kDa and 500-kDa) dextrans were expected to be excluded from the nucleoplasm when the nuclear pore complexes are intact. Nuclei were isolated with a sucrose gradient and incubated with fluorescent dextrans of different molecular weight. Intranuclear 155-kDa dextran indicated leakiness of the nuclear membrane. FIG. 12K and FIG. 12L shows the nuclear leakage as assessed by a dextran assay using 155 kDa fluorescently-label molecule APOE 3/3 hiPSC-derived neurons and 4/4 hiPSC-derived neurons, respectively. FIG. 12M shows the percentage of leaky nuclei for both APOE 3/3 and APO 4/4 hiPSC-derived neurons.


Example 12
Examining the Methylation Profile of the APOE Linkage Disequilibrium Region in hiPSC-Derived Neurons

Pyrosequencing was performed using bisulfite converted DNA to quantitatively determine the methylation levels according to the protocol set forth in Bassil C F, et al. (2013) Methods Mol Biol. 1049:95-107, which is incorporated by reference in its entirety for its teaching of a bisulfite pyrosequencing protocol. The assay was designed across APOE exon 4 covered CpG 11-38 (chr19: 45411858-45412063; hg19) as described by Tulloch J, et al. (2018) Brain Res. 1698:179-186, which is incorporated by reference in its entirety for its teaching of the CpG assay design.



FIG. 13A-FIG. 13E shows the methylation profile of the APOE linkage disequilibrium (LD) region in isogenic APOE hiPSC-derived neurons. FIG. 13A shows a map of MethylEPIC array probes in chromosome 19 from 45,393,000-45,424,000 (hg19). Those probes with >0.5 methylation levels are highlighted in red. Those probes with <0.5 methylation levels are highlighted in blue. Significant differences in methylation between the APOE neuronal lines are shown using asterisks as follows: black asterisk (>0.1) and red asterisk (>0.2). Because the APOE promoter region was hypomethylated, it was an excellent target region for enhancement of DNA-methylation. FIG. 13B shows a schematic representation of the 27 CpG islands for pyrosequencing in the APOE region, i.e., chromosome 19 from 45,411,858-45,412,079 (hg19). FIG. 13C shows those probes that had significant differences in DNA-methylation levels between isogenic APOE hiPSC-derived neurons. FIG. 13D shows the methylation level (%) of the CpG 11-38 that was quantitatively determined in the isogenic hiPSC-derived neurons using pyrosequencing. FIG. 13E shows a comparison of the methylation level (%) of CpG 11-38 between hiPSC-derived neurons and NeuN+ FANS-sorted nuclei using pyrosequencing. Here, the DNA-methylation profiles of the hiPSC-derived neurons were comparable to those observed for the human brain sorted neuronal nuclei (indicating that the hiPSC-derived neuronal system was suitable for drug discovery studies aiming at DNA-methylation editing).


Example 13
Examining Alzheimer's Disease Phenotypes in hiPSC-Derived Neurons

To generate the data presented in FIG. 14A, an ELISA kit and a V-PLEX Plus AR Peptide Panel 1 (6E10) Kit (Cat: K15200G-1) was used to measure secreted levels of Ab40 and Ab42. The Ab42/40 ratio was then calculated according to Lin Y T, et al. (2018) Neuron. 98(6):1294 and Wang C, et al. (2018) Nat Med. 24(5):647-657, both of which are incorporated by reference in their entirety for the teaching of these protocols. As shown in FIG. 14B, the total tau and pTau levels were measured by ELISA kits using (i) an Invitrogen Human Tau (Total) ELISA Kit (Cat: KHB0041) and (ii) an Invitrogen Human Tau [pT181] phosphoELISA™ ELISA Kit (Cat: KH00631). The neurite outgrowth in FIG. 14C and FIG. 14D was assessed by TUBB3 staining followed by a tracing analysis to determine (i) the number of neurites originating from the soma of each neuron, (ii) the individual length of the longest single neurite, and (iii) the total length of all neurites in a single neuron (Lin Y T, et al. (2018) and Wang C, et al. (2018)). FIG. 14A-FIG. 14D present the disease related cellular perturbations and pathological characteristics of the hiPSC-derived neuronal model system that are being used in the first stage for the in vitro studies.


Example 14
Examining DNA Methylation in the APOE Promoter Target Region


FIG. 15A shows a map of the targeted APOE promoter region was generated using a UCSC genome browser viewer. In the upper panel, black bars indicate the positions of the target region, the designed gRNAs, and the MethylEpic probes. In the lower panel, the APOE gene structure is shown with the promoter, exon 1, intron 1, and the TSS. FIG. 15B shows the analysis of DNA-methylation within the APOE-promoter target region, specifically those probes that overlapped the target region and showed differences in DNA-methylation levels between the isogenic APOE hiPSC-derived neurons. These lines will be used in the first stage for the in vitro studies for proof of concept of the developed epigenome-editing system as a therapeutic strategy for precision medicine in Alzheimer's.


Example 15
Targeting the APOE Promoter Region with a gRNA-dCas9-DNMT3A Lentiviral Vector

hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele were stably transduced with lentiviral vector carrying gRNA3 paired with dCas9-DNMT3A or dCAS9-DNMT3A null vectors. FIG. 16 shows the levels of RNA knockdown following the transduction as assessed by real-time PCR.


Similarly, hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele were stably transduced with lentiviral vector carrying gRNAs 1-4 paired with dCas9-DNMT3A or with a dCAS9-DNMT3A vector with no-gRNA. FIG. 17 shows the level of mRNA knockdown following the transduction as assessed by real-time PCR. The vectors having a gRNA all significantly knocked down the level of APOE mRNA compared to either a null vector or a vector having no gRNA.


Then, hiPSC-derived cholinergic neurons homozygote to the APOE e3 allele were stably transduced with lentiviral vector carrying gRNAs 1-4 paired with dCas9-DNMT3A or a dCAS9-DNMT3A vector with no-gRNA. FIG. 18 shows the level of mRNA knockdown following the transduction as assessed by real-time PCR. The vectors having gRNA3 or gRNA4 significantly knocked down the level of APOE mRNA compared to either a null vector or a vector having gRNA1 or gRNA2.


Example 16
Targeting the APOE Promoter Region with a gRNA-dVRER-DNMT3A Lentiviral Vector

hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele were stably transduced with a lentiviral vector carrying a gRNA that was 2′ paired with dVRER-DNMT3A or with a dVRER-DNMT3A lentiviral vector with no gRNA. FIG. 19 shows the level of mRNA knockdown following the transduction as assessed by real-time PCR assessed. The vector having gRNA2 achieved a 15% reduction in the level of APOE mRNA compared to the vector having no gRNA. Similarly, hiPSC-derived cholinergic neurons homozygote to the APOE e3 allele were stably transduced with a lentiviral vector carrying a gRNAs 2′ paired with dVRER-DNMT3A or a dVRER-DNMT3A lentiviral vector with no gRNA. FIG. 20 shows the level of mRNA knockdown following the transduction as assessed by real-time PCR assessed. No changes in the level of APOE mRNA were observed.


Example 17
Designing Lentiviral Vectors Having Additional Effector Molecules

A strategy to silence APOEe4 allele using DNMT3A-DNMT3L enzymes and KRAB repressor as the effector molecules was developed. FIG. 21A shows a schematic representation of the APOE gene including promoter region and exon 1-4. Here, two lentiviral vector systems are established. The first lentiviral vector carries dCAS9-gRNA-to-promoter. The vector also harbors a SunTag epitope recognized by single-chain scFv protein. The second lentiviral vector carries dVRER and gRNA for specific targeting of SNP rs429358 in the exon 4 (on the e4) and DNMT3A-DNMT3L effectors. The gRNA with the MS2 binding sites allows for the recruitment of KRAB repressor via the MS2-protein (fusion).



FIG. 21B shows that following lentiviral vector-delivery, the dCAS9-gRNA-SunTag binds to the promoter region on both alleles. However, it is inactive on the e3-allele as it lacks the effector molecules. The recruitment of dVRER via specific binding mediated throughout the recognition of the PAM (NGCG) brings the effector molecules in the action. Following interaction between SunTag-scFv, DNA on the e4 is looped out and two the effector molecules, KRAB and DNMT3A-L, repress and methylate the promoter of the e4. The SunTag-MS2-bridging system allows specific repression of the e4-allele.



FIG. 22 shows a schematic illustration of the lentiviral vector carrying gRNA-dCas9/dVRER-repressor transgene. The vector backbone was optimized by inclosing Sp1 binding sites2. dCas9-KRAB/MeCP2/KRAB-MeCP2 fusion expressed from EFS-NC promoter. Human U6 promoter drives gRNA expression. Other elements of the vector are highlighted2,3. The vector carries gRNA to target regulatory element within exon 4 overlapping the e4-SNP, to specifically target the ApoE4 allele. The expected downregulation in the transcription activity of the different APOE alleles is denoted. FIG. 23A-FIG. 23B show the targeting exon 4 region of APOE with a gRNA-dVRER-DNMT3A lentiviral vector system. FIG. 23A shows that the construct was identical to that of FIG. 5 but for the addition of the repressor to the fused domains of KRAB-MeCP2. FIG. 23B shows the mRNA level in hiPSC-derived cholinergic neurons homozygote to the APOE e4 allele following stable transduction with lentiviral vector carrying a gRNA 2′-paired with dVRER-CRAB MeCp2 or a lentiviral vector carrying a dVRER-KRAB MeCp2 vector with no gRNA. Real-time PCR assessed the levels of mRNA knockdown following the transduction. The vector have a gRNA caused a >50% reduction in the level of APOE mRNA.


SUMMARY OF EXAMPLES

The Examples provided herein show that epigenome-based therapy paired with lentiviral vector is an advantageous strategy for the treatment of LOAD because it has versatility, low immunogenicity, and remarkable suitability for viral-mediated gene transfers. Pre-existing approaches including antisense oligonucleotides (ASO) and immunotherapy are plagued by significant disadvantages such as low efficiency and specificity, low stability and solubility, adverse immunoreactivity, and inability to penetrate blood-brain barrier (BBB). Epigenome editing also holds key advantages over direct gene knockout because epigenome editing triggers the natural cellular system that leads to gene silencing by a defined mechanism (Rittiner J E, et al. (2020) Front Mol Neurosci. 13:148). By contrast, knocking out a gene by conventional genome editing depends on targeted DNA double-strand breakage followed by repair, which can occur via variable repair pathways that are not fully predictable.


The APOE-targeted epigenome therapy described herein combines emerging innovative genomic technologies and delivery techniques to overcome these limitations. As demonstrated by the data presented in the Examples, the allelic discrimination approach is innovative as it allows a precise and fine-tuned downregulation of APOEe4 allele expression. The utility of dCas9-variant, VRER (Kleinstiver B P, et al. (2015) Nature. 523:481-485) in gene therapy is innovative and the combination of the epigenomic modification approach and the strategy to target allele specific is novel. The novel vector system disclosed herein circumvents several challenges related to gene therapy. It has a high efficiency for delivery of oversized CRISPR/Cas9 components. It is suitable for a broad range of cellular tropisms. It has low cytotoxicity and immunogenicity. It generates long-term and sustainable expression of the transgene which will ensure that the epigenetic changes imprinted within APOE exon 4 are permanent. Importantly, lentiviruses are very efficient in transducing post-mitotic neurons in vivo.


Sequences

In an aspect, a disclosed ApoE gene can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:











(SEQ ID NO: 01)



ggaacttgatgctcagagaggacaagtcatttgcccaagg







tcacacagctggcaactggcagagccaggattcacgccct







ggcaatttgactccagaatcctaaccttaacccagaagca







cggcttcaagcccctggaaaccacaatacctgtggcagcc







agggggaggtgctggaatctcatttcacatgtggggaggg







ggctcccctgtgctcaaggtcacaaccaaagaggaagctg







tgattaaaacccaggtcccatttgcaaagcctcgactttt







agcaggtgcatcatactgttcccacccctcccatcccact







tctgtccagccgcctagccccactttcttttttttctttt







tttgagacagtctccctcttgctgaggctggagtgcagtg







gcgagatctcggctcactgtaacctccgcctcccgggttc







aagcgattctcctgcctcagcctcccaagtagctaggatt







acaggcgcccgccaccacgcctggctaacttttgtatttt







tagtagagatggggtttcaccatgttggccaggctggtgt







gaaactcctgaccttaagtgattcgcccactgtggcctcc







caaagtgctgggattacaggcgtgagctaccgcccccagc







ccctcccatcccacttctgtccagccccctagccctactt







tctttctgggatccaggagtccagatccccagccccctct







ccagattacattcatccaggcacaggaaaggacagggtca







ggaaaggaggactctgggcggcagcctccacattcccctt







ccacgcttggcccccagaatggaggagggtgtcttgatta







ctgggcgaggtgtcctcccttcctggggactgtggggggt







ggtcaaaagacctctatgccccacctccttcctccctctg







ccctgctgtgcctggggcagggggagaacagcccacctcg







tgactgggggctggcccagcccgccctatccctgggggag







ggggcgggacagggggagccctataattggacaagtctgg







gatccttgagtcctactcagccccagcggaggtgaaggac







gtccttccccaggagccggtgagaagcgcagtcgggggca







cggggatgagctcaggggcctctagaaagagctgggaccc







tgggaacccctggcctccaggtagtctcaggagagctact







cggggtcgggcttggggagaggaggagcgggggtgaggca







agcagcaggggactggacctgggaagggctgggcagcaga







gacgacccgacccgctagaaggtggggggggagagcagct







ggactgggatgtaagccatagcaggactccacgagttgtc







actatcatttatcgagcacctactgggtgtccccagtgtc







ctcagatctccataactggggagccaggggcagcgacacg







gtagctagccgtcgattggagaactttaaaatgaggactg







aattagctcataaatggaacacggcgcttaactgtgaggt







tggagcttagaatgtgaagggagaatgaggaatgcgagac







tgggactgagatggaaccggcggtggggagggggtggggg







gatggaatttgaaccccgggagaggaagatggaattttct







atggaggccgacctggggatggggagataagagaagacca







ggagggagttaaatagggaatgggttgggggcggcttggt







aaatgtgctgggattaggctgttgcagataatgcaacaag







gcttggaaggctaacctggggtgaggccgggttggggccg







ggctggggggggaggagtcctcactggcggttgattgaca







gtttctccttccccagactggccaatcacaggcaggaaga







tgaaggttctgtgggctgcgttgctggtcacattcctggc







aggtatgggggggggcttgctcggttccccccgctcctcc







ccctctcatcctcacctcaacctcctggccccattcaggc







agaccctgggccccctcttctgaggcttctgtgctgcttc







ctggctctgaacagcgatttgacgctctctgggcctcggt







ttcccccatccttgagataggagttagaagttgttttgtt







gttgttgtttgttgttgttgttttgtttttttgagatgaa







gtctcgctctgtcgcccaggctggagtgcagtggcgggat







ctcggctcactgcaagctccgcctcccaggtccacgccat







tctcctgcctcagcctcccaagtagctgggactacaggca







catgccaccacacccgactaacttttttgtattttcagta







gagacggggtttcaccatgttggccaggctggtctggaac







tcctgacctcaggtgatctgcccgtttcgatctcccaaag







tgctgggattacaggcgtgagccaccgcacctggctggga







gttagaggtttctaatgcattgcaggcagatagtgaatac







cagacacggggcagctgtgatctttattctccatcacccc







cacacagccctgcctggggcacacaaggacactcaataca







tgcttttccgctgggcgcggtggctcacccctgtaatccc







agcactttgggaggccaaggtgggaggatcacttgagccc







aggagttcaacaccagcctgggcaacatagtgagaccctg







tctctactaaaaatacaaaaattagccaggcatggtgcca







cacacctgtgctctcagctactcaggaggctgaggcagga







ggatcgcttgagcccagaaggtcaaggttgcagtgaacca







tgttcaggccgctgcactccagcctgggtgacagagcaag







accctgtttataaatacataatgctttccaagtgattaaa







ccgactcccccctcaccctgcccaccatggctccaaagaa







gcatttgtggagcaccttctgtgtgcccctaggtactaga







tgcctggacggggtcagaaggaccctgacccaccttgaac







ttgttccacacaggatgccaggccaaggtggagcaagcgg







tggagacagagccggagcccgagctgcgccagcagaccga







gtggcagagcggccagcgctgggaactggcactgggtcgc







ttttgggattacctgcgctgggtgcagacactgtctgagc







aggtgcaggaggagctgctcagctcccaggtcacccagga







actgaggtgagtgtccccatcctggcccttgaccctcctg







gtgggggctatacctccccaggtccaggtttcattctgcc







cctgtcgctaagtcttggggggcctgggtctctgctggtt







ctagcttcctcttcccatttctgactcctggctttagctc







tctggaattctctctctcagctttgtctctctctcttccc







ttctgactcagtctctcacactcgtcctggctctgtctct







gtccttccctagctcttttatatagagacagagagatggg







gtctcactgtgttgcccaggctggtcttgaacttctgggc







tcaagcgatcctcccgcctcggcctcccaaagtgctggga







ttagaggcatgagccaccttgcccggcctcctagctcctt







cttcgtctctgcctctgccctctgcatctgctctctgcat







ctgtctctgtctccttctctcggcctctgccccgttcctt







ctctccctcttgggtctctctggctcatccccatctcgcc







cgccccatcccagcccttctccccgcctcccactgtgcga







caccctcccgccctctcggccgcagggcgctgatggacga







gaccatgaaggagttgaaggcctacaaatcggaactggag







gaacaactgaccccggtggcggaggagacgcgggcacggc







tgtccaaggagctgcaggcggcgcaggcccggctgggcgc







ggacatggaggacgtgtgcggccgcctggtgcagtaccgc







ggcgaggtgcaggccatgctcggccagagcaccgaggagc







tgcgggtgcgcctcgcctcccacctgcgcaagctgcgtaa







gcggctcctccgcgatgccgatgacctgcagaagcgcctg







gcagtgtaccaggccggggcccgcgagggcgccgagcgcg







gcctcagcgagcaggcccagcagatacgcctgcaggccga







ggccttccaggcccgcctcaagagctggttcgagcccctg







gtggaagacatgcagcgccagtgggccgggctggtggaga







aggtgcaggctgccgtgggcaccagcgccgcccctgtgcc







cagcgacaatcactgaacgccgaagcctgcagccatgcga







ccccacgccaccccgtgcctcctgcctccgcgcagcctgc







agcgggagaccctgtccccgccccagccgtcctcctgggg







tggaccctagtttaataaagattcaccaagtttcacgcat







ctgctggcctccccctgtgatttcctctaagccccagcct







cagtttctctttctgcccacatactggccacacaattctc







agccccctcctctccatctgtgtctgtgtgtatctttctc







tctgcccttttttttttttttagacggagtctggctctgt







cacccaggctagagtgcagtggcacgatcttggctcactg







caacctctgcctcttgggttcaagcgattctgctgcctca







gtagctgggattacaggctcacaccaccacacccggctaa







tttttgtatttttagtagagacgagctttcaccatgttgg







ccaggcaggtctcaaactcctgaccaagtgatccacccgc







cggcctcccaaagtgctgagattacaggcctgagccacca







tgcccggcctctgcccctctttcttttttagggggcaggg







aaaggtctcaccctgtcacccgccatcacagctcactgca







gcctccacctcctggactcaagtgataagtgatcctcccg







cctcagcctttccagtagctgagactacaggcgcatacca







ctaggattaatttgggggggggggggtgtgtgtggagatg







gggtctggctttgttggccaggctgatgtggaattcctgg







gctcaagcgatactcccaccttggcctcctgagtagctga







gactactggctagcaccaccacacccagctttttattatt







atttgtagagacaaggtctcaatatgttgcccaggctagt







ctcaaacccctgggctcaagagatcctccgccatcggcct







cccaaagtgctgggattccaggcatggggctccgagcccg







gcctgcccaacttaataatacttgttcctcagagttgcaa







ctccaaatgacctgagattggtgcctttattctaagctat







tttcattttttttctgctgtcattattctcccccttctct







cctccagtcttatctgatatctgcctccttcccacccacc







ctgcaccccatcccacccctctgtctctccctgttctcct







caggagactctggcttcctgttttcctccacttctatctt







ttatctctccctcctacggtttcttttctttctccccggc







ctgcttgtttctcccccaacccccttcatctggatttctt







cttctgccattcagtttggtttgagctctctgcttctccg







gttccctctgagctagctgtcccttcacccactgtgaact







gggtttccctgcccaaccctcattctctttctttctttct







ttttttttttttttttttttttttttttttgagacagagt







cttgctctgttgcccagcctggagtgcagtggtgcaatct







tggttcactgcaacctccacttcccagattcaagcaattc







tcctgcctcagcctccagagtagctgggattacaggcgtg







tcccaccacacccgactaatttttgtatttttggtagaga







caaggcttcggcattgttggccaggcaggtctcgaactcc







tgacctcaagtaatctgcctgcctcaccctcccaaagtgc







tgggattacaggcatgagccacctcacccggaccatccct







cattctccatcctttcctccagttgtgatgtctacccctc







atgtttcccaacaagcctactgggtgctgaatccaggctg







ggaagagaagggagcggctcttctgtcggagtctgcacca







ggcccatgctgagacgagagctggcgctcagagaggggaa







gcttggatggaagcccaggagccgccggcactctcttctc







ctcccaccccctcagttctcagagacggggaggagggttc







ccaccaacgggggacaggctgagacttgagcttgtatctc







ctgggccagctgcaacatctgcttgtccctctgcccatct







tggctcctgcacaccctgaacttggtgctttccctggcac







tgctctgatcacccacgtggaggcagcacccctcccct.






In an aspect, a disclosed APOEe2 variant can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:











(SEQ ID NO: 02)



Atgaaggttctgtgggctgcgttgctggtcacattcctgg







caggatgccaggccaaggtggagcaagcggtggagacaga







gccggagcccgagctgcgccagcagaccgagtggcagagc







ggccagcgctgggaactggcactgggtcgcttttgggatt







acctgcgctgggtgcagacactgtctgagcaggtgcagga







ggagctgctcagctcccaggtcacccaggaactgagggcg







ctgatggacgagaccatgaaggagttgaaggcctacaaat







cggaactggaggaacaactgaccccggtggcggaggagac







gcgggcacggctgtccaaggagctgcaggcggcgcaggcc







cggctgggcgcggacatggaggacgtgtgcggccgcctgg







tgcagtaccgcggcgaggtgcaggccatgctcggccagag







caccgaggagctgcgggtgcgcctcgcctcccacctgcgc







aagctgcgtaagcggctcctccgcgatgccgatgacctgc







agaagtgcctggcagtgtaccaggccggggcccgcgaggg







cgccgagcgcggcctcagcgccatccgcgagcgcctgggg







cccctggtggaacagggccgcgtgcgggccgccactgtgg







gctccctggccggccagccgctacaggagcgggcccaggc







ctggggcgagcggctgcgcgcgcggatggaggagatgggc







agccggacccgcgaccgcctggacgaggtgaaggagcagg







tggcggaggtgcgcgccaagctggaggagcaggcccagca







gatacgcctgcaggccgaggccttccaggcccgcctcaag







agctggttcgagcccctggtggaagacatgcagcgccagt







gggccgggctggtggagaaggtgcaggctgccgtgggcac







cagcgccgcccctgtgcccagcgacaatcactga.






In an aspect, a disclosed APOEe3 variant can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth below:











(SEQ ID NO: 03)



Atgaaggttctgtgggctgcgttgctggtcacattcctgg







caggatgccaggccaaagtcgaacaggctgtcgaaactga







acccgaaccggagctgcgccagcagaccgagtggcagagc







ggccagcgctgggaactggcactgggtcgcttttgggatt







acctgcgctgggtgcagacactgtctgagcaggtgcagga







ggagctgctcagctcccaggtcacccaggaactgagggcg







ctgatggacgagaccatgaaggagttgaaggcctacaaat







cggaactggaggaacaactgaccccggtggcggaggagac







gcgggcacggctgtccaaggagctgcaggcggcgcaggcc







cggctgggcgcggacatggaggacgtgtgcggccgcctgg







tgcagtaccgcggcgaggtgcaggccatgctcggccagag







caccgaggagctgcgggtgcgcctcgcctcccacctgcgc







aagcttcgtaagcggctcctccgcgatgccgatgacctgc







agaagcgcctggcagtgtaccaggccggggcccgcgaggg







cgccgagcgcggcctcagcgccatccgcgagcgcctgggg







cccctggtggaacagggccgcgtgcgggccgccactgtgg







gctccctggccggccagccgctacaggagcgggcccaggc







ctggggcgagcggctgcgcgcgcggatggaggagatgggc







agccggacccgcgaccgcctggacgaggtgaaggagcagg







tggcggaggtgcgcgccaagctggaggagcaggcccagca







gatacgcctacaggccgaggccttccaggcccgcctcaag







agctggttcgagcccctggtggaagacatgcagcgccagt







gggccgggctggtggagaaggtgcaggctgccgtgggcac







cagcgccgcccctgtgcccagcgacaatcactga.






In an aspect, a disclosed APOEe4 variant can comprise the sequence set forth below or a sequence having 70%, 75%, 80%, 85%, 90%, 95%, or more identity to the sequence set forth











(SEQ ID NO: 04)



Atgaaggttctgtgggctgcgttgctggtcacattcctgg







caggatgccaggccaaagtcgaacaggctgtcgaaactga







acccgaaccggagctgcgccagcagaccgagtggcagagc







ggccagcgctgggaactggcactgggtcgcttttgggatt







acctgcgctgggtgcagacactgtctgagcaggtgcagga







ggagctgctcagctcccaggtcacccaggaactgagggcg







ctgatggacgagaccatgaaggagttgaaggcctacaaat







cggaactggaggaacaactgaccccggtggcggaggagac







gcgggcacggctgtccaaggagctgcaggcggcgcaggcc







cggctgggcgcggacatggaggacgtgcgcggccgcctgg







tgcagtaccgcggcgaggtgcaggccatgctcggccagag







caccgaggagctgcgggtgcgcctcgcctcccacctgcgc







aagcttcgtaagcggctcctccgcgatgccgatgacctgc







agaagcgcctggcagtgtaccaggccggggcccgcgaggg







cgccgagcgcggcctcagcgccatccgcgagcgcctgggg







cccctggtggaacagggccgcgtgcgggccgccactgtgg







gctccctggccggccagccgctacaggagcgggcccaggc







ctggggcgagcggctgcgcgcgcggatggaggagatgggc







agccggacccgcgaccgcctggacgaggtgaaggagcagg







tggcggaggtgcgcgccaagctggaggagcaggcccagca







gatacgcctacaggccgaggccttccaggcccgcctcaag







agctggttcgagcccctggtggaagacatgcagcgccagt







gggccgggctggtggagaaggtgcaggctgccgtgggcac







cagcgccgcccctgtgcccagcgacaatcactga.





Claims
  • 1. An isolated nucleic acid molecule, comprising: a nucleic acid sequence encoding (i) a Cas endonuclease,(ii) at least one polypeptide having repressor activity, and(iii) at least one guide RNA designed to target (i) exon 4 of the APOE gene, (ii) the promoter region of the APOE gene, or (iii) a regulatory element within the APOE gene.
  • 2. The isolated nucleic acid molecule of claim 1, wherein the Cas endonuclease comprises Cas9 or VRER Cas9.
  • 3. The isolated nucleic acid molecule of claim 1, wherein the at least one encoded polypeptide having repressor activity comprises Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).
  • 4. The isolated nucleic acid molecule of claim 1, wherein, in exon 4 of the APOE gene, the at least one gRNA is designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene.
  • 5. The isolated nucleic acid molecule of claim 1, where the Cas endonuclease comprises Cas9 VRER and the polypeptide having repressor activity comprises Krüppel-associated box (KRAB), the transcription repression domain (TRD) of Methyl-CpG Binding Protein 2 (MeCP2), or a fusion of KRAB-MeCP2 (KRAB-MeCP2).
  • 6. A viral vector comprising the isolated nucleic acid molecule of claim 1.
  • 7. The viral vector of claim 6, wherein the viral vector comprises one or more promoters operably linked to the isolated nucleic acid molecule, and wherein the one or more promoters drive the expression of the at least one gRNA and the Cas9 endonuclease.
  • 8. (canceled)
  • 9. The viral vector of claim 6, wherein the viral vector comprises one or more regulatory elements.
  • 10. The viral vector of claim 9, wherein the one or more regulatory elements comprise a Sp1 responsive element, a p2A signal, a woodchuck hepatitis virus post-transcriptional regulatory element, a Phi signal-packaging signal, a rev responsive element, a 5′-LTR, and a 3′-LTR.
  • 11. (canceled)
  • 12. The viral vector of claim 6, wherein the viral vector is a lentiviral vector.
  • 13.-24. (canceled)
  • 25. A method of administering precision gene therapy to a subject, the method comprising: administering to a human subject in need thereof a therapeutically effective amount of the viral vector of claim 6, wherein the expression of APOE is reduced or wherein the expression of the APOE e4 allele is reduced.
  • 26. (canceled)
  • 27. The method of claim 25, wherein the human subject is at risk of developing, suspected of having, or has been diagnosed with having Alzheimer's disease.
  • 28. The method of claim 25, wherein the pathological phenotype associated with Alzheimer's disease is reduced.
  • 29. The method of claim 25, wherein administering the viral vector to the subject comprises intravenous administration, intracerebral administration, intra-CSF administration, intracerebroventricular (ICV) administration, intraventricular administration, intra-cisterna magna (ICM) administration, intraparenchymal administration, intrathecal administration, or any combination thereof.
  • 30. The method of claim 25, further comprising administering to the human subject a therapeutically effective amount of a therapeutic agent and/or an immune modulator.
  • 31.-36. (canceled)
  • 37. The isolated nucleic acid molecule of claim 1, wherein the at least one encoded polypeptide comprises the sequence set forth in any one of SEQ ID NO:57, SEQ ID NO:58, SEQ ID NO:62, or SEQ ID NO:63.
  • 38. The isolated nucleic acid molecule of claim 1, wherein the at least one gRNA designed to target exon 4 of the APOE gene comprises the sequence set forth in any one of SEQ ID NO:05-SEQ ID NO:14.
  • 39. The isolated nucleic acid molecule of claim 2, wherein the Cas9 comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:64 or SEQ ID NO:65, or wherein the VRER Cas9 comprises a sequence having at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% identity to the sequence set forth in SEQ ID NO:15.
  • 40. The method of claim 25, wherein the at least one gRNA is designed to target the promoter region of the APOE gene or a regulatory element within the APOE gene, and wherein the expression of APOE is reduced.
  • 41. The method of claim 25, wherein the at least one gRNA is designed to target a protospacer-adjacent motif (PAM) created by a SNP rs429358 in exon 4 of the APOE gene, and wherein the expression of the APOE e4 allele is reduced.
I. CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of priority to U.S. Provisional Patent Application No. 63/104,343 filed 22 Oct. 2020 and U.S. Provisional Patent Application No. 63/132,286 filed 30 Dec. 2020, both of which are incorporated by reference herein in their entirety.

PCT Information
Filing Document Filing Date Country Kind
PCT/US21/54475 10/12/2021 WO
Provisional Applications (2)
Number Date Country
63132286 Dec 2020 US
63104343 Oct 2020 US